¬rª««æ¯g

¡@

°ª°¶®p¡B¾H¬LªÚ*¡B§õ«Ø½å**

¥x¥_ºaÁ`«æ¶E³¡¥DªvÂå®v

*¥x¥_ºaÁ`Á{§É¬rª«¬ì¥D¥ô

**¥x¥_ºaÁ`«æ¶E³¡¥D¥ô

¡@

¡@¡@¬rª«ªººØÃþ¤­ªá¤Kªù¡A¤@¯ë¤H¦b¥Í¬¡©Î¤u§@Àô¹Ò¸Ì¡A³£¥i¯àÀH®É¼ÉÅS¦b¦³¬rª«½èªºÀô¹Ò¤¤¡C¦³¬rª«½è¶i¤J¤HÅ骺³~®|¥]¬A1.§l¤J¡]¦p¦³¬r®ðÅé¡^2. Äá­¹¡]¦pÃĪ«¡B¹AÃÄ¡B²M¼ä¾¯¡^3.¥Ö½§§l¦¬¡]¦p¤ô»È¡B¦³¬r´Óª«¡^4.ª`®g¡]¦p¬r³D¡B©øÂΫr¶Ë¡^¡C

¡@¡@®Ú¾Ú¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ßªº²Î­p¡A©Ò¦³µn¿ý¤¤¬r­Ó®×¤¤¡A¤´¥HÄá­¹³~®|¶i¤J¤HÅ骺­Ó®×³Ì¦h¡A¬ù¥e©Ò¦³µn¿ý­Ó®×ªº75%¡C¸û±`¨£ªº¤¤¬r¨Ì§Ç¥]¬A¹AÃÄ(¥]¬A°£¯ó¾¯¡B±þÂξ¯µ¥)¡B¤@¯ëÃĪ«(¥]¬A¦w¯vÃÄ¡B¦w«D¥L©R¤Î¨ä¥L¤¤¼Ï¯«¸g¥ÎÃĵ¥)¡B²M¼ä¾¯¡B¦³¾÷·»¾¯¤Î°Êª««r¶Ëµ¥¡C¨ä¤¤¥H¦Û±þ¬°³Ì¥D­n¤¤¬r­ì¦]¡A¦ý¤»·³¥H¤U¤p«Ä«h¶W¹L90%ªº­ì¦]³£¬O·N¥~©Ò­P¡C¤¤¬r¾É­P¦º¤`ªÌ¡A¥H¹AÃÄ(¥]¬A°£¯ó¾¯¡B±þÂξ¯µ¥) ¬°³Ì¦h¡A¨ä¥¦¸û±`¨£ªº­ì¦]ÁÙ¥]¬A¦w«D¥L©R¡BÙæ¤Æª«¤Î¤@®ñ¤ÆºÒµ¥¡C¨ä¤¤¬ù3/4ªº¦º¤`­Ó®×³£¬O¦]¹AÃĤ¤¬r©Ò­P¡A¥i¨£¨ä¦b°ê¤ºªº­«­n©Ê¡C1µM¬r©Êª«½è¡A¦³¨ä¦a°ì©Ê¡A¦b¥xÆW±`¨£°Êª«¡]¦p¬r³D¡^«r¶Ë¡B´Óª«¡B¤¤¯óÃÄ¡B¥H¤Î¯S®íªºÃĪ«¤¤¬r´N©úÅã»P¬ü°ê¤£¦P¡Cªñ¦~¨Ó¡A¥xÆW¥Ñ©ó¥b¾ÉÅé¤u·~ªº§Ö³tµo®i¡A¤]¼W¥[¤F³\¦h»P¥b¾ÉÅé¤u·~¬ÛÃöªº²B¬t»Ä¤¤¬r¡C¦]¦¹«æ±Ï¤H­ûÀ³¤F¸Ñ°ê¤º©Î·í¦a¬rª«ªº¯S©Ê¡A¥H°µ¾A·íªº³B¸m¡C

¡@¡@Á{§É¤W¡A¯f¤H©Òªí²{ªº¯g­ÔÅܲ§©Ê«D±`¤j¡A«D¤¤¬r¯f±w¥i¯à·|¥HÃþ¦ü¤¤¬rªº¯f¥v¤Î¯gª¬¨Óªí²{¡A¡]¨Ò¦pµ§ªÌ¦b¬ü¶i­×´Á¶¡¡A¦b¤@­Ó«æ¶E³´¨À°Q½×·|¤W©Ò¹J¨ìªº¤@¦ì¦~»´¤k©Ê¸£½¤ª¢ªº¯f±w¡A§Y¬O«Ü¦nªº¨Ò¤l¡A¦o¦b°Ñ¥[§¹¨gÅw»R·|¤§«á¡Aªí²{¥X·NÃѤ£²M¡BÀû¤Õ·L¤j¡B¥Ö½§°®Àê¡B¤ß¸õ¥[³t¡BÅé·Å¤É°ªµ¥¯g­Ô¡A¦ý¨S¦³ÀV³¡»øµw¡A°_ªìÂåÀø¤H­û¨S¦³«ö·Ó·NÃѤ£²Mªº³B¸m¬yµ{¨Ó³B²z¡A¨S¦³¤Î¦­°µ¸y´Õ¬ï¨ë¨Ó¶EÂ_¡A¦Ó¤@ªÑ¸£¥u·Q¨ì¯f±w¥i¯à¬OAnticholinergic toxidromeªº¤¤¬r©Ò­P¡A¥h°µ³\¦h¦³Ãö¤¤¬rªºÀËÅç¤Î³B¸m¡A¦Ó¨S¦³¨Ï¥ÎªvÀø¸£½¤ª¢ªº§Ü¥Í¯À¡A´X¤Ñ¤§«á¤~°µ¸y´Õ¬ï¨ëµý¹ê¯f±w¬O¸£½¤ª¢¡A¦Ó¿ù¥¢¤F¨Ï¥Î§Ü¥Í¯À¨ÓªvÀø¸£½¤ª¢ªº«´¾÷¡^¡C

¡@¡@¦P®É¡A¤¤¬r¯f±w¤]±`¥H«D¨å«¬©Î«D¯S²§©Êªº¯g­Ô©ÎÃþ¦ü«D¤¤¬r¯f±wªº¯g­Ô¨Óªí²{¡]¨Ò¦pªÍ®ð¸~¯f±w¡A¦³©I§l§xÃøªº¯gª¬®É¡AÁ{§ÉÂå®v±`·|·Q¨ì¬OªÍ®ð¸~´c¤Æ¡A¦ÓÄ~Äò¨Ï¥ÎtheophyllineªvÀø¡FµM¦Ó¡Atheophylline¹L¶q¡A¦]¨ä¨ë¿E©I§l¤¤¼Ï¡A¤]·|Åý¯f±w¦³©I§l§xÃøÄ±±o³Ý¤£¹L®ð¨Óªº¯gª¬¡A¦ý³o¨âªÌªºªvÀø«o­è¦n¬Û¤Ï¡A¥²¶·´ú¦å¤¤¤§theophylline level¤~¥i¤À§O¡A¦]¦¹¡A¤@¯ë¹ï©óªÍ®ð¸~¯f±w¦³©I§l§xÃøªº¯gª¬®É¡A¦pªÍ³¡Å¥¤£¨ìwheezing(³Ý»ï­µ)®É¡A´NÀ³¦Ò¼{´ú¦å¤¤¤§theophylline¡A¨Ó¨M©wªvÀøªº¤è¦V¡^¡C2¨ä¥L¦p¯f±w¦³¸z­G¹D¯gª¬¦päú¤ß¡B¹Ã¦R¡B­¹¼¤¤£®¶µ¥®É¡A°£¤F«D¤¤¬rªº¯e¯f¥~¡A³\¦h¤¤¬r¦p¤@®ñ¤ÆºÒ¡Btheophylline¡Bdilantin¡Bdigitalis¡Bacetaminophen¡Bsalicylateµ¥¤]³£·|²£¥Í³o¨Ç¸z­G¹D¯gª¬¡A¦]¦¹¡A¦b­±¹ï³o¨Ç¦³¸z­G¹D¯gª¬ªº¯f¤H¡A³£À³¥J²Ó¸ß°Ý¯f¥v¨Ã¬d¬Ý¯f¾ú¡A¥H¤F¸Ñ¬O§_¦³ÃĪ«¹L¶q©Î¤¤¬rªº¥i¯à¡C¹ï©ó©âÝzªº¯f±w¡AÁ{§ÉÂå®v°£¤F­n¦Ò¼{¸£³¡¤Î¥NÁ¤譱ªº°ÝÃD¥~¡A¤]À³¦Ò¼{¦pÀÀ¥æ·P¯«¸g©Î°sºëµ¥¤¤¼Ï¯«¸g¿³¾Ä¾¯¡B¤¤¼Ï¯«¸g§í¨î¾¯¤§§ÙÂ_¯g­Ô¸s¡Btheophylline¡Bdilantin(Åöíw¯f±wdilantin¤£¨¬©Î¹L¶q³£¥i¯à·|©âÝz) ¡B­«ª÷ÄÝ¡]¦p¹]¤¤¬r¡^¡B¤TÀô§Ü§íÆ{¾¯¡B§Üµ²®ÖµßÃĪ«¡]¦pIsoniazid¡^¤Î°ê¤º¬°¼Æ¤£¤Öªº¼Ì¸£ªoµ¥¤¤¬r¡C¹ï©ó¨x¥\¯à²§±`ªº¯f±w°£·Q¨ì¯f¬r©Ê¨xª¢µ¥¥i¯à©Ê¥~¡A³\¦hÃĪ«¦pAcetaminophenµ¥¤]À³¦C¤J¦Ò¼{¡C¦]¦¹¡A«æ¶E¤u§@¦P¤¯¡A¦b­±¹ï«æ¶E¯f¤H®É¡A¹ï©ó¯f¤Hªº¯gª¬¡A³£À³±N«ä¸ô©ñ¼s¨Ç¡A¦P®É¦Ò¼{¯f±w¬O¤¤¬r©Î«D¤¤¬rªº¥i¯à©Ê¡A¤~¤£·|¿ù¥¢ªvÀøªº«´¾÷¡C3

¡@¡@«æ¶E¤u§@¦P¤¯¡A¦b­±¹ï«æ¶E¯f¤H®É¡A°£À³¥J²Ó¸ß°Ý¯f¥v¥~¹ï©ó¯f¥v¤£²Mªº¯f±w¥iºî¦X¯f¤H©Ò²£¥Íªº¤@¨Ç¯S®íªº¯g­Ô¸s¡A§Y©Ò¿×ªº¤¤¬r¯g­Ô¸s(Toxidrome)¡A§@¬°Å²§O¶EÂ_ªº°Ñ¦Ò¡A¥H«K¤Î¦­§ä¥X¯f±w¤¤¬rªº­ì¦]¨Ã±o¨ì¦³®ÄªºªvÀø¡C«æ¶E±`¨£ªº¤¤¬r¯g­Ô¸s¦p¤U3,4,5¡G

1. ÀÀ¥æ·P¯«¸g¯g­Ô¸s(Sympathomimetic syndromes)

a)±`¨£¯g­Ô:¦k·Q(delusions)¡B¤ß¸õ¥[³t(¦p¬°³æ¯Â£\-agonist«h¬O¤ß¸õ´îºC)¡B¦åÀ£¤É°ª¡BÅé·Å¤É°ª¡B¥X¦½¡B³±²ô«k°_¡BÀû¤Õ©ñ¤j¡B¤Ï®g¥[±j(hyperreflexia) µ¥¡CÄY­«¯f±w«h¥i²£¥Í©âÝz¡B§C¦åÀ£¡B¤ß«ß¤£¾ãµ¥¡C

b)±`¨£¤¤¬r­ì¦]:¦w«D¥L©R(Amphetamine)¥Ò°ò¦w«D¥L©R(Methamphetamine) ¥j¬_ÆP(Cocaine)»ó¶ëÃÄ(¦pPhenylpropanolamine, ephedrine, ¤ÎPseudoephedrine)µ¥¡C¦b©@°Ø¦](Caffeine)©ÎTheophylline¹L¶q®É¤]¦³Ãþ¦üªº¯g­Ô¡C

2. §Ü¤AñQÁxÆP¯g­Ô¸s(Anticholinergic syndromes)

a) ±`¨£¯g­Ô:¤¦k(delirium)¡B¤f¾¦¤£²M¡B¤ß¸õ¥[³t¡B¥Ö½§°®Àê¡B¥Ö½§ªx¬õ¡BÀû¤Õ©ñ¤j¡B¦Ù°}ÅË(myoclonus) ¡BÅé·Å·L¤É¡B¤p«K¶J¯d(urinary retention) ¡B¸zį°Ê­µ´î§Cµ¥¡CÄY­«¯f±w«h¥i²£¥Í©âÝz¡B¤ß«ß¤£¾ã¡C

b) ±`¨£¤¤¬r­ì¦]: §Ü²Õ´Ói(Antihistamine)¡B§Ü¤Úª÷´ËÃÄ¡BAtropine¡B´²Àû¾¯¡B§Üºë¯«¯fÃÄ(Antipsychotic agents)¡B§Ü¼~Æ{¾¯¡B¸Ñµj¾¯(Antispasmodic agents)¡BScopalamine¡B´Óª«(¦p¤jªá°ÒªûÅÚ)µ¥¡C

3. ¤AñQÁxÆP¯g­Ô¸s(Cholinergic syndromes)

a) ±`¨£¯g­Ô:·NÃѲV¶Ã¡B¤¤¼Ï¯«¸g§í¨î¡Bµê®z¡B¬y²C¡B¬y²\¡B¤p«K¥¢¸T¡B¤j«K¥¢¸T¡B¹Ã¦R¡B¸¡³¡µ±µh¡B¥X¦½¡B¦Ù¦×ÅÖºûŸ°Ê(muscle fasiculations) ¡BªÍ¤ô¸~¡BÀû¤ÕÁY¤p¡B¤ß¸õ´îºC©Î¥[³t¡B©âÝzµ¥¡C

b) ±`¨£¤¤¬r­ì¦]:¦³¾÷ÁC(Organophosphate)©Î®ò°ò¥Ò»ÄÆQ(Carbamate)µ¥±þÂξ¯¡BPhysostigmine¡BEdrophonium¡B¤Î¤@¨Ç¬rÛ£µ¥¡C

4. ¾~¤ùÃþ¡]Opiate¡^¡BÂíÀR¾¯(Sedative) ¡B©Î°sºë¤¤¬r

a) ±`¨£¯g­Ô:©ü°g¡B©I§l§í¨î¡Bµê®z¡B¬y²C¡BÀû¤ÕÁY¤p¡B¤ß¸õ´îºC¡B§CÅé·Å¡BªÍ¤ô¸~¡B¸zį°Ê­µ´î§C¤Ï®g´î§C(Hyporeflexia)¨­¤W¦³°w¤Õµ¥¡C

b) ±`¨£¤¤¬r­ì¦]: ³Â¾K¾¯Ãþ¡]Narcotics¡^¡BÂíÀR¾¯Ãþ¡A¥]¬A¤Ú¤ñ§´ÆQÃþ¡]Barbiturates¡^¡A¦p¬õ¤¤(Seconal)¡B«Cµo(Amytal¡^¡B¥ÕªO(Methaqualone)¡B­f­«´á°òÆQ(Benzodiazepines)¡e¦pÓþªY(Halcion) ¡BFM2(Rohypnol)µ¥¦w¯vÃÄ¡f¡B°sºë¡BMeprobamate¡BClonidineµ¥¡C

¡@

¹ï©ó¯f±wªº¥Í©R¼x­Ô¦p¦åÀ£¡B¯ß·i¡A¤]¥i¥H´£¨ÑÁ{§ÉÂå®v§@¬°Å²§O¶EÂ_ªº°Ñ¦Ò¡A¨ä¦UºØ±`¨£ªº­ì¦]¦p(ªí¤@)3,4,5,6,7,8:

ªí¤@¡B¦åÀ£¡B¯ß·i¤Î¥i¯à¯fªp

¦åÀ£¤Î¯ß·i

¥i¯à¯fªp

°ª¦åÀ£¤Î¤ß¸õ¥[³t

Anticholinergic agents, Sympathomimetics¦pAmphetamine¡BNicotine¡Bphenocyclidineµ¥¤¤¬r¡A Sedative©ÎNarcotic§ÙÂ_¯g­Ô¡BPheochromocytoma

°ª¦åÀ£¤Î¤ß¸õ´îºC

£\-adrenergic agents¦pPhenylpropapanolamine¤¤¬r¡A¸£À£¤W¤É(Cushing s response)

§C¦åÀ£¤Î¤ß¸õ¥[³t

Cyclic antidepressant¡B Theophylline¡BVasodilators¦pNitritesµ¥¤¤¬r¡A ¥ð§J¡B¯Ê®ñ,

§C¦åÀ£¤Î¤ß¸õ´îºC

Cholinergic agents¡A £]-blockers¡B Calcium antagonists¡BDigitalisµ¥¤¤¬r¡A¤ßŦ¥»¨­ªº¶Ç¾É²§±`

¡@

¤¤¬rªº¤@¯ë³B²z­ì«h3,5,7,9,10

1.¥ý¤F¸Ñ²{³õª¬ªp¬O§_¦w¥þ¡AÁ×§K¥»¨­¤]³Q¦Ã¬V¦Ó¤¤¬r¡C¦p¦b¤Æ¾Ç¤u¼t¡B¹êÅç

«Ç¡B²¸ÁD¦À©Î¦Ã¤ô¦À¡Aµo²{­ì¥»°·±dªº¤H­Ë¦a®É¡A§YÀ³ÄµÄ±¡A¬O§_¦³¦MÀIª«

½è¦s¦bªº¥i¯à¡C

2.¦p®É¶¡³\¥i¡AÀ³½Ð®Ç¤H¨ó§U©Î½Ð¨D¤ä´©¡C

3.í©w¥Í©R¼x¶H¡]§l¤J©Ê¬rª«À³µ¹¤©®ñ®ð¡^¡A¾¨³t°eÂå¡C

4.½T©w¬rª«ªº©Ê½è(¨ú±o¤¤¬rªº¯f¥v¤Î²{³õ¯d¤Uªº½u¯Á¦pªÅ²~¤l)

5.¥i¥H¥H¤U¤èªk´î¤Ö¬rª«§l¦¬¡G

a. ±N¯f±w·hÂ÷¦Ã¬V¡G¨¾¤î¬rª«Ä~Äò¶Ë®`¯f±w(¦p¤@®ñ¤ÆºÒ¤¤¬r)¡C

b. ²æ°£¦Ã¬V¦çª«¡G¨¾¤î¥Ö½§Ä~Äò§l¦¬¬rª«(¦p¦³¾÷ÁC¡B¼Ì¸£ªo¡B©Î²B¬t»Äµ¥)¡C

c. ¨R¬~¦Ã¬V³¡¦ì¡G²´·ú¡B¥Ö½§¡BÂH½¤¨ü«I¥Ç¡AÀ³¥ß§Y¥H²M¤ô¨R¬~¦Ü¤Ö15-30

¤ÀÄÁ¡^¡C

    1. ¥H¥ª°¼½ö¹B°e¡G¥ª°¼½ö¸û¨ä¥L¦UºØ«º¶Õ¹B°e¡A¦Ü¤Ö¦b§]ªA¬rª««e2¤p®É¡A¯à¦³®Ä´î½w¬rª«§l¦¬(¨ä­ì¦]¥Ø«e»{¬°¥D­n¬O¦]´î½w¬rª«¸g¥Ñ«Õªù¶i¤J¤p¸z)¡A¥Ø«e¤w³Qµø¬°¹B°e¤¤¬r¯f±wªº¼Ð·Ç«º¶Õ¡C
    2. ¶Ê¦R¡G¤fªAÃĪ«¤¤¬r¡A¦pµL¸T§Ò¡A¹ï©ó¥i¯à²£¥ÍÄY­«¤¤¬rªº¬rª«¡AÀ³¦b¤fªA30-60¤ÀÄÁ¤º¡A¤©¥H¶Ê¦R¡A¨ä¤èªk¦p(ªí¤G)¡C11¡]¥i¥ý»P¬rÃĪ«¿Ô¸ß¤¤¤ßÁpµ¸¡^¡C
    3. ¬~­G: ¹ï©ó¤fªAÃĪ«¤¤¬r¡A¦pµL¸T§Ò(¦p±j»Ä±jÆP¤¤¬r)¡A­ì«h¤W¥i¤©¥H¬~­G¡A¦ýÀ³ª`·N«OÅ@©I§l¹DºZ³q¡]Åý¯f±w¥H¥ª°¼½ö«º¶Õ©Î©ñ¸m®ðºÞ´¡ºÞ¡^¡C³q±`¬~­G©ó¤@¤p®É¤º¬I¦æ¤~¸û¦³®Ä¡C¹ï©óÁû²Éª¬ªºÃĤù¡AÀ³©ñ¸m¤f­GºÞ(Orogastric tube, OG tube) ¡A¤~¯à¦³®Ä¦a²M°£­G¤º¬rª«¡C
    4. µ¹¤©¬¡©ÊºÒ¡G§lªþ¬rª«¡A´î¤Ö¬r¯À§l¦¬¡C¬ã¨sÅã¥Ü¡A¶Ê¦R¤Î¬~­G¥u¥i´î¤Ö30%¬r¯À§l¦¬¡A¦Ó³æ¿Wµ¹¤©¬¡©ÊºÒ§Y¥i´î¤Ö50%¬r¯À§l¦¬¡C¨äªì´Á¾¯¶q¬°¨C¤½¤çÅé­«1¤½§J¡C¥Ñ©ó¬¡©ÊºÒ¹ï¤U¦C¬rª«§lªþ¤£¨}©Î¹ïªvÀø¦³§«Ãª¡A¬G¤£À³¨Ï¥Î¡A1)ª÷Äݤ¸¯À¦p¾YÆQ¡BÅK¾¯©Î­«ª÷Äݦp¹]µ¥¡F2)¾JÃþ¦p¥Ò¾J¡B¤A¾J¡F3) ¥Ûªo»s«~:¦pºÒ²B¤Æ¦Xª«¤Î¦³¾÷·»¾¯¡F4)Ùæ¤Æª«¡F5)»Ä¡BÆP(¨ä¦P®É¤]·|¼vÅT­GÃ誺Àˬd)¡C
    5. µ¹¤©Âm¾¯:¦psorbital¡A¥i´î¤Ö¬rª«¦b¸z­G¹D°±¯dªº®É¶¡¡A»P¬¡©ÊºÒ¤@°_¥Î¥i¨Ï¨ý¹DÅܲ¢¨Ç¡A¹ï©óªA¥Î»G»k©Êª«½è¡B¤w¦³ÄY­«¸¡Âm¡B¸zªý¶ë¡Bªñ´Á¦³¸¡³¡¤â³NªÌµ¥¡B«h¤£¾A¦X¨Ï¥Î¡C¨ä¨Ï¥Î¾¯¶q¬°0.5-1 gm/kg¡C

¡@

6.¨Ï¥Î¸Ñ¬r¾¯¡G¦p¨Ï¥Î®ñ®ðªvÀø¤@®ñ¤ÆºÒ¤¤¬rªº¯f±w¡CÁöµM¤j¦h¼Æªº

¨Ï¥Î¡A½T±`¥i¦¬¨ì¨}¦nªº®ÄªG¡A¦ý¤´¤£­n©¿²¤¤F°ò¥»ªº¤ä«ù©ÊÀøªk¡C«æ¶E

±`¥Î¸Ñ¬r¾¯¤Î¨ä¥Îªk¦p(ªí¤T) 3,4,5,7

  1. ¥[³t¬rª«±Æ°£¡G¦pµ¹¤©¥þ¸zÄé¬~¡B¥[³t§Q§¿¡B§¿²GÆP¤Æ¡]¥i¥[³tsalicylate¤Îbarbiturateªº±Æ°£¡^¡B¸¡½¤³zªR©Î¦å²G³zªRµ¥¡C
  2. ±±¨î¦X¨Ö¯g: ¦p¯f±w©âÝz¡A«h¥ý¥H§Ü©âÝz¤è¦¡³B²z¡C
  3. ¥Ñ©ó¬rª«ºØÃþ²³¦h¡AÁ{§ÉÂå®v¤£¥i¯à¹ï¨C¤@ºØ¤¤¬rªº³B¸m³£«Ü¼ô±x¡A¦p¹J¨ì¦³ÃhºÃªº¯g­Ô©Î¤£¼ô±x¤§¤¤¬r¡A¥iÀH®É¥´¹q¸Ü¦Ü¥x¥_ºa¥ÁÁ`Âå°|º[¦æ¬F°|½Ã¥Í¸pÁ{§É¬rÃĪ«¨¾ªv¿Ô¸ß¤¤¤ß¡A³o¸Ì¬O¥þ¦~µL¥ð¡A¨Ã´£¨Ñ24¤p®Éªº¿Ô¸ßªA°È¡C¨ä24¤p®É±M½uªA°È¹q¸Ü¬°¡G (02) 28717121¡C¦¹¥~¡A¥Ø«e¬rÃĪ«¨¾ªv¿Ô¸ß¤¤¤ß¤w«Ø¥ß¤F¤@®M¦Û°Ê¶Ç¯u¦^ÂШt²Î¡A¥i¨Ñ¯Á¨ú¤¤¤åªº¦hºØ¬rª«¸ê°T¡A¨ä±M½u¶Ç¯u¹q¸Ü¬O: (02)28742929¡A¤]¥iµ½¥[§Q¥Î¡C

¥i¯à¦³¤Æ¾Ç¦Ã¬Vªº²{³õ

³B²z¤¤¬r¯f±w¡A²Ä¤@¥ó¤]¬O³Ì­«­nªº¤@¥ó¨Æ¡A´N¬O«OÅ@¬I±ÏªÌªº¦w¥þ¡A¦pµo²{²{³õ©Î¯f±w¦³¥H¤U²{¶H¡AÀ³ÃhºÃ¦³¤Æ¾Ç¦Ã¬Vªº¥i¯à¡A¬I±ÏªÌÀ³¯S§Oª`·N¦Û¨­ªº¦w¥þ(À³µÛ«OÅ@©Ê¦çª«©Î¸Ë¸m¡A¨Ã¦Ò¼{½Ð¨D¤Æ¾Çª«½è¤§Å²©w)¡A¥H§K¦Û¤v¤]¦¨¬°¯f±w¡G14

1. ¤u·~·N¥~ (¤×¨ä¬O¤Æ¾Ç¤u¼t): Ãz¬µ¡B¥¢¤õ¡BºÞ½u¯}µõ¡B¥~¬ª¡C

2. ¹B¿é·N¥~:­¸¾÷¡B¤õ¨®¡B¥d¨®¡B¨T¨®¡B²î¡C(®Ú¾Ú¬ü°ê°w¹ï1993¦Ü1996¦~ªº¦MÀIª««~·N¥~¨Æ¥óªº³ø§iÅã¥Ü¡A¦MÀIª««~·N¥~¨Æ¥óµo¥Í¦b¹B¿é³~¤¤¡A´X¥G»Pµo¥Í¦b¤u§@³õ©Ò¤@¼Ë¦h)¡C

3. ²{³õ¦³¥H¤U²{¶H:»]®ð¶³¡B¦º¤`°Êª«©Î³½¡B¦h¦ì¯f±w¦³¦P¼Ëªº¥D­z©Î¯gª¬¡B©Î±q¤@±K³¬ªÅ¶¡±Ï¥X¡C

4. ¦pµo²{¯f±w¦³:·NÃѤ£²M¡BµLªk¸ÑÄÀ¤§¤ßŦ°±¤î¡B¨­Åé©Î¦çªA¤W¦³±j¯Pªº®ð¨ý¡B¨­Åé©Î¦çªA¤W¦³¥¼Å²©wªº²GÅé©Î¯»¥½¡B¦³¤Æ¾Ç¨`¶Ëªº²{¶H¡B¦³¯«¸g¯g­Ô(¦p³Â¤ì¡BµL¤O©Î©âÝz)¡B¦³Åܩʦå¬õ¯À²{¶H(¦pµoÖæ)¡B¦³¥Ö½§¡B²´¡BÂH½¤©Î©I§l¹D¨ë¿Eªº²{¶H¡C

¡@

ªí¤G¡B¶Ê¦Rªº¤èªk¡G¦pµL¸T§Ò¡A¦b30-60¤ÀÄÁ¤º§]ªA¬rª«¡A¥i¥H¤U¦C¤èªk¶Ê¦R11 ¡G

¦~ÄÖ

¦R®Ú¿}¼ß

¥[¤ô

6-12¤ë

5-10ml

15 ml /kg

1-12 ·³

15 ml

240 ml

12·³¥H¤W

30 ml

240-480 ml

¡@¡@¬ù90%ªº¯f¤H·|¦b30¤ÀÄÁ¤º¹Ã¦R¡A¤d¸U¤£¥i¦]µ¥¹Ã¦R¦Ó©µ»~°eÂå¡CªA¥Î¦R®Ú¿}¼ß«á¡A¥iÅý¯f±w§¤°_©Î°¼ª×¡A¤Å¥õª×ºÎ¡A¥H¨¾¤î§l¤J¹Ã¦Rª«¡C°±¹Ã¦R«á¡A¥iµ¹¤©¬¡©ÊºÒ¡A¥H´î¤Ö¬r¯À§l¦¬¡C

¡@

¶Ê¦Rªº¸T§Ò¡G

1. ¯«´¼¤£²M¡B©ü°g¯f±w¡A©ÎªA¥Îµu´Á¤º§Y©ö©ü°gªºÃĪ«¡]¦pÙæ¤Æª«¡B¾~¤ùÃþ¡B°sºë¡B§Ü²Õ´Óiµ¥¡^¡C

2. ¯f±w©âÝz¡A©Î¦³¨³³tµo¥Í©âÝzªº¥i¯à¡A¦pªA¥Î©ö»¤µo©âÝzªºÃĪ«¡]¦p¼Ì¸£ªo¡B¤TÀô§Ü¼~Æ{¾¯µ¥¡^¡C

3. ªA¥Î±j»Ä¡B±jÆPµ¥»G»k¾¯¡]¦p²M¼ä¾¯¡^¡C

4. ªA¥Î¥Ûªo»s«~µ¥´§µo©Êª«½è¡C

5. §]­¹¦y¾Uª««~¡C

6. Ãh¥¥¥½´Áªº¥¥°ü¡C

7. ¤w©úÅã¦b¹Ã¦Rªº¯f¤H¡C

8.ªA¤JµL¬rªºÃĪ«¡C

¡@

ªí¤T¡B«æ¶E±`¥Î¸Ñ¬r¾¯¤Î¨ä¥Îªk3,4,5,7,12,13

¬rª«

¸Ñ¬r¾¯

¥Îªk

Opaites

Naloxone

ªì¾¯¶q2mg©Î0.01-0.03 mg/kg¡A¤ÏÀ³¤£¨}¯f±w¥iµ¹¦Ü10mg©Î0.1mg/kg¡C

Methanol, ethylene glycol

Ethanol

Loading dose:10%°sºë 10ml/kg *

maintenance dose:0.1ml/kg/hr

Anticholinergic agents

Physostigmine

1-2 mg IV 5¤ÀÄÁ¡C

Organophosphate or carbamate

Atropine

test dose 0.5-2 mg IV¡A¤§«á¥i¯à»Ý¦Aµ¹¤©¬Û·í¤j¶q¡Aª½¨ìªÍ¤Àªcª«Åܰ®¬°¤î¡C

Isniazid, hydrazine

Pyridoxine

ªì¾¯¶q5mg¡A «áµ¹¤©»P¬rª«¬Ûµ¥­«¶q¤§pyridoxine¡C

Beta blockers

Glucagon

ªì¾¯¶q5-10mg

ºû«ù¾¯¶q 2-5 mg/hr (0.07 mg/Kg)

Tricyclic antidepressants

Bicarbonate

ªì¾¯¶q1meq/kgºû«ù°Ê¯ß¦åPH­È7.45-7.55¡C

Digitalis, glycosides

Digoxin-specific antibody fragments

$µ¹¤©»P¬rª«¬Ûµ¥²ö¦Õ¼Æ¶qªºDigibind¡A©Î¥Hdigitalisªº²@§J¼Æ(mg)­¼¥H0.6§Y¬O©Ò»ÝDigibind ªºvial¼Æ(¨C¤@vialªºDigibind¥iµ²¦X 0.6mg¤§digitalis)¦b¦³¥Í©R¦MÀI¤§¤ß«ß¤£¾ã®É¥i¥ýµ¹¤©10-20 vials¡C

Calcium channel blockers,hydrofluoric acid, fluorides

Calcium

ªì¾¯¶q10% CaCl2 1gm (©Î 0.2ml/kg) IV 5¤ÀÄÁ¡AÄY­«¯f±w¥i­«ÂШϥΡA¨Ã¥H¤ß¹q¹ÏºÊµø¡C

Benzodiazepines

Flumazenil

0.2mg IV 30¬í¡F¦p30¬í«á¤´µL¤ÏÀ³¦Aµ¹0.3mg IV 30¬í¡F¦p30¬í«á¤´µL¤ÏÀ³¦Aµ¹0.5mg IV 30¬í¡A¤§«á¨C¤ÀÄÁµ¹¤©¥iµ¹¨ìÁ`¾¯¶q3mg¡C**

*°ê¥~¦³ÀR¯ßª`®gªº°sºë¡A°ê¤º¥Ø«e¨S¦³ÀR¯ßª`®gªº°sºë¡A¥i¥H¤fªA¥N¤§¡C¥xÆW¤½½æ§½°âªº¦Ì°s¡A°sºë¿@«×¬°20%¡A¦]¦¹¥i¥H5ml/kgªº¾¯¶q¤fªA§ë¤©¡C²Ð¿³°s°sºë¿@«×¬°16%¡A¦]¦¹¥i¥H¬ù¥H7ml/kgªº¾¯¶q§ë¤©¡C

**¦p¦³¤TÀô§Ü¼~Æ{¾¯¤¤¬rªºÄp­Ô¡A©Î¥ÎBenzodiazepines¨Ó±±¨î©âÝzªº¯f±w¡A«h¤£¥i¨Ï¥ÎFlumazenil¡C

¡@

¤@¡BÄá­¹©Ê¬rª«

¡@¡@®Ú¾Ú¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ßªº²Î­p¡A©Ò¦³µn¿ý¤¤¬r­Ó®×¤¤¡A¤´¥HÄá­¹³~®|¶i¤J¤HÅ骺­Ó®×³Ì¦h¡A¬ù¥e©Ò¦³µn¿ý­Ó®×ªº75%¡C¸û±`¨£ªº¤¤¬r¨Ì§Ç¥]¬A¹AÃÄ(¥]¬A°£¯ó¾¯¡B±þÂξ¯µ¥)¡B¤@¯ëÃĪ«(¥]¬A¦w¯vÃÄ¡B¦w«D¥L©R¤Î¨ä¥L¤¤¼Ï¯«¸g¥ÎÃĵ¥)¡B²M¼ä¾¯µ¥¡C1

¡@

¡@¡@°£¯ó¾¯¤¤¬r¡]¤Ú©Ô¤Â¡B¦~¦~¬K¡^15,16,17

¡@¡@®Ú¾Ú¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ßªº²Î­p¡A©Ò¦³µn¿ý¤¤¬r­Ó®×¤¤¡A¦º¤`²v³Ì°ªªÌ§Y¬°¤Ú©Ô¤Â(paraquat)¡A¤@¯ë¥«°âªº¤Ú©Ô¤Â¡A¤j¬ù¥u­n¦Y¤U5-10cc§Y¥i­P©R¡A¥Ñ©ó¤Ú©Ô¤Âªº°ª¦º¤`²v¡Aªñ¦~¨Ó¡A¦b¹A©e·|¤Î¬rÃĪ«¿Ô¸ß¤¤¤ßªº±Ð¨|±À¼s¤U¡A¥Ø«e¡A¤w¦³³\¦h¹A¤Í§ï¥Î¬r©Ê¸û§Cªº¦~¦~¬K(glyphosate)¡A¦P®É¡A³\¦h¹A·|¤w¤£¦A³c°â¤Ú©Ô¤Â¡CµM¦Ó¡A¦~¦~¬KÁö¦º¤`²v¸û¤Ú©Ô¤Â§C¡A¦ý¤]¦³ªñ10%ªº¦º¤`²v¡C

¡@¡@¤Ú©Ô¤Â(paraquat)¤¤¬r

¡@¡@¥xÆW±`¨£§t¤Ú©Ô¤Âªº²£«~: §J¿¾ÂÜ¡B³t¯ó²b¡B¥i¼ÖªQ¡B¥þ¯ó·À¡B«C¯ó·Àµ¥¡C

­P¬r¾÷Âà:±µ¨üNADP/NADPH¤§¹q¤l¡A±N¨ä¹q¤lÂऩ®ñ®ð(O2)¡A²£¥Í¶W®ñ°ò(superoxide, O2-)¡A¶W®ñ°ò·|µL¿ï¾Üªº¯}Ãa²Ó­M½¤¡A¤HÅéºû«ù¥Í©Rªº­«­n¾¹©x¦p¸£¡BªÍ¡B¨x¡BµÇµ¥¡A¥i¥ß§Y¨ü¨ì¼vÅT¡A³Ü¶W¹L¤@¤f¥H¤Wªº¯f±w¡A¦h¦b72¤p®É¤º¦]¦h¾¹©x°IºÜ¦Ó­P©R¡A³Ü¤@¤f¥H¤U©Î©µ¿ð­P©RªÌ¡A«h¦h¦]¶i¦æ©ÊªÍÅÖºû¤Æ¦Ó­P©R¡C

¥D­n¤¤¬r¯g­Ô: ¤Ú©Ô¤Â¤¤¬r¦­´Á³q±`·|²£¥Í¤fµÄ¿N¨`·P¡Bäú¤ß¡B¹Ã¦R¡B¸¡µh¡B¸¡Âm¡A¼Æ¤p®É«á·|²£¥Í¤fµÄ¡B³ï³¡¤Î¸z­G¹Dµoª¢¤Î¼ìºÅ¡A´X¤Ñ«á´N·|³y¦¨ªÍ¡B¨x¡BµÇÃa¦º¡A³Ì«á¦h¥b·|¦º©ó©I§l°IºÜ¡CµM¦Ó¡A¦p¦­´Á¨S¦³¯gª¬¡A¤´¤£¯à±Æ°£¤Ú©Ô¤Â¤¤¬rªº¥i¯à¡C

¶EÂ_:°£¦³»~ªA¤Ú©Ô¤Â¯f¥v¥~¡A­GºÞ¬~¥X¯óºñ¦âª«½è¡B¯f±w¦³¤fµÄ¼ìºÅ©Î¤£©ú­ì¦]ªºªÍ®û¼íµ¥¡A¬Ò¬O¤Ú©Ô¤Â¤¤¬rªº­«­n½u¯Á¡CµM½T©w¶EÂ_«h¶·ÀË´ú¦å¤Î§¿²G¤¤ªº¤Ú©Ô¤Â¿@«×¡A¦b«æ¶E«Ç¡A¥i¥H¨È²¸»Ä¶u¸ÕÅç(sodium dithionite test)¡A©w©Ê¤ÀªR§¿²G¤¤¬O§_¦³¤Ú©Ô¤Â¡A¥ß§Y¶EÂ_¥X¯f±w¬O§_¬°¤Ú©Ô¤Â¤¤¬r¡C

³B¸m:¥Ø«e¨Ã¨S¦³¯S®í¸Ñ¬r¾¯¡A¨ä²{³õªvÀø­ì«h¦p¤U¡G

1. í©w¥Í©R¼x¶H¡A¦p¯f±wµLÄY­«ªº©I§l§xÃø¡AÀ³Á×§Kµ¹¤©®ñ®ð¡]®ñ®ð·|¥[³t ªÍÅÖºû¤Æ¡A¤@¯ë¤Ú©Ô¤Â¤¤¬rªº¦­´Á¡A³q±`¬O¤£·|¥X²{©I§l§xÃøªº¯gª¬¡^¡C

2. °£¦Ã¤Î¨R¬~¦Ã¬V³¡¦ì¡G¥ß§Y²æ¥h¦Ã¬V¤§¦çª«¡A¦p±µÄ²¨ì²´·ú¡B¥Ö½§¡BÂH½¤¡AÀ³¥H²M¤ô¨R¬~15-30¤ÀÄÁ¡C

3. ¦pµL¸T§Ò¥i¤©¥H¶Ê¦R¡C

4. ¥i¥H¥Õ³³¤g¤ô¡B¨m¤g¤ô¡B©Î¬¡©ÊºÒÅý¯f±w³Ü¤U¡A¥H§lªþ¤Ú©Ô¤Â¨Ã­°§C¨ä¬r©Ê¡C

5. ¥H¥ª°¼½ö«º¶Õ¡A¾¨³t°eÂå¡C

¨ä«æ¶EªvÀø­ì«h¦p¤U:

1. í©w¥Í©R¼x¶H¡C

2. ´î¤Ö¬rª«§l¦¬: °£¦Ã(²æ¥h¦Ã¬V¤§¦çª«¤Î¨R¬~¦Ã¬V³¡¦ì)¡B ¬~­G¡Bµ¹¤©¥Õ³³¤g(Fuller s earth)¡B¨m¤g(Bentonite)©Î¬¡©ÊºÒ¡Bµ¹¤©Âm¾¯µ¥¡C

3. ¸Ñ¬r¾¯: µL¡A¥Ø«e¤´µL¦³®Ä¸Ñ¬r¾¯¡C

4. ¥[³t¬rª«±Æ°£¡G¥]¬A¦å²GÄéª`(hemoperfusion)¡B©Î³sÄò°ÊÀR¯ß¦å²G¹LÂo(continuous arteriovenous hemofiltration)µ¥ªvÀø¤è¦¡¡C

¡@

¡@¡@¦~¦~¬K¤¤¬r(glyphosate) ¡G15,16

¥xÆW±`¨£§t¦~¦~¬Kªº²£«~: ¦~¦~¬K¡B¦n§A¬K¡B¤é¤é¬K¡B¤é²£¬K¡B¦n§B¬Kµ¥¡C

­P¬r¾÷Âà:¥i¯à»P¨ä©Ò§t¤§ªí­±ÂX±i¾¯¦³Ãö¡A¦¹¥~¡A¦]¨ä¬°®z»Ä(PH 4.8)¡A¬G¤]¦³»G»k§@¥Î¡C

¥D­n¤¤¬r¯g­Ô: ¤@¯ë¦~¦~¬K¤¤¬rªº¦­´Á¯gª¬¥D­n¥]¬A¤fµÄ¿N¨`·P¡B³ïµh¡B¤fµÄ¼ìºÅ¡Bäú¤ß¡B¹Ã¦R¡B¸¡µh¡B¸¡Âmµ¥¸z­G¹D¯gª¬¡C«á´Á«h¥i¯à·|¥X²{©I§l§xÃø¡BµoÖæµ¥©I§l¹D¯gª¬¡C¤@¯ë¤fªA¦~¦~¬K¤¤¬r¡A¤fµÄ¡B³ïÄV¯kµh¯gª¬¡A¥i¦b´X¤ÀÄÁ«á§Y¥X²{¡A¦Ó¤Ú©Ô¤Â¤¤¬r³q±`¦b¤@¤Ñ¤§«á¤~·|¥X²{¡C©I§l¹Dªº¶Ë®`¤Î¦]¸¡Âm¦Ó¾É­P§C¦åÀ£¬O¨ä­P¦ºªº¥D­n­ì¦]¡C

¶EÂ_:¥D­n¾a¯f¥v¡A¦ý»Ý¤p¤ß»P¤Ú©Ô¤Â°µÅ²§O¶EÂ_¡C

³B¸m:

1. í©w¥Í©R¼x¶H: ¦pµ¹¤©®ñ®ð¡B¤Î¸É¥R¤ô¥÷¤Î¹q¸Ñ½è¡C

2. ´î¤Ö¬rª«§l¦¬: ¥i¤©¥H°£¦Ã¡C¤@¯ë¨Ã¤£«ØÄ³¶Ê¦R©Î¬~­G¡C¬¡©ÊºÒ¹ï¦~¦~¬K§lªþ¤£¨Î¡A¤£«ØÄ³¨Ï¥Î¡C¥Ñ¸¡Âm¦Ó¾É­P§C¦åÀ£¬O¨ä¥D­n­P¦º­ì¦]¤§¤@¡A¦]¦¹¦]Á×§K¨Ï¥ÎÂm¾¯¡C

3. ¸Ñ¬r¾¯: µL¡A¥Ø«e¨Ã¨S¦³¯S®í¸Ñ¬r¾¯¡C

4. ¥[³t¬rª«±Æ°£¡G¦b¦X¨ÖµÇ¥\¯à¤£¨}®É¡A¥i¦Ò¼{¨Ï¥Î¦å²G³zªRªvÀø¡C

¡@

¡@

±þÂξ¯(¦³¾÷ÁC¡B®ò°ò¥Ò»ÄÆQ) 7,9,16,17,18,19

¡@¡@¦³¾÷ÁC(organophosphate)¤Î®ò°ò¥Ò»ÄÆQ(carbamate)µ¥±þÂξ¯¡A¨ã¦³±j¯P¨ë¿E©Ê»[¯ä¨ý¡A®e©ö¥Ñ¸z­G¹D¡B¥Ö½§¡B²´·ú¡B©I§l¹D§l¦¬¡A³y¦¨§½³¡©Î¥þ¨­¤¤¬r¡A¤@¯ë¦Ó¨¥¡A®ò°ò¥Ò»ÄÆQ¤¤¬r©Ò²£¥Íªº¯gª¬¸û»´¡A¦³¾÷ÁC¤¤¬r©Ò²£¥Íªº¯gª¬¸ûÄY­«¡CµM¦]¨ä¦³¸Ñ¬r¾¯¡A¦p¯à¤Î¦­«æ±Ï±o©y¡A³\¦hªì´Á¯gª¬«ÜÄY­«ªº¯f±w¡A¤´«Ü¦³¥i¯à·|§¹¥þ±d´_¡C¦³¾÷ÁCÃþ±þÂξ¯ªº¨Ï¥Î«D±`¼sªx¡A¤@¯ë±þÂξ¯¤¤¡A°Ó«~¦W³Ì«á¤@­Ó¦r¦³­Ó ªQ ¦r¡A¦p¤Ú©ÔªQ¡B¬ü¤åªQ¡Bªâ±þªQµ¥¡A¦hÄݩ󦳾÷ÁCÃþ¹AÃÄ¡C

¡@¡@°£¤F±þÂξ¯¥~¡A¾Ôª§¤¤ªº¯«¸g¬r®ð¡A±`±`§Y¬O¦³¾÷ÁC¡F¤é¥»µÛ¦Wªº¦a¤UÅK ¨FªL¡¨¬r®ð¤¤¬r¨Æ¥ó¡A¨ä¤¤¨FªL¬r®ð§Y¬O¦³¾÷ÁC¡A¥i§Ö³t­P¤H©ó¦º¡C¦ô­p¦p±N¤C¤½¾·¨FªL¬r®ð¡A§ë´²¦b¤é¥»ªF¨Ê¤WªÅ¡A¸Ó¥«¶È»Ý¥|¤ÀÄÁ§Y¥i¦¨¬°¦º¥«¡A¥i¨£¨ä«Â¤O¤§±j¤j¡C¦]¦¹¬ü°ê¹ï¨¾½d®£©Æ¥÷¤lµo°Ê¨aÃø¨Æ¥ó¡A±`±N¦³¾÷ÁCªº¸Ñ¬r¾¯ªü¦«¥­(Atropine)¤ÎPAM(pralidoxime)ªº¦s¶q¡A¤j´T¼W¥[

¥xÆW±`¨£§t¦³¾÷ÁCªº²£«~: ¬ü¤åªQ¡Bªâ±þªQ¡B¤Ú©ÔªQ¡B¤j·ÀªQ¡B¹F°¨ªQ¡B¼³·ÀªQ¡B¬rµ·¥»¡B¨È¯ÀÆF¡B¥þ·À¹çµ¥¡C

­P¬r¾÷Âà:§í¨î¤AñQÁxÆP»Ã¯À¤§¤À¸Ñ¡B¦Ó²£¥Í«ùÄò¯«¸g¨ë¿E¤§¯g­Ô¡C¥Ñ©ó¨ë¿E°Æ¥æ·P¯«¸g¤§¸`«e¤Î¸`«á¯«¸g¦Ó²£¥Í¤AñQÁxÆP§@¥Î(Cholinergic effects)¡A¥Ñ©ó¨ë¿E¥æ·P¯«¸g¤§¸`«e¯«¸g¦Ó²£¥ÍµÒÆP¼Ë§@¥Î(Nicotinic effects)¡C

¥D­n¤¤¬r¯g­Ô:¦³¾÷ÁC¥i¸g¥Ñ©I§l¹D¡B¸z­G¹D¡B¥Ö½§µ¥§l¦¬¨Ï¤H¤¤¬r¡C¨ä¤¤¬r¯gª¬±`¦b¥b¤p®É§Y¥X²{¡A¦ý¤Ö¼Æ¯f±w¤´¥i©µ¿ð¦Ü¼Æ¤p®É¬Æ¦Ü24¤p®É«á¤~¥X²{¡C¤¤¬rªº¥D­n¯gª¬Â²³æ¥i¤À¬°¿¸¬r¼Ë(Muscarinic)¯g­Ô¡BµÒÆP¼Ë(Nicotinic) ¯g­Ô¡B¤Î¤¤¼Ï¯«¸g¯gª¬µ¥¤TÃþ¡A¿¸¬r¼Ë¯g­Ô¥D­n¬O¥H°Æ¥æ·P¯«¸g¯gª¬¨Óªí²{¡A¥i¥H­^¤åDUMBELSªº¤CºØ¯gª¬¨Óªí¥Ü¡A¥]¬A¸¡Âm(Diarrhea)¡B¤j«K¥¢¸T¡B§¿¥¢¸T(Urination)¡BÀû¤ÕÁY¤p(Miosis)¡B®ðºÞ¦¬ÁY(Bronchospasm)¡B¤ß¸õ´îºC(Bradycardia)¡B¹Ã¦R(Emesis)¡B¤Î²´²\¡B¤f¤ô¡B·ð²Gµ¥¤Àªcª«¼W¥[(Lacrimation, Salivation)µ¥¡CµÒÆP¼Ë¯g­Ô¥]¬A¦åÀ£¼W°ª¡B¤ß¸õ¥[§Ö¡BªÏÅéµL¤O¡B¤Î¦Ù¦×©âÝzµ¥¡C¤¤¼Ï¯«¸g¯gª¬«h¥]¬AÀYµh¡B¯t·w¡B¨BºA¤£Ã­¡B©âÝz¡B·NÃѲV¶Ã¡B©I¥s§í¨î©Î¤£³W«hµ¥¡CÄY­«®É³q±`·NÃÑ·|¤£²M¡A¤ß²v·|´îºC¡A¥Ñ©ó·ð²Gªº¤j¶q¼W¥[­P©I§l§xÃø¡A¨Ã¦X¨Ö©I§l¦Ù§í¨î¦Ó­P©I§l°IºÜ¡C¨ä¥D­n¦º¦]¡A¦h¦]©I§l°IºÜ¦Ó­P©R¡C

¶EÂ_:¥D­n¾a¯f¥v¤ÎÁ{§É¯gª¬¡C¦¹¥~¡A¦å¤¤¤AñQÁxÆP×Q¡A¤×¨ä¬O¬õ¦å²y¤ºªº¤AñQÁxÆP×Q(RBC cholinesterase)ªº´ú©w¡A¥i¤F¸Ñ¦³¾÷ÁC¤¤¬rªºÄY­«©Ê¤Î¨ä¹w«á¡C

³B¸m: ²{³õªvÀø­ì«h¦p¤U¡G

1.í©w¥Í©R¼x¶H

2.¨R¬~¦Ã¬V³¡¦ì¡A¨Ã°£¥h¨ü¦Ã¬Vªº¦çª«¡A¥HÁ×§K¦³¾÷ÁCÄ~Äò³Q§l¦¬¡C

3.±N¸Ë¹AÃĪº®e¾¹±a¦ÜÂå°|¡]¼ÐÅҤſò¸¨¡C¡^

4¦pµL¸T§Ò¥i¤©¥H¶Ê¦R¡A¨Ãµ¹¤©¬¡©ÊºÒ¡C

5.¥H¥ª°¼½ö«º¶Õ¡A¾¨³t°eÂå¡C¡]±ÏÅ@¨®¤WÀ³«O«ù³q­·¡A¥H§K±ÏÅ@¤H­û¥ç§l¤J ¹AÃijy¤¤¬r¡^

6.¦p¦³¥²­n¥iµ¹¤©ª`®g¸Ñ¬r¾¯ªü¦«¥­¡]¥ýµ¹¤©1 ²@§JÀRª`¡A¦p¦³¥²­n¥iÄ~Äò µ¹¦Ü¤Àªcª«´î¤Ö©ÎªÍÅo­µ®ø¥¢¬°¤î¡^¡C

¡@¡@«æ¶EªvÀø­ì«h:

1. í©w¥Í©R¼x¶H

2. µ¹®ñ¡A¥²­n®É¤©¥H´¡¤J®ðºÞ´¡ºÞ¡C

3. °£¥h¨ü¦Ã¬Vªº¦çª«¡A¨R¬~¨ü¦Ã¬V³¡¦ì¡A¥HÁ×§K¦³¾÷ÁCÄ~Äò³Q§l¦¬¡C¦Ã¬Vªº¦çª«¤Î²~Åø¡AÀ³¸Ë¤J¶ì½¦³U¨Ã±K«Ê¡A¥H¨¾¤îÂåÅ@¤H­û¦]§l¤J¹L¶qªº¦³¾÷ÁC¦Ó¤¤¬r¡C

4.¤©¥H¬~­G¡Aµ¹¤©¬¡©ÊºÒ¡C

5.µ¹¤©¸Ñ¬r¾¯Atropine(¥D­n°w¹ï¿¸¬r¼Ë¤Î¤¤¼Ï¯«¸g§@¥Î)¤ÎPAM(¥D­n°w¹ïµÒÆP¼Ë§@¥Î)ªvÀø¡C

¡@

Á{§É¤W¡A³q±`¥i²³æ®Ú¾ÚÁ{§É¯gª¬¡A±N¯f±w¤À¦¨¼ç¦b¡B»´«×¡B¤¤«×¤Î­««×¤¤¬r¡C

1. ¼ç¦b¤¤¬r:¯gª¬: µL

serum cholinesterase: ¤j©ó¥¿±`­È¤§50%¡C

ªvÀø: Æ[¹î¤»¤p®É¡C

  1. »´«×¤¤¬r: ¯gª¬:¯f±w¥i¦Û¦æ¨«¸ô¡CÁ{§É¯gª¬¥]¬A¯h­Â¡BÀY·w¡BÀYµh¡BªÏÅéµo

³Â¡B ´c¤ß¡B¹Ã¦R¡B«_¦½¡B¬y²\¡B¤f¤ô¹L¦h¡B©I§l¹D¤Àªcª«¹L¦h¡B¸¡

µh¡B¸¡Âmµ¥¡C

serum cholinesterase: ¬ù¬°¥¿±`­È¤§20%¦Ü50%¡C

ªvÀø: ¥ýµ¹¤©atropine 1 mg IV¤ÎPAM 1 gm IV¡C

3. ¤¤«×¤¤¬r: ¯gª¬: ¯f±wµLªk¦Û¦æ¨«¸ô¡A¦ý·NÃѲM¿ô¡CÁ{§É¯gª¬¥]¬A¥þ¨­µL¤O¡B¤f

¾¦¤£²M¡B¦Ù¦×ÅÖºûŸ°Ê¡BÀû¤ÕÁY¤p¡B¤ÎÃþ¦ü»´«×¤¤¬r¤§§ó­«¤§

¯gª¬¡C

serum cholinesterase: ¬ù¬°¥¿±`­È¤§10%¦Ü20%¡C

ªvÀø: ¨C15-30¤ÀÄÁµ¹¤©atropine 1-2 mg IVª½¦Üatropinization¤ÎPAM

1 gm IV¡C

4. ­««×¤¤¬r: ¯gª¬: ¯f±w·NÃѤ£²M¡CÁ{§É¯gª¬¥]¬AÀû¤Õ©úÅãÁY¤p¡B¦Ù¦×ÅÖºûŸ°Ê¡B

¦Ù¦×µL¤O©Ê³Â·ô¡BªÍÅo­µ¡B©I§l§xÃø¡BµoÖæµ¥¡C

serum cholinesterase: ¤p©ó¥¿±`­È¤§10%¡C

ªvÀø:¨C15-30¤ÀÄÁ¥iµ¹¤©atropine 5 mg IVª½¦Üatropinization¤ÎPAM

1-2 gm IV¡C¦pµL©úÅã§ïµ½¥i¨C¤p®Éµ¹¤©PAM 0.5 gm IV¡C

¡@

Á{§É¤WatropineªvÀøªº³Ì­«­n«ü¼Ð¬O¨ÏªÍ¤Àªcª«Åܰ®¡A¦ÓÀû¤Õªº¤j¤p¤Î¤ß¸õªº§ÖºC«h¶È¨Ñ°Ñ¦Ò¡A¦Ó¤£¬O¥D­n«ü¼Ð¡C®Ú¾Ú³ø§iÅã¥Ü¡A¦³¾÷ÁC¤¤¬rªvÀø¥¢±Ñ³Ì¥D­nªº­ì¦]¡A§Y¬OµLªk¤Î®Éµ¹¤©¨¬¶qªºatropine¡A¹ï©óÄY­«¦³¾÷ÁC¤¤¬r¡A¬Æ¦Ü¥i±N¥þ°|ªºatropine³£¥Î¥ú¡A¨ä­«­n©Ê¥i¨£¤@¯ë¡C

¡@

§]ªA»Ä¡BÆP¤Î»G»k©Êª«½è7,9,20,21

±`¨£ªº±j»Ä¡B±jÆP²£«~: ±j»Ä¤Î±jÆP¬°®a®x¤¤±`¥Îªº®ø¬r²M¼ä¾¯¡A¦p²M²z¤ôºÞ©Î²M²z°¨±íµ¥²M¼ä¾¯¡C±j»Ä¥]¬AÆQ»Ä(HCl)¡B²¸»Ä(H2SO4)¡Bµv»Ä(HNO3)¡B¤Î°ª¿@«×¤§²B¬t»Ä(HF)µ¥¡C±jÆP«h¥]¬A²B®ñ¤Æ¶u(NaOH)¡B²B®ñ¤Æ¹[(KOH)¡B°¾ª¿»Ä¶u(Na2SiO3)¡B­«»Ì»Ä»Ï(¡£NH4¡¤2Cr2O7)¤Î°ª¿@«×¤§®ò(NH3) µ¥¡C

­P¬r¾÷Âà:²Õ´«æ©Ê¼ÉÅS±jÆP¡A¥i²£¥Í²G¤Æ©ÊÃa¦º(Liquefaction necrosis)¡A¯}Ãa¦åºÞ¡B²Ó­M¡B¥Ö¤U²Õ´¡A¾É­P²`³¡ªº²Õ´¯}Ãa¡C²Õ´«æ©Ê¼ÉÅS±j»Ä¡A«h²£¥Í¾®µ²©ÊÃa¦º(Coagulation necrosis)¡C¤@¯ë¥u­n30%´X²@¤Éªº±jÆP¡A§Y¥i©ó1¬í¤º(22.5%ªº±jÆP¬ù»Ý10¬í)³y¦¨ÄY­«ªº¸z­G¹D¶Ë®`¡A¨ä¤¤¤×¥H­¹¹Dªº¶Ë®`³Ì¬°ÄY­«¡C

¥D­n¤¤¬r¯g­Ô: ±jÆP¡B±j»Ä¤¤¬r©Ò²£¥Íªº¯gª¬¤Î¦X¨Ö¯g¤@¯ë«D±`Ãþ¦ü¡A¦ý¤@¯ë¦b¬Û¦P¿@«×¤U¡A±jÆP¸û±j»Ä§ó®e©ö«I®`²Õ´ªº²`³¡¡A²£¥Í§óÄY­«ªº¶Ë®`¡C©TºA±jÆP¥i³y¦¨¤fµÄ¯kµh¡A¦ý¤@¯ë¸û¤Ö¶Ë¤Î­¹¹D¤UºÝ©Î­G³¡¡C²GºA±jÆP¦]µL¦âµL­G¡A¸û©ö§]­¹¡A±`¾É­P¸ûÄY­«¤§¶Ë®`¡A¦p¤fµÄ¼ìºÅ¡B¸~µÈ¡B§]Ã`§xÃø¡B¦R¦å¡B¯Ý³¡¯kµh¡B¹Ã¦R¡B¸¡µh¡B¸z­G¹D¥X¦å¡B©I§l§xÃø¡B¥Ö½§¨`¶Ë¡B¨¤½¤©Îµ²½¤µoª¢¡B¼ìºÅ¡B©Îµo¿Nµ¥¡C¨ä¤¤¤fµÄ¼ìºÅ¨Ã¤£¯à§@¬°¤¤¬rÄY­««×ªº«ü¼Ð¡A¦]¬°10-30%ªº­¹¹D¨`¶Ë¯f±w¡A¨ÃµL¤fµÄ¼ìºÅ¡F¦Óµo¥Í¤fµÄ¼ìºÅªº¯f±w¡A¬ù¥u¦³33%¦X¨Ö­¹¹D¨`¶Ë¡C¦]¦¹¡Aµ´¤£¥i¦]¯f±w¨S¦³¤fµÄ¼ìºÅ¡A¦Ó±¼¥H»´¤ß¡C

¡@¡@±j»Ä¤¤¬r¦]¤J¤f¯kµh¡A±`·|»¤µo¦Ûµo©Ê¹Ã¦R¡A³q±`¤£·VªA­¹ªÌ¡A§]­¹¶q¨Ã¤£¦h¡A¦ý¦Û±þªÌ¤´¥i¯àªA­¹¤j¶q±j»Ä¡C±j»Ä¹ï¸z­G¹Dªº¶Ë®`¡A¤@¯ë¥H­G¬°¥D¡A¯S§O¬O»·ºÝªº­G³¡¤Î­GÄu¡A¦Ó±jÆPªº¶Ë®`«h¥H­¹¹D¬°¥D¡C

¶EÂ_: ¥D­n¾a¯f¥v¤ÎÁ{§É¯gª¬¡C¦¹¥~¡A¥i´ú¶q¼ÉÅSª«ªº»ÄÆP«×¡A¤Î¥H¤W¸z­G¹D¤ºµøÃè¬Ý¸z­G¹D¶Ë®`ªº±¡§Î¨Ó§@§PÂ_¡C

³B¸m:²{³õªvÀø­ì«h¦p¤U¡G

1.í©w¥Í©R¼x¶H¡C

2.¨R¬~¦Ã¬V³¡¦ì¡A¦p²´·ú©Î¥Ö½§¼ÉÅS¡AÀ³¦Ü¤Ö¨R¤ô20-30¤ÀÄÁ¡C

3.¥i¥H120-240cc²M¤ô©Î¤û¥¤µ}ÄÀ¡]¨àµ£¨C¤½¤ç¤Å¶W¹L15cc¡^

4.µ´¤£¥i¶Ê¦R©Î¤¤©M¡]¥H§K³y¦¨¤G¦¸¶Ë®`¡^

5.¾¨³t°eÂå¡C

«æ¶EªvÀø­ì«h:

1. í©w¥Í©R¼x¶H¡C

2. µ¹®ñ¡A¥²­n®É¤©¥H´¡¤J®ðºÞ´¡ºÞ¡C

3. ¤£¥i¤¤©M©Îµ¹¤©¬¡©ÊºÒ¡CÁöµM­GºÞ´¡¤J¤Î¬~­G¤´¦³ª§Ä³¡A¦ý¤@¯ë¤´¤£«ØÄ³¬I¤©­GºÞ´¡¤J¤Î¬~­G¡C

4. ¦b¤W¸z­G¹D¤ºµøÃèÀˬd¡A±Æ°£¤W¸z­G¹D¶Ë®`«e¡AÀ³¸T¤î¶i­¹¡C

5. À³ª`·N¸É¥R²GÅé¤Î¹q¸Ñ½è¡C

6. ¥Ø«e«ØÄ³¹ï©Ò¦³­¹¤J±j»Ä±jÆPªº¯f±w¡A³£¦Ò¼{¦b12¦Ü24¤p®É¤º¡A¬I¦æ¤W¸z­G¹D¤ºµøÃèÀˬd¡A¥H¨M©w«áÄò¤§³B¸m¡C(¦p¶W¹L48¤p®É¡A¨ü¶Ëªº¸z¾À·|¤ñ¸û¯Ü®z¡A¸û©ö¬ï¤Õ¡A¦]¦¹¤@¯ë¸û¤£«ØÄ³¦¹®É°µ¤W¸z­G¹D¤ºµøÃèÀˬd¡C)

¡@

²B¬t»Ä¤¤¬r22

²B¬t»Ä(Hydrofluoric acid, HF)¡A¼sªx¥Î©ó¬Á¼þ»k¨è¡B°£ùסB¥Ûªoºë·Ò¡B»s­²¡B¬~¬Vµ¥¤u·~¤Î®a®x¤¤¡A¦Û±q¥b¾ÉÅé¤u·~¶}©l¶q²£¥H¨Ó¡A¤w¦¨¬°¥b¾ÉÅé¤u·~³Ì­«­n¤§¬r©Êª«½è¡C®Ú¾Ú¬ü°ê¬rÃĪ«¤¤¤ßÁp¦X©e­û·|(AAPCC, American Association of Poison Control Center)ªº³ø§iÅã¥Ü¡A²B¬t»Ä¤¤¬rªº­Ó®×¥Ñ1984¦~ªº661¨Ò¡A§Ö³t¼W¥[¦Ü1996¦~ªº2940¨Ò¡C23,24ªñ¦~¨Ó¡A¥xÆW¥b¾ÉÅé²£·~ªº²£­È§Ö³t¦¨ªø¡A®Ú¾Ú¥x¥_ºaÁ`¬rª«¤¤¤ßªº²Î­p¡A°ê¤º²B¬t»Ä¤¤¬rªº­Ó®×¦bªñ¦~¨Ó¡A¦³³v¦~¼W¦hªºÁͶաA¥Ñ¥Á°ê¤C¤Q¤­¦~«×ªº¹s¤H¡A§Ö³t¼W¥[¦Ü¤K¤Q¤»¦~ªº28¨Ò¡A¦Ó¨ä¤¤¤S¥H¥b¾ÉÅé¤u·~±q·~¤H­û¾·~©Ê¼ÉÅS¦û³Ì¦h¼Æ¡A¨ä¤¤§ó¦³¦]¾·~©ÊÃnÅS¦Ó¾É­P¦º¤`ªÌ¡C25¦pµo¥Í¤j¶qªº²B¬t»Ä¥~¬ª¡A¬Æ¦Ü¥i³y¦¨¦¨¤d¤W¸U¤H¶Ë®`ªº¤j¨aÃø¡C26,27

­P¬r¾÷Âà:22,28,29,30 ²B¬t»Ä¥i¸g¥Ñ¥Ö½§¡B©I§l¹D¡BÂH½¤¡B¸z­G¹Dµ¥ªº±µÄ²²£¥ÍÄY­«ªº¨`¶Ë¤Î¤¤¬r¡C¹ï¤HÅ骺¶Ë®`¥D­n¸g¥Ñ²BÂ÷¤l¤Î¬tÂ÷¤l¨â­Ó¾÷Âà©Ò²£¥Í¡A³q±`¹ï²Õ´¥ß§Yªº¶Ë®`¥D­n¬O¥Ñ²BÂ÷¤l©Ò²£¥Í¡A¦¸µo©Êªº¶Ë®`«h¸g¥Ñ¬tÂ÷¤l¹ï²Õ´ªº¶Ë®`¦Ó²£¥Í: 1. ²B¬t»Ä¬O»Ä¡A¦ý¥Ñ©ó¨ä²BÂ÷¤l¹ï¬tÂ÷¤lªº¿Ë©M¤O¸û±j¡A¸ÑÂ÷«×¸û§C¡A©Ò¥H¦bµ}ªº·»²G¤¤´åÂ÷²BÂ÷¤l¸û¤Ö¡A¦]¦¹¦b±µÄ²®É±`¤£·|¥ß§Yªº¯kµh¡A¦ý¨ä¤¤ªº²BÂ÷¤l¹ï¤HÅ骺¶Ë®`¤@¯ë¥u¦û¦¸­nªº¨¤¦â¡A¦Ó¬tÂ÷¤l«I¤J²Õ´²`³¡¡A¤~¬O²B¬t»Ä³y¦¨¤HÅé¶Ë®`ªº¥D­n¤¸¥û¡C¦]¦¹¡AÁöµM§C¿@«×ªº²B¬t»Ä¬°®z»Ä¡A¦ý¨ä¹ï¤HÅé²£¥Íªº¶Ë®`¡A¤@¯ë¬Æ¦Ü¤ñ¦P¿@«×ªº±j»Ä¦pÆQ»ÄÁÙ­nÄY­«¡C2. °ªº¯³z©Êªº¬tÂ÷¤l¡A¥iº¯¤J²Õ´²`³¡¡A²£¥Í²G¤Æ©ÊÃa¦º(liquefaction necrosis)¡B°©Àf²æ¶t¡B¤ÎÄY­«ªº²`³¡²Õ´¯kµh¡C¥¦·|»PÅ餺¶t¡BÁâµ¥¶§Â÷¤lµ²¦X¡A²£¥Í¤£¥i·»ªº¬t¤Æ¶t©Î¬t¤ÆÁâµ¥ÆQÃþ¡A¦Ó¾É­P§C¦å¶t¤Î§C¦åÁâ¡C¥Ö½§ÃnÅS¡B§l¤J¡B©Î¤fªA¤¤¬rªº¯f±w¡A¬Ò¥i¦]¦¹²£¥ÍÄY­«ªº§C¦å¶t¤Î§C¦åÁâ¡A¬Æ¦Ü¥i§Ö³t­P¤H©ó¦º¡C¦¹¥~¡A¬tÂ÷¤l¤]·|»P§t¦³ª÷ÄÝ­ì¤lªº»Ã¯Àµ²¦X¡A§í¨î»Ã¯Àªº¬¡©Ê¡C

¥D­n¤¤¬r¯g­Ô: 22,28,29,30¤HÅé¼ÉÅS²B¬t»Ä«á¡A²£¥Í¯gª¬ªºÄY­«©Ê»P³t«×§ÖºC¡A¥iÀH¼ÉÅS¿@«×¡B¼ÉÅS®É¶¡¡B²Õ´¹ï»Ä¤§§Ü¤O¡B¼ÉÅS³¡¦ì¡B­±¿n¡B»P¼ÉÅSÁ`¶qµ¥¦]¯À¦Ó¦³©Ò®t²§¡C¤åÄm¤¤¦]¥Ö½§±µÄ²¦Ó¤¤¬rªº³ø§i³Ì¦h¡A·í¥Ö½§±µÄ²°ª¿@«×ªº²B¬t»Ä®É¡A¤ñ¸û·|¥ß§Yµo¥Í¯kµhµ¥¯gª¬¡A¦ý¦p±µÄ²§C¿@«×ªº²B¬t»Ä®É¡Aªì´Á¥i¯à¨S¦³¯gª¬¡A¥~ªí¤]¬Ý¤£¥X²§±`¡A¯gª¬±`·|¦b¬tÂ÷¤l³vº¥º¯¤J²`³¡²Õ´¡A¤~·|Åܱo©úÅã¡C¬ü°ê½Ã¥Í¬ã¨s°|(National Institute of Health)´¿®Ú¾Ú¤£¦Pªº¿@«×¡A±N²B¬t»Ä¨`¶Ë¥[¥H¤ÀÃþ¡A ¥Ö½§±µÄ²²B¬t»Ä¿@«×¶W¹L50%¡A¤@¯ë³£·|³y¦¨¥ß§Yªº¯kµh¤Î©úÅ㪺²Õ´¶Ë®`¡C¿@«×¤¶©ó20%¦Ü50%¡A¨`¶Ë³q±`·|¦b¼Æ¤p®É¤ºÅܱo©úÅã¡C­Y¿@«×¤p©ó20%¡A¨`¶Ë¥i¯à·|©µ¿ð¦Ü24¤p®É¡A¤~Åܱo©úÅã¡C29,30¦]¦¹¡A¹ï©ó¤£¤F¸Ñ¨ä¬r©Êªº¥Á²³©Î±q·~¤H­û¡A«Ü®e©ö©¿²¤¥ß§Y³B¸mªº­«­n¡A¦Ó©µ»~´NÂ媺®É¶¡¡C

¥þ¨­©Ê¬r©Ê¡G22,28,29,30¤£½×¬O¸g¥Ñ¥Ö½§¡B§l¤J¡B©Î¤fªAªº³~®|¶i¤J¤HÅé¡A²B¬t»Ä¤¤¬r³£¥i²£¥Í§C¦å¶t¡B§C¦åÁâ¡BªÍ¤ô¸~¡B¥NÁ©ʻĤ¤¬r¡B¤ß«Ç©Ê¤ß«ß¤£¾ã¡B¬Æ¦Ü¦º¤`µ¥ÄY­«ªº¥þ¨­©Ê¤¤¬rªº¯g­Ô¡CÁ{§É¤W¡A§C¦å¶t©Ò²£¥Íªº¦Ù¦×»øª½©Ê©âÝz(tetany)¡B Chvostek s sign¡B¤ÎTrousseau s sign¡A¦b¬t¤Æª«¤¤¬r¯f±w¨­¤W¤£±`¥X²{¡A28,29,31­È±o±q·~¤H­û­«µø¡C¤åÄm¤¤©Ò³ø§iªº³Ì¤p¤fªA­P¦º¾¯¶q¬°1.5 gm (©Î20 mg/kg)¡A¯f±w¥i¦b¼Æ¤Q¤ÀÄÁ¤º¡A¦b¨S¦³©úÅã«e¥üªºª¬ªp¤U¡A¬ðµM¤ßŦ°±¤î¡C30,32¥Ö½§±µÄ²70%ªº²B¬t»Ä¡A¦ûÅéªí­±¿n2.5%¡A§Y¦³­P©Rªº³ø§i¡C33¹ï©ó²B¬t»Äªº¼ÉÅS¡A¤@¯ë«ØÄ³¡A¥u­n¯f±w¦³¥H¤U±¡ªp¡A´NÀ³±N¯f±wµø¬°¥i¯à²£¥Í§C¦å¶t¡B·|¦M¤Î¥Í©Rªºª¬ªp¨Ó³B²z: 1. ¥Ö½§±µÄ²¿@«×¶W¹L50%Åéªí­±¿n¶W¹L1%ªÌ¡C2. ¥Ö½§±µÄ²¥ô¦ó¿@«×¶W¹LÅéªí­±¿n5%ªÌ¡C3. §l¤J²B¬t»Ä¿@«×¶W¹L60%ªÌ¡C4. ­¹¤J²B¬t»ÄªÌ¡C28,34

¤fªA¼ÉÅS¡G¤åÄm¤¤©Ò³ø§iªº¤fªA²B¬t»Ä¤¤¬rªº¯f±w¦h¾É­P¦º¤`¡C¤fªA²B¬t»Ä°£¥i²£¥Í¤f«|¨ëµh¡B¨`¶Ë¡B¸z­G¹D¯gª¬¦p´c¤ß¡B¹Ã¦R¡B¸¡µh¡B¦R¦åµ¥§½³¡¯gª¬¥~¡B¥ç¥i³y¦¨¥þ¨­©Ê¯gª¬¦pÀY·w¡B­Â«å¡B©âÝz¡Bļ°Ê¡B·NÃѲV¶Ã¡B©ü°g¡B¤ß«ß¤£¾ã¡B¬Æ¦Ü¤ßŦ°±¤î¡CÄY­«¯f±w¥i¦b¼Æ¤Q¤ÀÄÁ¤º¡A¦b¨S¦³©úÅã«e¥üªºª¬ªp¤U¡A¬ðµM¤ßŦ°±¤î¡C28,29,31,34,35

¥Ö½§¼ÉÅS¡G³Ì±`µo¥Í²B¬t»Ä¼ÉÅSªº³¡¦ì´N¬O¥Ö½§¡C29±µÄ²²B¬t»Äªºªì´Á¡A¥Ö½§¥i¶È²£¥Í»´«×ªº¥Ö½§ªx¬õ©Î¥iÄY­«¦Ü²£¥Í¤T«×¨`¶Ë¡A¦p¤£¤©¥HªvÀø¡A²Õ´·|Ä~Äò¯}Ãa¡A²£¥Í¤ô¯p¡BÅÜ¥Õ¡BÅܵw¡BÅܶ©μìºÅ¡A¬Æ¦Ü¥i³y¦¨¾ã¼h¥Ö½§Ãa¦º¡BÃa¯j¡B³à¥¢ªÏÅé¡B¥Ã¤[©Êµ²¬Í¡BÅܧΤΥä[©Ê¥¢¯à¡C¦¹¥~¡A¥Ö½§¼ÉÅS¤]¥i²£¥Í¥þ¨­©Êªº¯g­Ô¨Ã¾É­P¦º¤`¡C28,29,30,34¦b°ê¤º¡A¤]´¿¦³¤@¦ì¦~»´¤H¡A¦]¾·~¤Wªº¥Ö½§±µÄ²¡A¦Ó­P©Rªº³ø§i25¡A¦]¦¹¡Aµ´¤£¥i±¼¥H»´¤ß¡C

©I§l¹D§l¤J¡G©I§l¹D§l¤J²B¬t»Ä¥i²£¥Í«y¹Â¡B§½³¡¨ëµh¡B©I§l§xÃø¡B¯Ý´e¡B¯Ýµh¡B®ðºÞ©Î¤ä®ðºÞ¥X¦å¡BªÍ¥X¦å¡BªÍ¶ò³´¡B¤Î¦¨¤H©I§lµ~­¢¯g­Ô¸s(Adult Respiratory Distress Syndrome, ARDS)µ¥¡A28,29,30,34ÄY­«¯f±w¡A¬Æ¦Ü¥i¦b§l¤J30¤ÀÄÁ¤º§Ö³t¦º¤`¡C36¦¹¥~¡A§l¤J²B¬t»Ä¡A¥ç¥i²£¥Í©µ¿ð©Ê¶Ë®`¡A¯f±w¥i¦b§l¤J«á¼Æ¤Ñ©Î¼Æ¶g«áµo¥Í¥X¦å©ÊªÍª¢©Î¦¨¤H©I§lµ~­¢¯g­Ô¸s¡A¾É­P©µ¿ð©Ê¦º¤`¡C37Kirkpatrickµ¥«ØÄ³¡A¥u­n¦³¥H¤Uª¬ªp¡A´NÀ³¥ý°²³]¯f±w¦³§l¤J©Ê¶Ë®`ªº¥i¯à: 1.±µÄ²²B¬t»Ä¿@«×¶W¹L50%. 2.ÀY¡BÀV³¡¼ÉÅS²B¬t»Ä. 3.¨­Åé¼ÉÅS²B¬t»Ä¶W¹L5%ªºÅéªí­±¿n. 4. ¯f±wªº¦çªA¦³®ûªw¨ì²B¬t»Ä¡A©Î¦³©µ¿ð²æ¥h¦çªAªº±¡§Î. 5.¦b±K³¬ªÅ¶¡¼ÉÅS²B¬t»Ä¡C28

²´·ú¼ÉÅS¡G²´·ú¼ÉÅS²B¬t»Ä¥i§Ö³t²£¥Í¯kµh¡B¬y²\¡Bµ²½¤µo¬õ¡B¨¤½¤²V¿Bµ¥¯g­Ô¡C29,30,34®Ú¾Ú¬ã¨sÅã¥Ü¡A²B¬t»Ä¹ï²´·úªº¶Ë®`¡A¤ñ¬Û¦P¿@«×ªºÆQ»ÄÁÙ­nÄY­«¡AÆQ»Ä³q±`¥u²£¥Í²´·úªí­±ºc³yªº¶Ë®`¡A¦Ó²B¬t»Ä«h¥i¦]¬tÂ÷¤l«I¤J²`³¡²Õ´¡A¦Ó¾É­P§ó²`³¡²´²y²Õ´ªº¯}Ãa¡C38²B¬t»Ä¹ï²´·úªº¶Ë®`¡A¥i²£¥Í³\¦h¦X¨Ö¯g¡A¥]¬A¨¤½¤²V¿B¡Bµø¤OÅÜ®t¡B¥¢©ú¡B¸²µå½¤ª¢(Uveitis)¡B«C¥ú²´¡Bµ²½¤µ²¯m¡B²´Â¥ÅܧΡB°®©Ê¨¤½¤ª¢¡B²´²y¬ï¤Õµ¥¡C29,30,34²´·ú¥u­n¼ÉÅS¿@«×0.5%¥H¤Wªº²B¬t»Ä¡A§Y¥i²£¥ÍÄY­«ªº¶Ë®`¡C29

¶EÂ_: ¥D­n¾a¯f¥v¤ÎÁ{§É¯gª¬¡C¦pµo²{¯f±w¦³ÄY­«ªº§C¦å¶t©Î§C¦åÁâ¡B©Î¤ß¹q¹Ïµo²{QT©µªø(prolongation)¡AÀ³ª`·N¬O§_¦³ÄY­«²B¬t»Ä¤¤¬rªº¥i¯à¡C29,30,34¹ï©ó¦å©Î§¿²G¤¤¬tÂ÷¤lªºÀËÅç¡A¨Ã¤£¯à¨M©w¹w«á¡A29,30¦P®É¡A¥Ø«e°ê¤º¤]©|µLªk´ú©w¡C

³B¸m: 29,30,34

²{³õªvÀø­ì«h¦p¤U¡G

1. ºûÅ@¬I±ÏªÌªº¦w¥þ¡C

2. í©w¥Í©R¼x¶H¡C

3. ¥ý°£¥h¦Ã¬Vªº¦çª«¡C

4. ¥Î¤j¶qªº¤ô¨R¬~±w³¡ (À³¦Ü¤Ö¨R¤ô30¤ÀÄÁ)¡A­Y¼â¤Î²´·ú¡AÀ³¥ß§Y¨R¤ô30¤ÀÄÁ¥H¤W¡A¤èªk¬O¥Ñ²´¤º¨¤©¹¥~¨R¬~¡A¥H§K¶Ë¤Î¥t¤@°¦¦nªº²´·ú¡C

5. ¬I¤©¶t©MÁâ¡C¹ï©ó¥Ö½§±µÄ²ªÌ¡A±w³¡¥i¶î©Ù¸²µå¿}»Ä¶t(Calcium gluconate)©Î®ñ¤ÆÁâ(Magnesium oxide)³n»I¡A³q±`¶·¦Ü¤Ö¶î©Ù30¤ÀÄÁ¥H¤W¡A¨ÃÄ~Äòª½¨ì¯kµh®ø°£15¤ÀÄÁ¥H¤W¡A¤~¥i°±¤î¡C¹ï©ó¤fªA¯f±w¥i¬I¤©¡A¥iµ¹¤©¤fªA§t¶t©ÎÁâÃľ¯©Î¶¼®Æ¦p¤û¥¤µ¥¡C

6. ¾¨³t°eÂå¡C

«æ¶EªvÀø­ì«h: 29,30,34

1. í©w¥Í©R¼x¶H¡C

2. °£¦Ã¡B¨R¬~¶Ë¤f:°£¥h¦Ã¬Vªº¦çª«¡A2¤p®É¤º¥¼¦³¹Ã¦R²{¶H¡AÀ³¦Ò¼{¤©¥H­GºÞÄé¬~(¨Ï¥Î1%¸²µå¿}»Ä¶t)¡C

3. À³¤©¥H¤ß¹q¹ÏºÊµø¡Aª`·N¬O§_¦³QT©µªø(prolongation)¡BQRSÅܼe¡B¤ß«Ç©Ê¤ß²v¤£¾ãµ¥²{¶H¡C(¦]ÄY­«¯f±w¥i¯à·|¦b¼Æ¤Q¤ÀÄÁ¤º¡A¦b¨S¦³©úÅã«e¥üªºª¬ªp¤U¡A¬ðµM¤ßŦ°±¤î¡C¦]¦¹¡A¤ß¹q¹ÏºÊµø¤´¬O§Y®É³Ì­«­nªººÊµø¤u¨ã¡C)

4. ¸g±`ÀWÁcªººÊ´ú¦å¤¤¶t¡BÁâ¡B¹[Â÷¤lªº¿@«×¡C

5. ¦pÃhºÃ©I§l¹D§l¤JÀ³¤©¥H¦å®ñºÊµø¤ÎX¥ú°lÂÜ¡C

6. ¬I¤©¶t©ÎÁâ:¹ï©ó¥ô¦ó³~®|ªº¼ÉÅS¡A¦p¦³¦M¤Î¥Í©R¤§¸·¡AÀ³¦Ò¼{¤©¥HÀR¯ßª`®g¶t©ÎÁâ¡C

-¤fªA¯f±w:¥iµ¹¤©¤û¥¤¡B§t¶t©ÎÁâ·»²G¡B§tÁâ­G¨Å¡B¶t¤ù©Î§tÁâ­G¨Å¤ù¡C¥i¦Ò¼{¸gÅç©Êµ¹¤©ÀR¯ßª`®g¶t©ÎÁâ¡CµM½T¹ê¶t©ÎÁâµ¹¤©ªº¾¯¶q¤Î¤è¦¡¡A¥Ø«e¤´¥¼©w½×¡A¦ý¥i¯à»Ýµ¹¤©»P¤fªA²B¬t»Ä¬Ûµ¥·í¶q¼Æªº¶t©ÎÁâ¡A¤~¨¬°÷¹ï§Ü¬tÂ÷¤l©Ò³y¦¨ªº¬r©Ê¡C

-¥Ö½§±µÄ²:±w³¡¶î©Ù¸²µå¿}»Ä¶t©Î®ñ¤ÆÁ⪺³n»I¡B·»²G©Î¨Å½¦¡AÀ³¤@ª½»´»´«ö¼¯¦Ü¤Ö30¤ÀÄÁ¡A¨ÃÄ~Äò¨Ï¥Î¦Ü¯kµh®ø°£15¤ÀÄÁ¥H¤W¡A¤~¥i°±¤î¡C28,29,30,34¥Ñ©ó²B¬t»Ä¨`¶Ë©Ò²£¥Íªº¯kµh¡A¬O°»´ú²B¬t»Ä¬O§_²£¥Í²Õ´ÂX´²ªº¤@­Ó«Ü¦nªº«ü¼Ð¡A¦]¦¹¡A¹ï©ó¨ä¥L§½³¡¤îµh¾¯ªº¨Ï¥Î¡A¤@¯ë«ØÄ³¡A¦b§½³¡¶t¡BÁâªvÀø©|¥¼§¹¥þ®É¡A¼È®É¥ý¤£­nµ¹¤©§½³¡¤îµh¾¯¡C¹ï©ó²B¬t»Ä¨`¶Ë§Î¦¨ªº¤ôªw¡A³£À³¤©¥H§Ë¯}¡BÂX¶Ë¡B¨Ã°£¥h¨ä¤¤¥i¯àÁôÂìtÂ÷¤lªº¥ô¦óÃa¦º²Õ´¡AÂX¶Ëªº¤ôªw©³­±À³¶î¥H§t¶t©ÎÁ⪺¨Å½¦¡A¥H¹ï§Ü¬tÂ÷¤l©Ò³y¦¨ªº¬r©Ê¡C¤w¦³°Êª«¬ã¨sÅã¥Ü¡AÀR¯ßª`®gÁâÆQ¤ñ°_¸²µå¿}»Ä¶t¡A¯à§ó¦w¥þ¦³®Äªº§í¨î¶Ë¤f½d³ò¡B²`«×ªºÂX´²¡B¨Ã¥i­°§C¦º¤`²v¡A¥Ñ©óÀR¯ßª`®gÁâÆQ¡A¤@¯ë¤ñ¶tÆQ¦w¥þ¡A¦]¦¹¡A¹ïÄY­«¯f±w¥i¦Ò¼{¨Ï¥Î¡C30,39,40,41

¹ï©ó§½³¡²B¬t»Ä¶Ë®`¡A©|¥i¨Ï¥Î§½³¡®û¼íª`®g(local infiltration)¡B°Ê¯ßÄéª`(Intraarterial infusion)¡B¤ÎÀR¯ß§½³¡Äéª`(Intravenous regional perfusion)µ¥¤èªk¡A±N§t¶t©ÎÁâ·»²GÄéª`¦Ü§½³¡²Õ´¤¤¡A¥H¹ï§Ü¬tÂ÷¤l©Ò³y¦¨ªº¬r©Ê¡C29,30,34,42,43,44®Ú¾Ú¬ü°ê¬rÃĪ«¿Ô¸ß(POISINDEX)«ØÄ³¡A¦p¯f±w¦b¥Ö½§±µÄ²«á¡A¦³¥ß§Yªº²Õ´¶Ë®`¡A©Î¦b¨R¬~«á¤´¦³§½³¡¬õ¡Bµhªº²{¶H¡A´NÀ³¸Ó¦Ò¼{¨Ï¥Î§½³¡®û¼íª`®gªvÀø¡C30

-©I§l¹D§l¤J:¹ï©ó©I§l¹D§l¤J¡A¦³¤H«ØÄ³¥i¦Ò¼{µ¹¤©¯f±w§l¤J2.5%¤§¸²µå¿}»Ä¶t·»²G¡C29,30,34

-²´·ú¼ÉÅS:¹ï©ó¶î¥H§t¶t©ÎÁ⪺²´ÃÄ»I¡A©Îµ²½¤¤Uª`®g¸²µå¿}»Ä¶tµ¥¤èªk¡A¥Ø«e³£»{¬°¤Ï¦Ó·|¼W¥[²´·úªº¶Ë®`¡A¤£«ØÄ³¨Ï¥Î¡C29,30,34,45

-¦Ò¼{¨Ï¥Î¦å²G³zªR:¹ï©óÄY­«ªº²B¬t»Ä¤¤¬r¡A°£¥i¬I¤©ÀR¯ßª`®g§t¶t©ÎÁ⪺·»²G¥~¡A¥Ñ©ó¬tÂ÷¤l¦bÅ餺ªº¤À§G®e¿n(volume distribution)¬°¨C¤½¤çÅé­«0.5¦Ü0.7¤½¤É¡A¨Ã¤£ºâ°ª¡A¦]¦¹¦³¾ÇªÌ«ØÄ³¦p¯f±w¦X¨Ö°ª¦å¹[¤Î°ª¦å¬t®É¡A¥i¦Ò¼{¨Ï¥Î¦å²G³zªRªvÀø¡C29,30,34,46

¤@¯ëÃĪ«¤¤¬r

¤@¯ëÂå¥ÎÃĪ«ºØÃþÁc¦h¡B¬r©Ê¦U¤£¬Û¦P¡B¤@¯ë®a®x¥ÎÃÄ¡AÀ³©ñ©ó¤p«Ä®³¤£¨ìªº¦a¤è¡A¥H§K³Q»~­¹¡C¦pµo¥Í¤¤¬r¡A°ò¥»¤W¡B¥i¥ý¥H²{³õ¤@¯ëªvÀø­ì«h³B¸m¡A¦p¦³ºÃ°Ý¡AÀ³¥ß§Y»P¬rÃĪ«¿Ô¸ß¤¤¤ßÁpµ¸¡C

¡@

¤AñQ®ò×ô(Acetaminophen, APAP)¤¤¬r7,9,47,48

±`¨£ªº²£«~:´¶®³¯k(Panadol)¡BScanol¡Btynololµ¥¬O¤@¯ë®a®x¤¤±`¥Îªº¤îµh¡B°h¿NÃÄ¡C

­P¬r¾÷Âà: ÁöµM¤j³¡¤À(80-90%)ªº¤AñQ®ò×ô³£¸g¥ÑµÇŦ±Æ°£¡A¦ý¤AñQ®ò×ô¬r©Ê¡A½T¬O¥D­n¨Ó¦Ü¨ä¤p³¡¤À¸g¥Ñ¨xŦ¥NÁ²£¥Íªº¬r©Êª«½èNAPQI(N-acetyl-p-benzoquinonimine¡A³y¦¨²Ó­MÃa¦º¡A©Ò¾É­P¡C

¥D­n¤¤¬r¯g­Ô:¤@¯ë»{¬°¦p¯f±wªA¥ÎAcetaminophen(APAP)¶W¹L7.5§J¡A©Î¤p«ÄªA¥Î¶W¹L¨C¤½¤ç150²@§J¡A´NÀ³¦Ò¼{¦³¤¤¬rªº¥i¯à¡C«æ©Ê¤¤¬rªº¯gª¬¤@¯ë¥i¤À¬°¥|­Ó¶¥¬q¡A³ÌÀ³ª`·Nªº¬O¡A¨ä¦­´Á±`µL©úÅ㪺¯gª¬¡A¥H­P®e©öÅýÂåÀø¤H­û©¿²¤¤F¥¦ªºÄY­«©Ê¦Ó¿ù¥¢¤FªvÀøªº«´¾÷¡C

²Ä¤@´Á(0-24¤p®É):¯f±w¥i¯à¨S¦³©úÅ㪺¯gª¬¡A¤]¥i¯à¥X²{¹½­¹¡Bäú¤ß¡B¹Ã¦R¡B­Â«å¡B©Î¥X¦½µ¥¯gª¬¡C

²Ä¤G´Á(24-72¤p®É): ¥i¯à·|«ùÄò²Ä¤@´Áªº¯gª¬¡A¦ý³o¨Ç¯gª¬³q±`¦b³o®É´Á·|´î»´¡F¦ý¦¹®É¨x¥\¯à¤Îprothrombin time·|¶}©l²£¥Í²§±`¡A¨Ã¥i¯à¥X²{¥k¤W¸¡¯kµhªº²{¶H¡C

²Ä¤T´Á(3-5¤Ñ):·|²£¥Í¶À¯n¡B©úÅã¨x¥\¯à¤Î¾®¦å¥\¯àªº²§±`¡B¨x¸£¯fÅÜ¡B¨x©ü°g¡B§C¦å¿}¡B©ÎµÇ°IºÜµ¥²{¶H¡C

²Ä¥|´Á(5-14¤Ñ):¯f±¡³vº¥´c¤Æ¦Ü¦º¤`¡A©Î³vº¥«ì´_¥¿±`¡C

¶EÂ_:¦­´Á¥D­n¾a¯f¥v¡A¤fªA4-24¤p®É¥i´ú¦å¤¤Acetaminophenªº¿@«×¡A¹ï·ÓNomogram¡A§@¬°ªvÀø¤Î¹w«áªº«ü¼Ð¡C­È±oª`·Nªº¬O¡A¯f±wªA¥Îªº¾¯«¬¦p¬°ªø®Ä«¬©Î²GºAªºacetaminophen®É¡A«h¤£¯à¥HNomogram¨Óµû¦ô¯f±w¤¤¬rªº±¡ªp¡A¥H§K¿ù¥¢¤FªvÀøªº«´¾÷¡C¦p¯f±wªA¥Îªø®ÄªºAPAP®É¡AÀ³¦bªA¥Î¥|¤p®É«á¥ý©â¤@¦¸¦å¡AµM«á¦b©â§¹²Ä¤@¦¸¦å«á4-6¤p®É«á¦A©â¤@¦¸¦å¡A¦p¥ô¤@¦¸¦å¤¤ªºAPAPªº¿@«×°¾°ª¡A³£À³¤©¥H¥þµ{ªºN-Acetylcysteine(NAC)ªvÀø¡C

³B¸m:²{³õªvÀø­ì«h¦p¤U¡G

1.í©w¥Í©R¼x¶H¡C

2.±N¸ËÃĪº®e¾¹±a¦ÜÂå°|¡]¼ÐÅҤſò¸¨¡C¡^

3.¦pµL¸T§Ò¥i¤©¥H¶Ê¦R¡A¨Ãµ¹¤©¬¡©ÊºÒ¡C

4.¥H¥ª°¼½ö«º¶Õ¡A¾¨³t°eÂå¡C

«æ¶EªvÀø­ì«h:

1.í©w¥Í©R¼x¶H

2.¤©¥H¬~­G¡Aµ¹¤©¬¡©ÊºÒ¤ÎÂm¾¯¡C

3.µ¹¤©¸Ñ¬r¾¯N-Acetylcysteine(NAC)¡G°ò¥»¤WNAC¬O¤@­Ó¬Û·í¦w¥þªº¸Ñ¬r¾¯¡A¦p¯à¦b¯f±wªA¥ÎAcetaminophen«á8¤p®É¤º¡A¨Ï¥ÎNACªvÀø¡A¯f±w´X¥G³£¥i§¹¥þ«ì´_¡C¶W¹L8¤p®É¤~¶}©l¨Ï¥Î¡AªvÀø®ÄªG«h³vº¥ÅÜ®t¡A¦p¶W¹L24¤p®É¤~¶}©l¨Ï¥Î¡AªvÀø®ÄªG«h¤£²z·Q¡C¦]¦¹Á{§ÉÂåÀø¤H­ûÀ³¯S§Oª`·N¡A¤£¥i¦]¯f±w¦­´Á¨S¦³¤°»ò¯gª¬¡A©¿²¤¯fªpªºÄY­«©Ê¡A¦Ó³à¥¢¤FªvÀøªº«´¾÷¡C¨ä¨Ï¥Î¤èªk¬°¡A¥ýµ¹¤©¤fªAªì¾¯¶q140 mg/kg (¥i¥Î4-5­¿ªº¤ô©ÎªG¥Ä¨Rªw)¡A¦A¨C¥|¤p®Éµ¹¤@¦¸¡Aµ¹¤©17¦¸(³sªì¾¯¶q¦@18¦¸)¡A¨C¦¸¾¯¶q¬°70 mg/kg¡C¦p¯f±w¦bªA¥Î¤@¤p®É¤º¦R¥XªÌÀ³¤©¥H¸É¥R¤@·sªº¾¯¶q¡C¥Ø«e¦b¼Ú¬w¤w¸g¥ÎÀR¯ßª`®gªºNAC¨ÓªvÀøAPAP¤¤¬rªº¯f±w¡A¦ý¬ü°ê«h¤´¥¼³q¹L¡C

4.¤ä«ù©ÊÀøªk:¥]¬A¨x¸£¯fÅÜ¡B¾®¦å¥\¯àªº²§±`¡B¤Î§C¦å¿}µ¥ªºªvÀø¡C

5.ÄY­«¯f±w¡A¨ä°eÂå®É¶¡¦b8¤p®É¥H¤WªÌ¡A¥i¦Ò¼{¦å²G³zªRªvÀø¡C

¡@

ºC©ÊAcetaminophen¤¤¬r47,49

ºC©ÊAcetaminophen¤¤¬r¡A«Ü®e©ö³Q²¨©¿¡A¦Ó¦­´Á¦pªG©¿²¤¤F³o­Ó¶EÂ_¡A©¹«á¦p¯f±wµo¥Í¨x¸£¯fÅÜ©ü°g¡A¦¹®ÉÁa¨Ï·Q¨ì¦A´ú¦å¤¤¿@«×¡A¤]µLªk´ú¥X¡C¨ä¥D­nµo¥Í©ó¦³ºC©Ê¯kµh©Îµo¿N¦h¤éªº¯f±w¡A¨ä±K¶°¡B¦h¦¸¡B¦h¶q¨Ï¥Îacetaminophenªº¯f¥v(¹ï©ó³o¼ËªºªA¥Î¯f¥v¡A¦pÂå®v¨S¦³¥D°Ê¸ß°Ý¡A¯f±w³q±`¤]¤£·|ĵı©Î¥D°Ê´£°_¡AÁ{§É¯gª¬ªºªí²{¦p«æ©Êacetaminophen¤¤¬r¤@¼Ë¡A¦­´Á¥D­n¬O¥X²{¸z­G¹D¯gª¬¦päú¤ß¡B¹Ã¦Rµ¥¡A±ß´Á«h¥D­n¥H¨x¥\¯à²§±`¦Ü¨x°IºÜ¬°¥D¡C¤@¯ë»{¬°¦p¦³24¤p®É¤ºacetaminophenªA¥ÎÁ`¾¯¶q¶W¹L50 mg/kg(¥ç¦³§@ªÌ»{¬°¨C¤Ñ¶W¹L150 mg/kg³sÄò2-4¤Ñ)¡Bacetaminophen¥b°I´Á¶W¹L4¤p®É¡B©Î¦³¤£©ú­ì¦]GOT¡BGPT¤É°ª§YÀ³¦Ò¼{¦³acetaminophenªººC©Ê¤¤¬r¡A¦Ó¦Ò¼{¨Ï¥Î¸Ñ¬r¾¯N-acetylcysteine¡C

¡@

ßÓª«ÀݥΡB¤¤¬r¤Î§ÙÂ_7,9,50,51

¡@¡@ªñ¦~¨Ó¥xÆWªºßÓª«ÀݥΡA¦³¤éº¥¼W¦hªºÁͶաA®Ú¾Ú½Ã¥Í³æ¦ìªº±À¦ô¡AÀ³¦b¤T¡B¥|¤Q¸U¤H¥H¤W¡A¤w¦¨¬°ªÀ·|¡B®a®x¤é¯qÄY­«ªº°ÝÃD¡C

¡@¡@¤@¯ëÀÝ¥ÎßÓª«ªººØÃþ¡A²³æ¥i¤À¬°¥H¤U¤TÃþ¡G

1¡B ¤¤¼Ï¯«¸g¿³¾Ä¾¯¡G¦p¦w«D¥L©R¡B¥j¬_ÆP¡C

2¡B ¤¤¼Ï¯«¸g§í¨î¾¯¡G

¡]1¡^³Â¾K¾¯Ãþ¡G¥]¬A¶Ü°Ø¡B®ü¬¥¦]¡B³t½ç±d¡B¥i«Ý¦]¤ÎÆQ»Ä°t¦è¥Åµ¥¡C

¡]2¡^ ¦w¯v¡BÂíÀR¾¯Ãþ¡G¥]¬A¤Ú¤ñ§´ÆQÃþ¡A¦p¬õ¤¤(Seconal)¡B«Cµo(Amytal¡^¥ÕªO¡B­f­«´á°òÆQ¡]¦pÓþªY¡AFM2µ¥®e©ö¶R¨ìªº¦w¯v¡B§ÜµJ¼{ßÓª«¡^¤Î°sºëµ¥¡C

¡]3¡^¦³¾÷·»¾¯¡G¦p±j¤O½¦¡C

3¡B¤Ûı¾¯¡G¦p¤j³Â¡B¤Ñ¨Ï¹Ð¡C

¡@

¡@¡@¤@¯ë¤¤¼Ï¯«¸g¿³¾Ä¾¯¤¤¬r±`ªí²{ªº¯gª¬¥]¬A¥X¦½¡BÀû¤Õ©ñ¤j¡B¤ß¸õ¥[§Ö¡B¦åÀ£¤W¤É¡B¿³¾Ä¡BÀê°Ê¡B¥¢¯v¡B­¹¼¤´î§C¡B¦k·Q¡B°ª¿N¡A­«ªÌ¥i­P©âÝz¡B·NÃѧïÅÜ¡B©ü°g¬Æ¦Ü¦º¤`¡C

¡@¡@¦Ó¤¤¼Ï¯«¸g§í¨î¾¯¤¤¬r¡A¤@¯ë«h·|ªí²{¬Û¤Ïªº¯gª¬¡A¦p¶ÝºÎ¡BÀû¤ÕÁY¤p¡B¤ß¸õ´îºC¡B¦åÀ£¤U­°¡B©I§l§í¨î¡B·NÃÑ©ü°g¡A¦º¤`«h¦h¦]©I§l§í¨î¡A¯Ê®ñ¦Ó­P©R¡C

¡@¡@·í¨Ï¥Î³oÃþÀÝ¥ÎßÓª«¦¨Å}«á¡A¬ðµM§ÙÂ_®É¡A³q±`·|²£¥Í¬Û¤Ïªº¯gª¬¡A¦p¤¤¼Ï§í¨î¾¯§ÙÂ_®É¡A©ö²£¥Í¤¤¼Ï¯«¸g¿³¾Äªº¯gª¬¡A¦p¶Ü°Øµ¥³Â¾K¾¯ÃþßÓª«§ÙÂ_®É¡A®e©ö²£¥Í¡Bļ°Ê¡B¥¢¯v¡BÀû¤Õ©ñ¤j¡B¤ß¸õ¥[§Ö¡B¦åÀ£¤W¤É¡B¥´¨þ¤í¡B¬y²\¡B«_¦½¡Bäú¤ß¡B¹Ã¦R¡B¦Ûıµh¤£±ý¥Íµ¥¯gª¬; ¦p¤¤¼Ï¯«¸g¿³¾Ä¾¯§ÙÂ_¡A«h®e©ö²£¥Í¤¤¼Ï¯«¸g§í¨îªº¯gª¬¡A¦p¦w«D¥L©R§ÙÂ_©ö²£¥Í¼~Æ{¡B¶ÝºÎ¡B¤ß¸õ´îºC¡B¦åÀ£¤U­°µ¥¯gª¬¡C

¡@¡@·íÂåÀø¤H­û¦bÀˬd¯f¤H®ÉÀ³ª`·N¤â¸}©Î¹«Áѳ¡¡A¬O§_¦ñ¦³¬I¥´¬r«~ªº°w¤Õ²ª¸ñ¡A¦P®É¹ï©ó¤@¨Ç©üºÎ©Î¤¤¼Ï¯«¸g§í¨î¾¯¤¤¬rªº¯f¤HÀ³¯S§Oª`·N¨ä©I§l°ÝÃD¡]±`·|¦]©I§l¹Dªý¶ë©Î©I§l§í¨î¦Ó­P©R¡^¡C°ò¥»¤W¡A¦³¨ÇÀÝ¥ÎßÓª«¬O¦³¸Ñ¬r¾¯ªº¡A¦pNaloxone¬O³Â¾K¾¯Ãþªº¸Ñ¬r¾¯¡A¦ÓAnexate«h¬O¤@¯ëßөЮe©ö¶R¨ìªº¦w¯vßÓ­f­«´á°òÆQªº¸Ñ¬r¾¯¡C¦]¦¹¹ï©óÃhºÃ¤¤¬rªº¯f¤H¡]¯f¤H¦³©ü°g¡BÀû¤ÕÁY¤p¡B©I§lÅܲL¡BÅܺCµ¥¯gª¬¡^¥i¦Ò¼{µ¹¤©¡C

¡@

¡@¡@¤¤ÃĤδӪ«¤¤¬r52-4

¡@¡@¤¤Âåºûô¤¤°ê¤­¤d¦~¤å¤Æ¡A¨ä»ù­È½T¹ê¤£®e©¿µø¡CµM¦Û¥j¥H¨Ó¤H­Ì¦h¦³ "Áô´c´­µ½" ªº²ß©Ê¡A¦UºØ¨åÄy¡B¤è¾¯¡A±`¹ï¤¤ÃĪº¥\®Ä¥[¥H«Å´­¡A¦Ó¹ï¨ä°Æ§@¥Î¤Î¬r©Ê¡A«h±`ÁצӤ£½Í¡A¥H­P¤j®a«w»{¬°¤¤ÃÄÃĩʷũM¡B¬r©Ê¤p¡AµM¨ä½T¹ê¥i²£¥ÍÄY­«¬r©Ê¡CÂåÀø¤H­û¡AÀ³¤F¸Ñ§Ú­Ì³o¸Ì¦³¯S®í¦a°ì©Êªº¬rª« ¡C

¡@¡@®Ú¾Ú¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ßªº²Î­p¡A»OÆW¤¤ÃĤδӪ«¤¤¬r­Ó®×¸û¦hªº¥]¬A¼Ì¸£ªo¡Bªo®ä¤l¡B´îªÎµæ¡B¤K¨¤½¬¡B¬rÛ£¡B¥H¤Î¥HÃþ§O°Ï¤ÀªÌ¥]¬A¡G§Ü¤AñQÁxÆPÃþ(¦p¤jªá°ÒªûÅÚ¡B°¨ÅÕ¤¦)¡BÀÀ¤AñQÁxÆPÃþ(¥]¬A¶À½¬¡B¯ó¯Q¡BÂb·}µ¥)¡B§t¯ó»ÄÆQÃþ(¦p©h±C¨¡¡B®ü¨¡¡B¥ÕÅb¨¡¡BÂL¯»¸­¡B²Ê¦Ø¯ó¡B¶Àª÷¸¯µ¥)¡B¤Î§t°tÁÞÅéÃþ(¦pÃʶp¡B¤ò¦a¶À¡B§¨¦Ë®ç¡B®üÂcªG¡B±Ï¤ßµ¥)¡C

¡@¡@¼Ì¸£ªo¡A¬O¤@ºØ¦b»OÆW¦U®È¹C­·´º°ÏªºÅu³cÅu¦ì¤W¡A«Ü®e©ö¶R¨ìªºÃĪ«¡AµM¥¦«o¬O¤@ºØ¬r©Ê«D±`±jªºÃĪ«¡A¦pªA¤U20%ªº¼Ì¸£ªo5cc¡A§Y¥i­P©R¡A¦]¦¹¥¦À³©ñ©ó¤p«Ä¤l®³¤£¨ìªº¦a¤è¡A¥H§K³Q»~­¹¡C¨ä¤¤¬rªº¯gª¬¥D­n¥]¬A¤f´c¤ß¡B¹Ã¦Rµ¥¸z­G¹D¯gª¬¡A¤Î·NÃѲV¶Ã¡B©ü°g¡B©âÝzµ¥¤¤¼Ï¯«¸g¿³¾Äªº¯gª¬¡C²{³õ«æ±Ï®É¡AÀ³ª`·N¨R¬~¦Ã¬V³¡¦ì¡]¦]¥i¸g¥Ñ¥Ö½§¤Î©I§l¹D§l¦¬¡^¡B¤£­n¶Ê¦R¡]¦]¥i¦b²@µL«e¥ü¤U¬ðµo©âÝz¡^¡A¨ä¥L«h»P¤@¯ë¤¤¬rªvÀø­ì«h¬Û¦P¡C

¡@¡@§t¯ó»ÄÆQÃþ´Óª«(¦p©h±C¨¡¡B®ü¨¡¡B¥ÕÅb¨¡¡BÂL¯»¸­¡B²Ê¦Ø¯ó¡B¶Àª÷¸¯µ¥)

¡@¡@®Ú¾Ú¤é¥»²Î­p¡A©Ò¦³¶éÃÀ¬Ö®â´Óª«¤¤¬ù¦³¥|¤À¤§¤@¬OÄÝ©ó¦¹Ãþ´Óª«¡A³oÃþ´Óª«¦b»OÆWªº®x¶é¡A¦P¼Ë¤]¬O«D±`±`¨£ªº´Óª«¡C¤@¯ë¦b©CÄZ©Î«r­¹¡B©Î¥Ö½§±µÄ²³oÃþ´Óª«ªº¸­¤ù«á¡A¥ß§Y·|²£¥Í¤fµÄ¡B³ïÄVÄY­«©Î§½³¡ªº¯kµh¡AÄY­«®É¥i²£¥Í³ïÀY¤ô¸~¦Ó¼vÅT©I§l¹D¡A©Î§C¦å¶t¦Ó¦³¥Í©R¦MÀI¡C¤@¯ë¥i¥H¦B¼Å¡B¤fµÄ§t¦B¤ô¥H´î¤Ö¯kµh©Î¨Ï¥Î¤îµh¾¯ªvÀø¡A³q±`¦b¤G¡B¤T¤Ñ¤º¯gª¬´N·|®ø¥¢¡C

¡@

¡@

¤G¡B§l¤J©Ê¬rª«9,55,56

¡@¡@¤@¯ë§l¤J©Ê¬r®ð¥D­n¤À¬°1.²¿®§©Ê¬r®ð¦p¤@®ñ¤ÆºÒ¡BÙæ¤Æª«¡B¤Î²¸¤Æ²Bµ¥¡A¨ä¥D­nªº¼vÅT§Y¬O§«Ãª²Ó­Mªº®ñ®ðÀò±o¡A¦Ó³y¦¨²Ó­M¯Ê®ñ2.¨ë¿E©Ê¬r®ð¦p®ò®ð¡B´â®ð¨ä¥D­nªº¼vÅT§Y¬O³y¦¨ÂH½¤ªº¨ë¿E¡AµM¥ç¥i¦]©I§l¹D¨ü¨ë¿E¤ô¸~¦Ó²£¥Í©I§l§xÃø3. ¨ë¿E©Ê¦X¨Ö²¿®§©Ê¬r®ð¦p²¸¤Æ²B. ¦ÓÅF°Ê¤@®Éªº¤é¥»¨FªL¬r®ð¤Î¾Ôª§®É©ó¥Îªº¯«¸g¬r®ð«h¦hÄݩ󦳾÷ÁC¤¤¬r¡C¥xÆW±`¨£ªº§l¤J©Ê¬rª«¥]¬A¤@®ñ¤ÆºÒ¡B®ò®ð¡B´â®ð¡B¤Î²¸¤Æ²Bµ¥

¡@

¤@®ñ¤ÆºÒ¤¤¬r

¡@¡@®Ú¾Ú¬ü°êªº²Î­p¡A¤@®ñ¤ÆºÒ¤¤¬r¬O©Ò¦³¤¤¬r¦º¤`¤¤¡A±Æ¦W²Ä¤@ªÌ¡F9 ¦b¥xÆW¡A¤@®ñ¤ÆºÒ¤¤¬r¨ÌµM«D±`±`¨£¡A®Ú¾Ú¥x¥_ºaÁ`Á{§É¬rÃĪ«¿Ô¸ß¤¤¤ßªº²Î­p¡A56¤j¬ù¤E¦¨ªº¤¤¬r¯f¤H¡A³£¬O¦]¥Ë´µ¼ö¤ô¾¹¨Ï¥Î¤£·í¡]¦p©ñ¸m¦b¯D«Ç¤º¡^©Ò¤Þ°_¡C³q±`¶V¬O¥_³¡(¤Ñ®ð§N¡Aªùµ¡©öºò³¬)¡B ¶V¬O¤j³£·|°Ï¡]©Ð»ù¶Q¡A¥Ë´µ¼ö¤ô¾¹©ö¸m©ó«Ç¤º¡^¤@®ñ¤ÆºÒ¤¤¬rµo¥Í²v¶V°ª¡C¦P®É¥¦¬O¤@­Ó±`±`»~¶Eªº¤¤¬r¡A®Ú¾Ú²Î­p¤@®ñ¤ÆºÒ¤¤¬rªº»~¶E²v¥i¶W¹L30%¡A±`±`³Q·í§@¦ü¥G²@¤£¬Û¤zªº­¹ª«¤¤¬r¨Ó³B²z¡A¥D­n¬O¦]¬°¤@®ñ¤ÆºÒ¤¤¬rªº¯gª¬¤¤±`¦³äú¤ß¡B¹Ã¦Rµ¥¸z­G¹D¯gª¬¡A¦P®É®Ú¾Ú¥x¥_ºaÁ`Á{§É¬rÃĪ«¿Ô¸ß¤¤¤ßªº³ø§i¡A¦Ê¤À¤§¤K¤Q¥H¤W¤§¤@®ñ¤ÆºÒ¤¤¬r¡A§¡¬°¨â¤H¥H¤W¤§¶°Å餤¬r¡A³oºØ¶°Å餤¬rªº¯S©Ê¡A¤]¬O³y¦¨¥¦®e©ö»~¶Eªº­ì¦]¡C56³o¨Ç¯f±w¦p¤£¯à¦­´Áµ¹¤©°ª¿@«×®ñ®ð©Î°ªÀ£®ñªvÀø,±N·|©úÅ㪺¼vÅT¯f¤Hªº¹w«á,©Ò¥H·í§Ú­Ì¹J¨ì·NÃѤ£²Mªº¯f±w,¤×¨ä¦P®É¦³¶W¹L¨â¤H¥H¤W¤@°_µo¥Í®É¡AÀ³·Q¨ì¦³¤@®ñ¤ÆºÒ¤¤¬rªº¥i¯à,²¦³º¤@®ñ¤ÆºÒ¤¤¬r¬O¤@ºØ¥iªvÀøªº¯e¯f, ¥B¦­´Á¶EÂ_¦­´ÁªvÀø¹ï¨ä¹w«á±N¦³©úÅ㪺¼vÅT,¦]¦¹§^¤HÀ³¯S§Oª`·N¦¹¤¤¬rªº¥i¯à©Ê¡C9,55,56

¡@¡@¤@®ñ¤ÆºÒ¬O¤@ºØµL¦â¡BµL¯ä¡BµL¨ýªº®ðÅé¡A¤¤¬rªº¤H±`¦b¤£¦Ûıªºª¬ªp¤U¡A³vº¥©ü°g¦Ó¦º¤`¡C¨ä¥D­n¨Ó·½¬O¥Ñ§tºÒ¤Æ¦Xª«¡]¦p¥Ë´µ¡B¤ì§÷¡B¤ì¬´¡B¨Tªoµ¥¡^¤£§¹¥þ¿U¿N©Ò²£¥Í¡£¤Ö¼Æ¥ç¥i¦]¼ÉÅS´â¤A²m¡]methylene chloride¡^¸gÅ餺¥NÁ¦Ӳ£¥Í¡¤¡A57±`¨£ªº¤¤¬rª¬ªp¥]¬A1.¥Ë´µ¼ö¤ô¾¹¸Ë©ó«Ç¤º¡A¨Ã¦b³q­·¤£¨}ªº¯D«Ç¤¤¬~¾þ2.¦b¤õ¨a¤¤¦p§l¤J¿@·Ï3.¦b³q­·¤£¨}ªº¦a¤è¡B¿N¤ì¬´¨ú·x©Î¬´¯N­¹ª«4.¦b³q­·¤£¨}ªºªÅ¶¡¤¤¡]¦p¨®®w¤¤¡^¡A«ùÄò§l¤J¨T¨®©Î¤@¯ë¤ÞÀº©Ò±Æ¥Xªº¼o®ð¡C¤@®ñ¤ÆºÒ¤¤¬r¥D­n¹ï¨­Å骺¼vÅT§Y¬Oªýê²Ó­MÀò±o®ñ®ð¡A·í¨ä¦b¦å¬õ¯À¤¤¿@«×¶V°ª¡A¤¤¬r¯Ê®ñªº¯gª¬´N·|¶VÄY­«¡A¨ä¤¤¬rªº¥D­n¯gª¬(¦pªí¥|)¡C¨ä³Ì­«­nªºªvÀø§Y¬Oµ¹¤©°ª¿@«×ªº®ñ®ð(¦p¨Ï¥Î«D¦A©I§l©Ê®ñ®ð­±¸n©Î©ñ¸m®ðºÞ´¡ºÞ)¡C¦b°ª¿@«×ªº®ñ®ðªvÀø¤U¥iÅãµÛ¦a­°§C¦å¤¤¤@®ñ¤ÆºÒ¦å¬õ¯À(carboxyhemoglobin, HbCO) ªº¥b°I´Á¦p(ªí¤­)¡C¥Ñ©ó¯à§_¦­´ÁªvÀø±N·|ÅãµÛ¼vÅT¤@®ñ¤ÆºÒ¤¤¬r¯f±wªº¹w«á¡A¦]¦¹¤@¯ë«ØÄ³©Ò¦³±q¤õ³õ±Ï¥X¨Ó©ÎÃhºÃ¥i¯à¬°¤@®ñ¤ÆºÒ¤¤¬rªº¯f±w¡A³£À³µ¹¤©°ª¿@«×ªº®ñ®ð(¦p¨Ï¥Î«D¦A©I§l©Ê®ñ®ð­±¸n)¡A¦]¦b¤õ³õ¤¤¥u­n2-3¤ÀÄÁªº¼ÉÅS¡A§Y¥i¨Ï¦å¤¤HbCOªº¿@«×¤W¤É¦Ü40-50%¡C58,59¹ï©ó¤@®ñ¤ÆºÒ¤¤¬rªº¯f±w¡A¦p¯f±w°Ê¯ß¦å¤¤carboxyhemoglobin¿@«×¶W¹L25%¡B¦³¯«¸g©Î·NÃѪº»Ùê¡B¦³¤ßµ±µh©Î¤ß¹q¹ÏÅܤơB¥NÁ©ʻĤ¤¬r¡B©ÎÃh¥¥°ü¤k¡A³£À³¦Ò¼{¤©¥H°ªÀ£®ñªvÀø(¦pªí¤»)¡C55,60

¡@

ªí¥|¡B¤@®ñ¤ÆºÒ¤¤¬rªº¯gª¬

¦å¤¤HbCO % ¯gª¬

0 µL

10 «eÃBÀYµh

20 ±ª°Ê©ÊÀYµh¡B©I§l§xÃø

30 §PÂ_¤O²§±`¡B¤f´c¤ß¡B¹Ã¦R¡Bµø¤O¼Ò½k

40 ·NÃѲV¶Ã

50 ©ü°g©âÝz

60 §C¦åÀ£¡B©I§l°IºÜ

70 ¦º¤`

¡@¡@HbCO¡G ¦å¤¤¤@®ñ¤ÆºÒ¦å¬õ¯À¶q

¡@

ªí¤­¡B¦å¤¤¤@®ñ¤ÆºÒ¦å¬õ¯Àªº¥b°I´Á»P§l¤J®ñ®ðªºÃö«Y

§l¤J®ðÅé

HbCOªº¥b°I´Á(¤ÀÄÁ)

ªÅ®ð

240-320

100% ®ñ®ð

45-60

°ªÀ£®ñ(3¤j®ðÀ£)

20-30

¡@

ªí¤»¡B°ªÀ£®ñªvÀøªº¾AÀ³¯g

°Ê¯ß¦å¤¤HbCO¿@«×¶W¹L25%

¥ô¦óHbCO¿@«×¦X¨Ö¯«¸g¯gª¬(¦p©ü°g©Î¯«´¼²§±`µ¥)©Î´¿¦³µu¼È·NÃѳॢ

Ãh¥¥°ü¤kHbCO¿@«×¶W¹L10% ©Î¦³­L¨àµ~­¢¯g­Ô

¦³¤ßµ±µh©Î«æ©Ê¤ß¹q¹Ï²§±`

¦X¨Ö¥NÁ©ʻĤ¤¬r

¡@

¡@

´â®ð¤Î®ò®ð¤¤¬r7,9,55,60,61

´â®ð¬O¤@ºØ¶Àºñ¦â¡B¨ã±j¯P¨ë¿E©Êªº¦³¬r®ðÅé¡A±`¦]´åªa¦À¡B¦Û¨Ó¤ô¼t©Î¤Æ¾Ç¤u¼tµ¥³Bªº´â®ð«ß¥~¬ª¡A¦Ó²£¥Í¤¤¬r¡C³q±`¦b±µÄ²´â®ð«á¼Æ¤ÀÄÁ¤º§Y·|²£¥Í¯gª¬¡C®ò®ð(ªü¼¯¥§¨È)±`¥Î©óªÎ®Æªº»s³y¡A¬O¤@ºØ¨ã±j¯P¯ä¨ý¨ë¿E©Êªº¦³¬r®ðÅé¡C´â®ð¤Î®ò®ð§¡¥i¹ï²´·ú¤Î¤W©I§lµ¥ÂH½¤¡B®ðºÞ¡B¤ÎªÍªwµ¥³y¦¨¶Ë®`¡C»´ªÌ¦³¬y²\¡Bµ²½¤¨ë¿E¡B¬y®÷¡BÀYµh¡B«y¹Â¡B³ïµh¡BÁn­µ¨F°×¡B¯Ý´e¡B¯Ýµhµ¥¯gª¬¡A­«ªÌ¥i²£¥Í©I§l§xÃø¡B©I§l°IºÜµ¥¯gª¬¡C

¨ä²{³õ«æ±Ï­ì«h¥]¬A:

1.½T«O¬I±ÏªÌ¦Û¨­ªº¦w¥þ¡A¥i¥HÀã¤ò¤y±»¦í¤f»ó¡A´î¤Ö¬r®ð¶i¤J¤U©I§l¹D¡C

2.±N¯f±w²¾¦Ü¤W­·³B¡A¥H¨¾¤îÄ~Äò¨ü¬r®ð«I¥Ç¡C

3.µ¹¤©®ñ®ð

4.¦p²´·ú©Î¥Ö½§¨ü¨ì«I¥Ç¡AÀ³¥Î²M¤ô¨R¬~20-30¤ÀÄÁ¡A¤d¸U¤£¥iµ¥¨ìÂå°|¤~ ¤©¥H¨R¤ô¡C

5.¥ß§Y°eÂå¡C

«æ¶EªvÀø­ì«h:

1.í©w¥Í©R¼x¶H

2.µ¹¤©®ñ®ð¡A¦pÃhºÃ©I§l¹D¤ô¸~¡AÀ³¦Ò¼{¦­´Á¤©¥H®ðºÞ´¡ºÞ¡C

3.¤ä«ù©ÊªvÀø:¦p¯f±w¦³¨`¶Ë¡A«h¦p¤Æ¾Ç¨`¶Ë³B²z¡C

¡@

Ùæ¤Æª«¤Î²¸¤Æ²B¤¤¬r7,9,55,60

¡@¡@Ùæ¤Æª«¬O¤@ºØ§@¥Î«D±`§Öªº¼@¬rª«½è¡AÙæ¤Æª«¹J¨ì»Ä·|²£¥ÍµL¦â¡BµL¯äªºÙæ»Ä®ð¡C°ê¤ºÙæ¤Æª«¤¤¬rªº­Ó®×¡A°£¤F´X¦¸Ùæ»Ä®ð¥~¬ª¥~¡A¤j¦h¹s¬P­Ó®×³£¬O¦]­¹¤J¦³¬rÙæ¤Æª«©Ò¤Þ°_¡C¨ä¥D­n¨Ó·½¥]¬A1.¹qÁá¤u·~¡B¬r³½¥Îªº­W§ö2.®ç¡B§õ¡B§öµ¥¥Í®Ö¤¯¡AÅK¾ð¡BÄå®ç¡BÄ«ªGµ¥ºØ¤l3.¿U¿N§t´á¡BºÒ¤Æ¦Xª«¡]¦p¶ì½¦¤Î¤@¯ë«Ø§÷¡^¦]¦¹¤@¯ë©ÐªÙ¥¢¤õ´X¥G³£·|²£¥Í¦³¬rªºÙæ»Ä®ð¡C

¡@¡@Ùæ¤Æª«¥D­nªº¬r©Ê¬Oµ²¦X²Ó­M¦â¯À®ñ¤Æ×Q(cytochrome oxidase)¤¤ªº¤T»ùÅKÂ÷¤l¡A§í¨î®ñ¤ÆÁC»Ä¤Æ(oxidative phosphorylation)¡A¦Ó§í¨î²Ó­M¹ï®ñ®ðªº§Q¥Î¡A¦]¦¹²Ó­M·|²£¥ÍÄY­«ªº¯Ê®ñ¡C¶EÂ_Ùæ¤Æª«¤¤¬r¥D­n®Ú¾Ú¯f¥v¡A¦p¯f¤H¦b§l¤J©Î­¹¤J¬rª«¡A¼Æ¤ÀÄÁ¤º§Y·NÃѳॢ¡A¦³©úÅã¯Ê®ñ²{¶H¡A¦ý¨S¦³µoÖæ(¥Ñ©ó²Ó­MµLªk§Q¥Î®ñ®ð¡A¦]¦¹ÀR¯ß¦å®ñ´X¥G»P°Ê¯ß¬Ûµ¥¡A¤´§e²{ÂA¬õ¦â)¡A©Î²{³õ¦³­W§ö¤¯¨ý®É¡A§YÀ³¦Ò¼{¦³Ùæ¤Æª«¤¤¬rªº¥i¯à©Ê¡C¦p¯f±w±q¤õ¨a²{³õ³Q±Ï¥X¡A¨Ï¥Î®ñ®ðªvÀø®ÄªG¤£¨Î¡A¦³©úÅ㪺¥NÁ©ʻĤ¤¬r®É¡A´NÀ³¦Ò¼{¦³Ùæ¤Æª«¤¤¬rªº¥i¯à©Ê¡C55

Ùæ¤Æª«¤¤¬r²{³õ«æ±Ï­ì«h: 7,9,55,60

1.½T«O¬I±ÏªÌ¦Û¨­ªº¦w¥þ

2.±N¯f±w²¾¦Ü¤W­·³B¡A¥H¨¾¤îÄ~Äò¨ü¬r®ð«I¥Ç¡C

3.µ¹¤©°ª¿@«×®ñ®ð(¨Ï¥Î«D¦A©I§l©Ê®ñ®ð­±¸n)¡C

4.¨Ï¥ÎÙæ¤Æª«ªº¸Ñ¬r¾¯¡]CYANIDDE KITS¡^¡C¦b²{³õµLÀR¯ßª`®gªºª¬ªp¤U¥i±NAmyl nitrite®º¸H¡AÅý¯f±w¨C¤ÀÄÁ§l¤J30¬í¡A¥i¨C3¤ÀÄÁµ¹¯f±w¥Î¤@Áû·sªºAmyl nitrite¡A¥H²£¥ÍÅܩʦå¬õ¯À(methemoglobin)¡A´î¤ÖÙæ¤Æª«»P²Ó­M¦â¯À®ñ¤Æ×Q¤§µ²¦X¡C

5.¹ï­¹¤JÙæ¤Æª«ªº¯f±w¤£­n¤©¥H¶Ê¦R¡]¦]¥i¯à¦b«Üµuªº®É¶¡¤º§Y·NÃѳॢ¡A ¦p¤©¥H¶Ê¦R¡A«Ü®e©ö³y¦¨©I§l¹D§l¤J¡C¡^

6. ¥ß§Y°eÂå¡C

«æ¶EªvÀø­ì«h:

1. í©w¥Í©R¼x¶H

2. µ¹¤©®ñ®ð

3. ¨Ï¥ÎÙæ¤Æª«ªº¸Ñ¬r¾¯¡]CYANIDDE KITS¡^¡Ca)µ¹¤©sodium nitrite¡A¨ä¨Ï¥Î¾¯¶q¬°300mg©Î3%ªºsodium nitrite 10ml¡A¤p«Äªº¾¯¶q¬°10mg/kg©Î3%ªºsodium nitrite 0.2ml/kg¡A¥H2.5-5 ml/minªº³t«×µ¹¤©¡A§Æ±æºû«ù¦å¤¤Åܩʦå¬õ¯À¦b10-40%¡A³q±`Amyl nitrite¥i¨Ï¦å¤¤ªºÅܩʦå¬õ¯À¤W¤É¦Ü5%¡A¦Óªì¾¯¶qªºsodium nitrite§Y¥i¨Ï¦å¤¤ªºÅܩʦå¬õ¯À¤W¤É¦Ü25%¡Cb) µ¹¤©sodium thiosulfate¥H»Pcyanide§@¥Î²£¥ÍµL¬rªºthiocyanate¦Ó¥ÑµÇŦ±Æ°£¡A¨ä¨Ï¥Î¾¯¶q¬°12.5gm(25%,50ml)©Î1.5 ml/kg ÀR¯ßª`®g1-2¤ÀÄÁ¡C¹ï©óÃhºÃªºÄY­«¯f±w¡AÀ³¦Ò¼{¨Ï¥Î¸Ñ¬r¾¯¡A§@ªvÀø©Ê¶EÂ_(therapeutic trial)¡C

¡@

¡@¡@²¸¤Æ²B(Hydrogen Sulfide)¤§¬r©Ê§@¥Î»PÙæ¤Æª«Ãþ¦ü¡A¤]¬O¤@ºØ§@¥Î«D±`§Öªº¦³¬r®ðÅé¡A¦b±K³¬ªÅ¶¡¤¤¡]¦p·Å¬u²¸ÁD»W¤ô¦À©Î¤U¤ô¹D¡^¡A·¥©ö¦bÀþ¶¡§Y¨Ï¨ü®`ªÌ·NÃѳॢ¨Ã²£¥ÍÄY­«¯Ê®ñ¡C¸g±`¡A¦b¬I±ÏªÌ¤U¥h±Ï¯f±w®É¡A¦Û¤v¤]¦¨¬°¤¤¬rªº¯f¤H¡C¥Ñ©ó²{³õ±`±`¦³²¸ÁD¨ý¹D¡A¦]¦¹¡A·í¬I±ÏªÌ¦b¦³²¸ÁD¨ýªº²{³õ±Ï¯f±w®É¡AÀ³ª`·N¬O§_¦³²¸¤Æ²B¤¤¬rªº¥i¯à©Ê¡CµMÁöµM¦b§C¿@«×®É¥i»D¨ì²¸ÁD¨ý¡A¦ý²¸ÁD¨ý¨Ã¤£¬O¤@­Ó¥i¨Ì¿àªº¾ÌÃÒ¡A¦]¨ä¦b¿@«×¶W¹L150ppm®É¡A§Ú­Ìªº¶å¯«¸g§Y·|§Ö³t·ò·ô¡C55¦b¿@«×¶W¹L1000ppm®É¥i¦b§l¤J¤@¤f©Î´X¤f§Y¥i§Ö³t³à¥¢·NÃÑ¡C62

¡@¡@²¸¤Æ²B¥D­nªº¬r©Ê¬O§í¨î²Ó­M¹ï®ñ®ðªº§Q¥Î¡A¦]¦¹²Ó­M·|²£¥ÍÄY­«ªº¯Ê®ñ¡A²¸¤Æ²B¤¤¬rªº²{³õ«æ±Ï»PÙæ¤Æª«¤¤¬rªº«æ±Ï­ì«h¬Û¦ü¡A¤]¥ÎCYANIDDE KITS¨ÓªvÀø¡A ¦ý¹ï²¸¤Æ²B¥u¥ÎAmyl nitrite¤Îsodium nitrite¦Ó¤£»Ý­n¥Îsodium thiosulfate¡C¹ï©ó¤ÏÀ³¤£¹Åªº¯f±w¥ç¥i¦Ò¼{¨Ï¥Î°ªÀ£®ñªvÀø¡C55,60

¡@

­¹ª«¤¤¬r63

¡@¡@­¹ª«¤¤¬r¤@¯ë¥i¤À¬°²Óµß©Ê¤Î«D²Óµß©Ê¤¤¬r¡A±`¨£ªº²Óµß©Ê­¹ª«¤¤¬r¥]¬A¸²µå²yµß¡B¨Fªù¤óµß¡B¸zª¢©·µß¡B±ôª¬²£®ð²ó½¤±ìµß¡B§Ó¶Pµß¤Î¦×¬r±ìµßµ¥¡F«D²Óµß©Ê¤¤¬r«h¥]¬Aªe³b¬r¡B³Â·ô©Ê¨©¬r¡B¨ý¯À¡B­«ª÷Äݵ¥¡C

¡@¡@¤@¯ë±`¨£­¹ª«¤¤¬rªº¯gª¬¡A¥D­n¥]¬A¸z­G¹D¤Î«D¸z­G¹D¡]¯«¸g¯gª¬¡^¯gª¬¡A¨ä¤¤¸z­G¹D¯gª¬¥D­n¥Häú¤ß¡B¹Ã¦R¡B¸¡Âm¬°¥D¡F«D¸z­G¹D¯gª¬¥D­n¥H¯«¸g¯gª¬¬°¥D¡A¥]¬A¤f¡B¦Þ³Â¤ì¡B²´¥Ö¤U««¡B¤â¡B¸}³Â·ô¡B©I§l§xÃøµ¥¡C

¡@¡@¤@¯ë¦Ó¨¥¡A¹ï©ó¥H¤W¦R¤UÂm¬°¥D­n¯gª¬ªº­¹ª«¤¤¬r¡AÀ³ª`·N¤ô¥÷»P¹q¸Ñ½èªº¥­¾î¡]¦pµ¹¤©¥Í²z­¹ÆQ¤ô¡^¡A¦p¥H¯«¸g¯gª¬¬°¥D¡A«hÀ³¯S§Oª`·N¦³©I§l°IºÜªº¥i¯à¡C

¡@

«r¶Ë¤Îîg¶Ë

¡@¡@°Êª««r¶Ë¬O«Ü±`¨£ªº±¡ªp¡A¨ä¤¤¤j¦h¼Æ¥u²£¥Í»´·Lªº¤£¾A¡C¤£¹L¡A·í°Êª««r¶Ë¦³¤j¶Ë¤f¡B¦³¬r²G¶i¤J©Î·|Åý¯f±w²£¥Í¹L±Ó®É¡A±¡ªp¥i¯à¥ß§Y·|Åܱo«Üºò«æ¡A¦¹®É­Y¯à¥¿½T¶EÂ_¡B¨³³tªvÀø¡A±`¥i¦]¦¹¬@±Ï¯f¤Hªº¥Í©R¡A¨Ã¨¾¤î²Õ´¥Ã¤[ªº¶Ë®`¡C

¡@

³D«r¶Ë

¡@¡@®Ú¾Ú¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ßªº²Î­p¡A©Ò¦³°Êª««r¶Ë¤¤¦º¤`²v³Ì°ªªÌ¡A§Y¬°³D«r¶Ë¡A¥i¨£¨ä¦b°ê¤ºªº­«­n©Ê¡C1

¡@¡@¥xÆWªº³DÃþ¬ù¦³55ºØ¡A¨ä¤¤¬r³D¦³19ºØ¡AµL¬r³D¦³36ºØ¡A¬r³D¤¤³°³D¦³14ºØ¡A®ü³D¦³9ºØ¡A ¤@¯ëÁ{§É¤W¤ñ¸û±`¨£¡A¬y¦æ¯f¾Ç¤W¤ñ¸û­«­nªº¬r³D¡A¥D­n¬°«C¦Ëµ·(¨ª§Àì|)¡BÀt´ßªá¡B¦Ê¨B³D¡B²´Ãè³D(¶º°Í­Å)¡B«B³Ê¸`¡B¤ÎÂêÁå³Dµ¥¤»ºØ³°³D¡C64

¡@¡@¤@¯ëµL¬r³D«r¶Ë¡A¦h¥b¸û¤£ÄY­«¡A¥u­nµø¬°»´¶ËªvÀø§Y¥i¡F¦ý¦p³Q¬r³D«r¶Ë¡A«hÀ³µø¬°«æ¯g¡A¦p¤£ºò«æ³B¸m¡A«h·|¦³¥Í©R¦MÀI¡C¥xÆWªº¬r³D«r¶ËÁöµM¥D­nµo¥Í¦b¨C¦~ªº3-11¤ë¡A¦Ó¥H7-8¤ë³Ì¦h¡A¦ý®Ú¾Ú¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ßªºµn¿ý¡A¤@¦~¤¤¨C¤@­Ó¤ë¥÷³£¦³¬r³D«r¶Ëªº³ø§i¡C¦]¦¹¡A§Y¨Ï¦b¥V¤Ñ¡A¥ç¤£¥i±Æ°£¬r³D«r¶Ëªº¥i¯à¡C64

¡@

¬r³D«r¶Ëªº¯SÄp64,65

¡@¡@¨å«¬ªº¬r³D«r¶Ë·|¦³¨â­ÓÅãµÛªº¬r¤ú²ª¡A¦ý¬O¨S¦³¬Ý¨ì©úÅ㪺¬r¤ú²ª¡A½T¤£¯à±Æ°£¬r³D«r¶Ëªº¥i¯à©Ê¡A¨Ò¦p²´Ãè³D¤Î«B³Ê¸`«r¶Ë´N±`±`¨S¦³©úÅ㪺¬r¤ú²ª¡A¦Ó¬r¤ú²ª¤]¤£¤@©w¥u¦³¨â­Ó¡A±q¤@Áû¨ì¥|Áû¬r¤úªº¬r³D³£¦³¥i¯àµo¥Í¡C·íµM¡A¦pªG¯f±w¡B¯f±wªº¦P¦ñ©Î±Ï´©¤H­û¯à²M·¡»{ÃѬr³Dªºªø¼Ë¡A±N§ó¥i¤F¸Ñ¬O³Q¦óºØ¬r³D«r¶Ë¡C

Á{§É¯gª¬64,65

¡@¡@¤@¯ë¥i®Ú¾Ú¬r³D«r¶Ë©Ò²£¥ÍªºÁ{§É¯gª¬¡A§â³D¬r¤À¬°¥X¦å©Ê³D¬r¤Î¯«¸g©Ê³D¬r¡A¥xÆW±`¨£ªº«C¦Ëµ·¡BÀt´ßªá¡B¦Ê¨B³Dªº³D¬r§YÄÝ©ó¥X¦å©Ê³D¬r¡F²´Ãè³D¡B«B³Ê¸`«hÄݩ󯫸g©Ê³D¬r¡A¦ÓÂêÁå³D©Ê«h¥H¥X¦å¬r¬°¥D¦ý¥ç¦³¯«¸g¬rªº¯gª¬¡C

¡@¡@³Q¥X¦å¬r¬r³D«r¶Ë¡A¤@¯ë·|¦b30¤ÀÄÁ¦Ü¤@¤p®É¤º²£¥Í¯gª¬¡A¦ý±`¦b³Q«r¤­¤ÀÄÁ¤º¡A¥ß§Y·|µo¥ÍÄY­«ªº¨`µh¡A¨Ã³ò¶¬r¤ú²ª¤¤¤ß¶}©l¸~µÈ¡C±`¨£ªº¯gª¬°£§½³¡ªº¬õ¡B¸~¡B¼ö¡Bµh¡B·ï«C¡B¥Ö¤U¥X¦å¡B©Î§Î¦¨¤ôªw¥~¡A¥ç·|²£¥Í¸z­G¹D¥X¦å¤Î¦å§¿µ¥¥þ¨­©Ê¥X¦å²{¶H¡C

¡@¡@¤@¯ë¦Ó¨¥¡A¯«¸g©Ê³D¬r¶Ë¤f¸û¤Ö¥X²{©úÅ㪺¸~µh¡]¦p«B³Ê¸`«r¶Ë¡A¶Ë¤f±`¤£µh¡A¤]¤£¸~¡^¡A¦ý²´Ãè³D«r¶Ë¡A¶Ë¤f«h±`·|¦³©úÅ㪺¬õ¡B¸~¡B¼ö¡Bµh¡C¯«¸g¬r¬r³D«r¶Ë¡A±`¦b10-15¤ÀÄÁ¤º¡A§Y·|¦Û«r¶Ë³B¥X²{³Â¤ìªº·Pı¡A¨ä«á³vº¥·|²£¥Í²´¥Ö¤U««¡B¤fµÄ©P³ò³Â¤ì¡BÀû¤Õ©ñ¤j¡B¤f¾¦¤£²M¡B§]Ã`§xÃø¡BªÏÅé³Â¤ì(¨Ã¦VªñºÝº¥º¥ÂX®i)¡B¥þ¨­¦Ù¦×µL¤O¡B©I§l§xÃø¡B¬Æ¦Ü©I§l°IºÜµ¥¯gª¬¡C¦p¥¼¤©¥HªvÀø¡A¥i¦b«r¶Ë2-72¤p®É¤º¡Aº¥º¥²£¥Í©ü°g¡B©I§l¦Ù·ò·ô¦Ó­P¦º¤`¡C¦p4-6¤p®É¥H¤W¤´¥¼¥X²{¯gª¬¡AÁa¨Ï¬O¯uªº³Q¬r³D«r¶Ë(®Ú¾Ú³ø§iÅã¥Ü¡A¬ù¦³¥|¤À¤§¤@ªº¬r³D«r¶Ë¡A¨S¦³¥ô¦ó¬r²G¶i¤J¤HÅé)¡A66¨äª`¤Jªº¬r²G¶q³q±`¤]¤£·|¤Ó¦h¡C

¡@

¬r³D«r¶Ëªº²{³õ³B²z64,65,66,67,68,69

¡@¡@¥Ñ©ó¨Ï¥Î¹ï©ó¬r³D«r¶Ëªº²{³õ³B²z¡Aªñ¦~¨Ó¦³«Ü¤jªº§ïÅÜ¡A¥H«e±`¨Ï¥Îªº¶Ë¤f¤Á¶}¥Ø«e¤w¤£«ØÄ³¨Ï¥Î (¦]¤Á¶}¶Ë¤f¡A³q±`µLªk¦³®Ä´î¤Ö¬r²G§l¦¬¡A¤Ï¦Ó·|³y¦¨°ª¤ñ¨Òªº·P¬V¾÷·|¡F¦P®É¤]·|¶Ë¨ì¯«¸g©Î¦Ù¸x¡A³y¦¨µLªk«ì´_ªº«áªG¡F¹ï©ó¥X¦å©Ê¬r³D«r¶Ë¡A§ó¥i¦]¦å²GµLªk¾®©T¡A¦Ó¼W¥[¦å²Gªº¬y¥¢) ¡C¹ï©ó¥H«e±`¨Ï¥Îªººò¸j¤î¦å±aªº¤èªk¥Ø«e¤w¤£«ØÄ³¨Ï¥Î¡]¦]§Y¨Ï±N¤î¦å±aºò¸j¨ì¥iªý¤î°Ê¯ß¦å¬yªººò«×¡A³q±`¤]µLªk¦³®Ä´î¤Ö¬r²G§l¦¬¡A¤Ï¦Ó·|¼W¥[ªÏÅéÃa¦ºªº¾÷·|¤Î¯«¸g¶Ë®`ªº¾÷·|¡A¦]¦¹¥Ø«e«ØÄ³¦pªG­n¸j¡A¥i¥Î¼u©ÊÁ^±a©Î¿ÇÄû¡A¸jªºÃPºò«×»P¤@¯ë°©§é©T©w¥´¼uÁ^¬Û·í¡A¤j¬ù¬O¥iªý¤î²O¤Ú¦^¬y¦ý¤£·|¼vÅTÀR¯ßªº¦^¬y¡^¡C

¡@¡@¥Ø«e¹ï©ó¬r³D«r¶Ëªº²{³õ³B²z­ì«h¦p¤U:

1.í©w¥Í©R¼x¶H(¯«¸g¬r¬r³D«r¶Ë¡A©I§l°IºÜ¥i¯à«Ü§Ö§Yµo¥Í¡A¦p¤Î®É¤©¥H¤H¤u©I

§l¡A«h¥i¯à¤Î®É®¾±Ï¯f¤Hªº¥Í©R)

2.±N¯f±w²¾¶}¬r³D¡A¥H¨¾¤î­«ÂЫr¶Ë(ÁöµM³D³q±`¶]¤£»·¡A¦ý³\¦h¯f±w¦b§ì³D¹Lµ{

¤¤¡A¤S­«ÂгQ³D«r¶Ë¡A¦P®É¡AªÏÅé¶Ã°Ê·|¼W¥[³D¬r§l¦¬¡A¦]¦¹¡A¦b¥u¦³¤@¤H®É¡A

­«ÂI¦bÆ[¹î¬r³Dªº¥~Æ[¤Î¯S¼x¡A¤£­n¦Ò¼{¥h°l¥´³D¡C) 69

3.«O«ù§NÀR, ´î¤Ö¬¡°Ê¡C

4.°£¥h¤âÀô©Î§Ù«üµ¥§ô¿£ª«(¦]ªÏÅé¸~µÈ®É¡A§ô¿£ª«¥i¯à¤£©ö²¾°£¡A¦Ó¥i¯à¼vÅT

ªÏÅé¥\¯à)

5.©T©w¶ËªÏ¨Ã¨Ï¤§§C©ó¤ßŦ¡A¥i¥Î¼u©ÊÁ^±a²Ï©óªñºÝ¡A¦ýÀ³¤£§«Ãª°Ê¡BÀR¯ß¦å¬y¡C

¦p¦³§l¤¹¾¹¡A¥i¨Ï¥Î§l¤¹¾¹ª½±µ§l¤Þ¡C

6.¤£­n¨Ï¥Î¦B¼Å©Î¤î¦å±a¡A¤£­n§½³¡¤Á¶}¶Ë¤f¡A¤£­n³Ü°s¡A¤£­n¥Î¤£¼äªº¤ô²M¬~

¶Ë¤f¡C

7.¾¨³t°eÂå(²{³õ³B¸mµLªk¨ú¥NÂå°|ªvÀø¤Î§Ü³D¬r¦å²Mªºµ¹¤©¡A³Ì¦³®ÄªvÀø¬r³D

«r¶Ëªº¤èªk§Y¬O¥¿½Tªº¨Ï¥Î§Ü³D¬r¦å²M¡A¦]¦¹¤£­n¦]¬°²{³õ³B¸m¦Ó©µ»~¤F°e

Âå¡CÁa¨Ï¯f±w¨S¦³¤¤¬r¼x­Ô¡A¤]À³¾¨³t°eÂå¡A¦]¯gª¬¥i¯à·|©µ¿ðµo¥Í¡C

¡@¡@ªvÀø¬r³D«r¶Ë©Ò¥Îªº§Ü³D¬r¦å²M¡A¥Ø«e°ê¤º¦@¦³¥|ºØ¡A¥]¬A1.ºî¦X§Ü¥X¦å¬r³D¬r¦å²M(¹ï§Ü«C¦Ëµ·¡BÀt´ßªá«r¶Ë)¡B2.ºî¦X§Ü¯«¸g¬r³D¬r¦å²M(¹ï§Ü²´Ãè³D¡B«B³Ê¸`«r¶Ë)¡B3.§Ü¦Ê¨B³D³D¬r¦å²M¡B4.§ÜÂêÁå³D³D¬r¦å²M¡C¤@¯ëÂåÀø°|©Ò³q±`¥u³Æ¦³²Ä1.2¶µ³D¬r¦å²M¡A¦ÓµL3.4¶µ³D¬r¦å²M¡CµM«æ¶EÂå®vÀ³¤F¸Ñ¡A¦p³Q¦Ê¨B³D«r¶Ë¡AÀ³ª`®g§Ü¦Ê¨B³D³D¬r¦å²M¡Aºî¦X§Ü¥X¦å¬r³D¬r¦å²M¬O¤£§t§Ü¦Ê¨B³D³D¬r¦å²M¡A¦]¦¹¬O¨S¦³®ÄªGªº¡C¦p¦³»Ý­n©Î¥ô¦ó¦³Ãö¬rª«ªº°ÝÃD¡A¥iª½±µ»P¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ßÁpµ¸¡A¹q¸Ü:(02) 28757525Âà102¡C

«æ¶EªvÀø­ì«h:

1.í©w¥Í©R¼x¶H¡C¯«¸g©Ê¬r³D«r¶ËÀ³ª`·N©I§l¹Dªººû«ù¡A¥X¦å©Ê¬r³D«r¶ËÀ³ª`·N¾®¦å¥\¯à¡C

  1. ¦pªÏÅé¸~µÈ¡AÀ³¦b¶Ë¤f¸~µÈªº¤W¤è°µ¼Ð°O¡Aªì´Á¨C15¤ÀÄÁ´ú¶q¤@¦¸¶Ë¤f¶i®iªº±¡§Î¡A¦b¸~µÈªº³t«×´î½w«á¡A¨C¤p®É¼Ð°O¸~µÈÂX®iªº±¡§Î¡C¥H§@¬°°l¥[§Ü³D¬r¦å²M©Î¶Ë¤f·P¬Vªº«ü¼Ð¡C64,69
  2. ¨Ì¯f±w¯}¶Ë­·¬Ì­]ªºª`®g±¡ªp¡A¤©¥Hª`®g¯}¶Ë­·Ãþ¬r¯À¡CÁöµM³Dªº¤fµÄ¤º³q±`¨Ã¨S¦³¯}¶Ë­·µß¡A¦ý¶Ë¤f¥i¯à³Qªd¤g©Î¥Ö½§¤WªºÅ¼ªF¦è©Ò¦Ã¬V¡A¦]¦¹¤´À³¤©¥Hª`®g¯}¶Ë­·¹w¨¾¡C69

4.µø±wªÌ¯gª¬¡A¦Ò¼{¬I¤©§Ü³D¬r¦å²M: ¬I¤©¥¿½Tªº§Ü³D¬r¦å²M¡A¤´¬OªvÀø¬r³D«r¶Ë³Ìª½±µ³Ì¦³®ÄªºªvÀø¡AµM¨Ã¤£¬O¨C¤@¦ì¬r³D«r¶Ëªº¯f±w³£À³µ¹¤©§Ü³D¬r¦å²M¡A¦p¯f±w¶W¹L6-8¤p®É¤´µL¯gª¬¡A©Îªì©l¯gª¬¨Ã¥¼ÂX´²¡A¥i¥H¤£¥Î§Ü³D¬r¦å²M¡C¨ä¨Ï¥Î¤èªk°Q½×¦p¤U¡C64,65,69

5. »´·Lªº«r¶Ë¡A§Ü¥Í¯À¥i¤£¥²µ¹¤©¡C¦ý¦p¥i¯à¬°¦Ã¬Vªº¶Ë¤f(¤×¨ä¬O³Q¤H¥Î¼L§l¤¹¹Lªº¶Ë¤f)«hÀ³µ¹¤©§Ü¥Í¯À¡C³D¤fµÄ¤ºªº²Óµß¥H­²Äõ¦¡³±©Ê¤Î¹½®ñµß¬°¥D¡A¦pµo¥Í¦¸µo©Ê·P¬V®É¡A«ØÄ³¥i¥ýµ¹¤©²Ä¤G¥N¤§ÀY­MªÞ¯À(cephalosporin)¡F¦p³Q¤Hªº³è²G¦Ã¬V¡A«h¥i¤©²Ä¤G¥N¤§ÀY­MªÞ¯À¦pCefadoxil, 500²@§J¡A¨C¤Ñ¨â¦¸¡AªvÀø¤­¤Ñ¡F©Îdicloxacillin 250¦Ü500²@§J¡A¨C¤Ñ¥|¦¸¡AªvÀø7-10¤Ñ¡C69

6.(¶¡«Ç¯g­Ô¸s)compartment syndrome66,69,70: ¬r³D«r¶Ë(¤×¨ä¬O¥X¦å¬r)¡A±`·|³y¦¨ªÏÅé©úÅ㪺¸~µÈ¡A¨ä³q±`ªí¥Ü§Ü³D¬r¦å²M¥Î±o¤£°÷¡A¾A¶qªºµ¹¤©§Ü³D¬r¦å²M¡A³q±`¥iÁ×§K¦¹¨Öµo¯gªº²£¥Í¡C¥Ñ©ó¬r²G³q±`¥u®g¤J¥Ö¤U(subcutaneous)¦Ó¨S¦³®g¤Jµ¬½¤(fascia)¤U¡A¦]¦¹¸~µÈ³q±`¥u¦b¥Ö¤U¦Ó¤£¦b¶¡«Ç¤º(intracompartment) ¡C³q±`Á{§É¤W­Y¥u¾aÁ{§É¯gª¬­n¶EÂ_¶¡«Ç¯g­Ô¸s¡A°£¤F¦³©úÅ㪺¯«¸g¯g­Ô¥~¡A¤@¯ë¸û¬°§xÃø¡A¨ä²z¥Ñ¬O1. «r¶ËªºªÏÅ饻¨­§Y·|µh¡A¦]¦¹¤£©ö»P¶¡«Ç¯g­Ô¸sªº¯kµh°Ï§O2.¬r³D«r¶Ë©ö¦³¥Ö¤U¥X¦å¡A¦]¦¹¬Ý°_¨Ó»P¶¡«Ç¯g­Ô¸sªºcyanosis¤£©ö°Ï§O3. ¥Ö¤UÄY­«¤ô¸~®ÉÁa¨Ï¤U­±¯ß·i¤´«Ü¦n¤]¤£©öºN¨ì¡C¥Ñ©óÁ{§É¯gª¬¤£©ö½T©w¬O§_¦³¶¡«Ç¯g­Ô¸s¡A¬G¶·¥Hª½±µ´ú¶qcompartment pressure(ª½±µ´ú¶qcompartment ªºÀ£¤O¡A¤@¯ë«ØÄ³¤j©ó30 mmHg¥H¤WÀ³¦Ò¼{fasciotomy)©Î¥HPulse Doppler flowmeter(¬Æ¦Ü·|¦b¦³©úÅã¤ô¸~¥BªÏºÝªº·Å«×¤w­°§Cªºª¬ªp¤U¡A°Ê¯ß¦å¬y¤]¨S¦³¤U­°) 70¨Óµû¦ôcompartment ªºÀ£¤O©Î¦å¬y¡A¥H¨M©w¬O§_­n°µfasciotomy¡C

¡@

§Ü³D¬r¦å²M¨Ï¥Î¤èªk: 64,65,71

¡@¡@¤@¯ë§Ü³D¬r¦å²M¦b³Q«r¶Ë«á¥|¤p®É¤º¨Ï¥Î¡A³Ì¦³®ÄªG¡A¶W¹L8¤p®É¥H¤W¡A«h®ÄªG¸û®t;¦ý¦b«r¶Ë3-4¤Ñ«á¡A¤~¨Ï¥Î§Ü³D¬r¦å²M¡A¤´¦³¦³®Äªº³ø§i¡C§Ü¬r¦å²M¨Ï¥Î«e¡A»Ý¥ý°µ¹L±Ó¸ÕÅç¡A¤èªk¬O¨ú10ml¤§µ}ÄÀ²Gµ}ÄÀ1000U§Ü³D¬r¦å²M¡A¦A¨ú¨ä¤¤1ml·»²G¥[¤Jµ}ÄÀ²G¦¨¬°10ml¡A¨ú¨ä¤¤0.1ml°µ¥Ö½§¸ÕÅç¡A¦p30¤ÀÄÁ¤º²£¥Í½üª¬¯B¸~¡A©Î©P³ò°_¬õ·wªÌ¡Aµø¬°¶§©Ê¡CµM¸ÕÅç³±©Ê¨Ã¤£¯à«OÃÒ¤£·|µo¥Í¹L±Ó¡C©Î¥H¤@¾¯¶qµ}ÄÀ¦¨¬°10ml¡A¨ä¤¤³Ìªìªº1mlÀR¯ßºwª`5¤ÀÄÁ¡A¥H«á¨C¤ÀÄÁ¤£­nºw¶W¹L1ml¡A¥i¦b15-30¤ÀÄÁ¤ººwª`§¹²¦¡C¦p¥Ö½§¸ÕÅ笰¶§©Ê¡A¦Ó¯f±w¤S½T¹ê»Ý¨Ï¥Î§Ü³D¬r¦å²M¡A¥i¥ý¦æª`®gantihistamine¤Î decadron¡A¨Ã´îºC¦b30¤ÀÄÁ¦Ü2¤p®É¤ººwª`¡A¦P®É·Ç³Æ¦n®ðºÞ´¡ºÞ¤Î epinephrineµ¥«æ±Ï¸Ë³Æ¡A¥H«Kµo¥Í¹L±Ó©Ê¥ð§J®É«æ±Ï¡C

¡@¡@Á{§É¤W¨Ï¥Î§Ü³D¬r¦å²Mªº¾¯¶q¡A¤@¯ë¬°1-3²~(vials)¡A¦ý¦³®É¤´»Ý¥Î¨ì¶W¹L10²~¡A®Ú¾Ú¬r³D¬ã¨s©Ò¹ù©Òªøªº³ø§i¡A¹ï©ó¥xÆWªF³¡ªº²´Ãè³D«r¶Ë¥­§¡»Ý¥Î12²~§Ü³D¬r¦å²M¨ÓªvÀø¡F¹ï©ó¥xÆW¦è³¡ªº²´Ãè³D«r¶Ë¥­§¡¬ù»Ý¥Î6²~§Ü³D¬r¦å²M¨ÓªvÀø¡F¹ï©ó«B³Ê¸`«r¶Ë¥­§¡¬ù»Ý¥Î2²~§Ü³D¬r¦å²M¨ÓªvÀø¡F¹ï©ó¦Ê¨B³D«r¶Ë¥­§¡¬ù»Ý¥Î2²~§Ü³D¬r¦å²M¨ÓªvÀø¡F¹ï©ó«C¦Ëµ·©ÎÀt´ßªá«r¶Ë¥­§¡¬ù¨Ï¥Î1²~§Ü³D¬r¦å²M¨ÓªvÀø¡F¹ï©ó¤p«Ä¾¯¶q¶·¥[­¿¡C71

¡@¡@¥H§Ü³D¬r¦å²MªvÀø¦p§½³¡©Î¥þ¨­©Ê¯gª¬¤´Ä~Äò´c¤Æ©Î¨S¦³§ïµ½¡A¥i¦b¥b¤p®É¦Ü¨â¤p®É¤º¡A¦Aª`®g¤@¾¯¶q¡Aª½¦Ü§ïµ½¬°¤î¡C¹ï©ó¦b°ê¥~ª`®g§Ü³D¬r¦å²M±`µo¥Íªº¦å²M¯f(serum sickness),¦b°ê¤º¨Ã¤£±`¨£¡C

¡@

©øÂΫr¶Ë

¡@¡@¤j¦h¼Æªº©øÂΫr¶Ë¡A¥u¤Þ°_»´«×ªº¸~µh¡A¨ä¤@¯ë³B²z­ì«h¥]¬A¡G

1¡B ¥Î¤ô©MªÎ¨m²M¬~¶Ë¤f¡C

2¡B ¥Î¯½¥¬±N¶Ë¤fÂл\¡A¨Ãªý¤î¯f±w·k§ì¶Ë¤f¡C

3¡B ¥Î§N¼Å¥H´î¤Ö¸~µÈ©MÄoªº·Pı¡A¦ý¤£­n¦b¶Ë¤f¤Wª½±µ¥Î¦B¼Å¡C

¡@

¡@¡@¦ý¦p¦³¥H¤U¹L±Ó¼x«J®É¡A«hÀ³ºû«ù¨ä¥Í©R²{¶H¥ß§Y°eÂå¡G

1¡B «r¶Ë³¡¦ì¦³¨`µh©MÄoªº·Pı¡C

2¡B ¤â´x©M¸}©³µoÄo¡C

3¡B ÀV³¡©M¸¡ªÑ·¾³BµoÄo¡C

4¡B ¥þ¨­©Ê¤ô¸~¡C

5¡B ¥þ¨­¦³ëC³Â¯l¡C

6¡B ©I§l§xÃø¡C

7¡Bäú¤ß¡B¹Ã¦R¡B·w­Ë¡B¥ð§J¡B©ü°g¡C

¡@

«æ¶EªvÀø­ì«h:

  1. í©w¥Í©R¼x¶H¡Aª`·N¹L±Ó¥ð§Jªº³B¸m
  2. ¥Î¤ô©MªÎ¨m²M¬~¶Ë¤f¡C
  3. µ¹¤©§N¼Å¡C
  4. »Ý­n®É¤©¥H¯}¶Ë­·¹w¨¾¡C
  5. ¥iµ¹¤©¤îµh¾¯ªvÀø¯kµh¡Aµ¹¤©§Ü²Õ´ÓiªvÀøÄo¤Î»´«×¹L±Ó¡Aµ¹¤©µÇ¤W¸¢¯À(epinephrine) ªvÀø¤¤¦Ü­««×¹L±Ó¤ÏÀ³¡C

¡@

¡@

¸ÁÁ±¶Ë

¡@¡@®Ú¾Ú¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ßªº²Î­p¡A©Ò¦³°Êª««r¶Ë¤¤µo¥Í³ÌÀWÁcªÌ¡A§Y¬°¸ÁÁ±¶Ë¡C1¦b¥xÆW¡A´¿µo¥Í¦h°_ªêÀY¸Á(­J¸Á)Á±¶Ë­P¦ºªº¨Æ¥ó¡A¸g¹L´CÅ骺³ø¾É¡A®æ¥~¤Þ¤Hª`·N¡C¦ý¨Æ¹ê¤W¡A»e¸Á©M­J¸Á³£·|¤Þ°_ÄY­«ªº¹L±Ó¤Î¤¤¬r¤ÏÀ³¡A¥¦­Ì©M¤õ¿ÂÃÆ³£¬OÄݩ󽤯ÍÃþ©øÂΡA®Ú¾Ú¬ü°êªº²Î­p©øÂΫr¶Ë¤¤³Ì±`¤Þ°_¦º¤`ªÌ§Y¬°½¤¯ÍÃþ©øÂΡA¦Ó¨ä¥L©øÂΫh«Ü¤Ö³y¦¨¦º¤`¡C72¦Óµ´¤j¦h¼Æ¸ÁÁ±­P¦ºªÌ¡A³£¬O¦]µo¥ÍÄY­«¹L±Ó©Ê¥ð§J¦Ó­P©R¡C73

¡@¡@¤j¦h¼Æ¸ÁÁ±¶Ë¥u²£¥Í§½³¡¤ÏÀ³¡A¤Ö¼Æ·|¥X²{ÄY­«¤¤¬r¤Î¹L±Ó¤ÏÀ³¡A¦Ó¦­´Á­P¦ºªÌ¦h¥b¦]µo¥ÍÄY­«¹L±Ó¤ÏÀ³¦Ó¦º¡A¨ä¤¤¤j¦h¼Æµo¥Í©ó«e15¤ÀÄÁ¤§¤º¡A¦Ó³Q¤j¸Á¡B¤p¸ÁÁ±¶Ë¡A¨äµo¥Í¹L±Ó©Êªº¾÷·|´X¥G¨S¤°»ò®t§O¡A¦P®É¾i¸Áªº¤H¨Ã¤£·|¦]¦¹¦Ó§K¬Ì¡A¤]¦P¼Ë·|µo¥Í¹L±Ó¡A¦Ó¹L±Óªº¯gª¬³q±`¤@¦¸·|¤ñ¤@¦¸ÄY­«¡C¥Ñ©ó¸ÁÁ±­P¹L±Ó©Ê¥ð§J¦º¤`¡A¦h¦b°e¹FÂå°|«e§Yµo¥Í¡A¦]¦¹¡A¦b¬ü°ê«ØÄ³¤@¯ë¾i¸Á¤Î­¥¹C¡Bµn¤sªÌ¡A³Ì¦nÀH¨­±a¦³ªvÀø¹L±Ó©Ê¥ð§Jªº¯S§O¸Ë³Æ¡A¦pAna-Kit©ÎEpi-Pen (¤º§tªvÀø¹L±Ó©Ê¥ð§J³Ì­«­nªºÃĪ«--µÇ¤W¸¢¯À¡A¥u­n¥Î¤â»´»´¤@«ö¡AÃĪ««Ü§Ö§Y¥i¶i¤JÅ餺)¥H³Æ¤£®É¤§»Ý¡C72

¡@¡@¸ÁÂǵۧÀ³¡ªºÁ±°w±N¬r²Gª`¤J§ðÀ»ªº°Êª«¡A­J¸ÁÁ±¤H®ÉÁ±°w¤£·|³Q©Ô¥X¡A¥i³sÄò¥m¤H¡F¦Ó»e¸ÁÁ±¤H®Éîg°w·|³Q©Ô¥X¯d¦b¯f¤H¶Ë¤f¤W¡A¦P®É¬r²GÅn¤]·|³Q¤@¨Ö©Ô¥X¡AÁ±°w¤Î¬r²GÅn¦bÂ÷¶}»e¸Á§À³¡«á¡A¤´¥iÄ~Äò©â°Ê¹F30-60¤ÀÄÁ¡A¤£Â_¦a©ñ¥X¬r²G¡A¦]¦¹¡A¦pµo²{¶Ë¤f¤W¦³¨ë°w¡AÀ³±N¨ä°£¥h¡A¥H¨¾¤î¬r²GÄ~Äò¶i¤JÅ餺¡C°£¥hªº¤èªk¡A¥i¥Î«ü¥Ò¡B¤M¤ù©Î«H¥Î¥d»´»´ªº±N¨ë¤Î¬r²GÅn¨í°£¡A¤£­n¥Î¤â¥hÀ£À½¡A¥H§Kª`¤J§ó¦hªº¬r²G¡C74,75

¡@

¸ÁÁ±¶ËªºÁ{§É¯gª¬68,72,73,74,75,76

¡@¡@¸ÁÁ±«á¡A¤j¦h¼Æ¥u²£¥Í§½³¡¤ÏÀ³¡A¤Ö¼Æ·|¥X²{ÄY­«¤¤¬r¤Î¹L±Ó¤ÏÀ³¡A¤@¯ë¥i±N¨ä¯gª¬¤À¬°:

¤@¡B§½³¡¤ÏÀ³¡G§½³¡¬õ¡B¸~¡B¼ö¡Bµh©Î¦³»´«×·kÄo¡C

¤G¡B¬r©Ê¯gª¬¡G¤@¯ë¶W¹L¤Q­Ó¥H¤Wªº¸Áîg¤ñ¸û·|²£¥Í¬r©Ê¯gª¬¡A¥D­n¦³¤f´c¤ß¡B¹Ã¦R¡B¸¡Âmµ¥¸z­G¹D¯gª¬¡A§]Ã`§xÃø¡B©âÝz¡B¯«´¼¤£²Mµ¥¯«¸g¯gª¬¡A¥H¤Îµo¿N¡B¥þ¨­¤ô¸~¡B¦åÀ£¤U­°¡B¥ð§Jµ¥¯gª¬¡C

¤T¡B¹L±Ó¤ÏÀ³¡G¥u­n¤@°¦¥m«r¡A¤£ºÞ¤j¸Á¡B¤p¸Áîg¶Ë¡A³£¥iµo¥ÍÄY­«ªº¹L±Ó©Ê¥ð§J¡A¤@¯ë¦³¹L±ÓÅé½èªº¤H¡A§ó®e©öµo¥ÍÄY­«ªº¹L±Ó©Ê¥ð§J¡C¥D­n¯gª¬¥]¬A°®«y¡B³ïÄV©Î¯Ý³¡¦³ºòÁYªº·Pı¡B²´¥Ö¯B¸~¡BµoÄo¡B¥þ¨­ëC³Â¯l¡B©I§l§xÃø¡BÁy¦âµo¥Õ©Îµo«C¡B¦³§Ö¦º±¼ªº·Pı¡B¦åÀ£¤U­°¡B©ü°gµ¥¡C¨ä¤¤³Ì±`¨£ªº¬O¥Ö½§¯gª¬¡A¸g±`¦b¸ÁÁ±«á2-3¤ÀÄÁ´N²£¥Í¡A¦Ó­P¦º¦h¥b©ó«e15¤ÀÄÁ¤§¤ºµo¥Í¡C­Y¥ý«e¦³³Q¸Áîgªº°O¿ý¡A¤U¦¸¦p¦A³Qîg¨ì¡A¦³35-60%ªº¾÷·|·|³y¦¨¹L±Ó©Ê¥ð§J¡C76

¥|¡B©µ¿ð©Ê¹L±Ó¤ÏÀ³¡G¤@¯ë¦b¸ÁÁ±«á10-14¤Ñ²£¥Í¡A¥i³æ¿W¥X²{¡A¤]¥i¥ý¸g¹L¤@¬q¸û»´ªº«æ¦æ©Ê¹L±Ó¤ÏÀ³¤§«á¦Aµo¥Í¡C¨ä¥D­n¯gª¬¥]¬Aµo¿N¡B²O¤Úµ²¸~¤j¡BÃö¸`µh¡B¥Ö½§°_¯l¡BÀYµh ¤Î¥þ¨­µL¤Oµ¥¡C

¡@

²{³õªvÀø68,72,73,74,75

¤@¡B§½³¡¤ÏÀ³ªºªvÀø:1.¦p¨ë°w¯d¦b¥Ö½§¤W¡A¥i¥Î«ü¥Ò¡B¤M¤ù©Î«H¥Î¥d»´»´ªº±N¨ë¤Î¬r²GÅn¨í°£¡A¤£­n¥Î¤â¥hÀ£À½¡A¥H§Kª`¤J§ó¦hªº¬r²G¡C2.¥ÎªÎ¨m¤ô©Î®ø¬r¤ô²M¬~¶Ë¤f¡A¨Ã»\¤W¯½¥¬¡C3.¥Î§N¼Å¡A¥H´î¤Ö¸~µÈ¤ÎÄo¡A¦ý¤£­n¦b¶Ë¤f¤Wª½±µ¥Î¦B¼Å¡C

¤G¡B¬r©Ê¤ÏÀ³ªºªvÀø: »´«×ªº¬r©Ê¤ÏÀ³¡AªvÀø»P§½³¡¤ÏÀ³ªºªvÀø¬Û¦P¡C¦p¯gª¬ÄY ­«¡A«hÀ³Ã­©w¥Í©R¼x­Ô¡A±NÁ±¶Ë³¡¦ì©ñ§C¡A¨Ã¥ß§Y°eÂå¡C

¤T¡B¹L±Ó¤ÏÀ³ªºªvÀø: 1.±NÁ±¶Ë³¡¦ì©ñ§C

2.¥Î«ü¥Ò¡B¤M¤ù©Î«H¥Î¥d»´»´ªº±N¨ë¤Î¬r²GÅn¨í°£

3.¦p©I§l§xÃø¡Aµ¹®ñ®ð¡A¥²­n®Éµ¹¤©¤H¤u©I§l

4.ªvÀø¥ð§J¡A«O«ù·Å·x

5.¦p¹L±ÓÄY­«¡AÀ³µ¹¤©ª`®gµÇ¤W¸¢¯À

6.¶Ë¤f¤Î¸~µÈ³¡¦ì¥i¤©¥H§N¼Å

7.¥ß§Y°eÂå

«æ¶EªvÀø­ì«h68,72,73,74,75

  1. í©w¥Í©R¼x¶H¡Aª`·N¹L±Ó¥ð§Jªº³B¸m
  2. ¥Î«ü¥Ò¡B¤M¤ù©Î«H¥Î¥d»´»´ªº±N¨ë¤Î¬r²GÅn¨í°£
  3. ¥ÎªÎ¨m¤ô©Î®ø¬r¤ô²M¬~¶Ë¤f
  4. ©ï°ª±wªÏ¡A¥i¤©¥H§N¼Å
  5. ¥iµ¹¤©¤îµh¾¯¡B§Ü²Õ´Ói(¦pbenadryl 25-50mg¡B©Î§½³¡¤îÄo¾¯(¦pcalamine lotion)
  6. ¤j¤ùªº§½³¡¤ÏÀ³¥i¯à»Ýµ¹¤©µu´ÁªºÃþ©T¾JªvÀø
  7. ¦p³Q¦h°¦»e¸ÁÁ±¨ìÀ³Æ[¹î24¤p®É¡Aª`·N¬O§_¦³µÇ°IºÜ©Î¾®¦å²§±`ªº²{¶Hµo¥Í¡C
  8. ¤¤«×¥H¤Wªº¹L±Ó(¦p²£¥Íangioedema©Îbronchospasm)¡A°£µ¹¤©ÀR¯ßª`®gantihistamine©Î§l¤J®ðºÞÂX±i¾¯(bronchodilator)¥~¡A§Y¬O¾A¦X¨Ï¥ÎµÇ¤W¸¢¯À)(epinephrine)ªº®É¾÷¡A¨ä¾¯¶q¬°¥Ö¤Uª`®g(subcutaneous) 1:1000¤§epinephrine 0.3-0.5ml¡A¦p¦³¥²­n¥i¨C20-30¤ÀÄÁ­«ÂШϥΡC
  9. ¦p¥ð§JÄY­«¡A°£¤©¥H¸É¥R²GÅé¥~¡A¥iµ¹¤©1:10000¤§epinephrine 3-5ml ¦p¦³¥²­n¥i¨C3-5¤ÀÄÁ­«ÂШϥΡC

¡@

¹w¨¾68,72,73,74

¡@¡@¹w¨¾³Ó©óªvÀø¡A¹ï¸ÁÁ±¹L±Óªº¯gª¬¡A³q±`¤@¦¸¤ñ¤@¦¸ÄY­«¡A¦]¦¹¹ï¸ÁÁ±¹L±Óªº¤H¡AÀ³¯S§O¤p¤ßÁ×§K³Q¸ÁÁ±¨ì¡C¹w¨¾¤§¹D¥]¬A1.½Ð±M·~¤H­û¥h°£©~®aªþªñªº¸Á±_2.¤á¥~¤£­n¨ª¸}©Î¬ï²æ¾c3.¦b¤á¥~Á×§K¬ïªá¦â©ÎÂA«Gªº¦çªA¡A¾¨¶q¬ï¥Õ¦â¡Bºñ¦â¡B¤Î¤g½Å¦âªº¦çªA4.Á×§K¨Ï¥Î­»¤ô¾v½¦µ¥§t­»®Æªºª««~5.¦b¤á¥~¾¨¶q¬ïªø³S¡Bªø¿Ç¨ÃÀ¹¤â®M6.¹ï¸ÁÁ±´¿ÄY­«¹L±ÓªÌ¡AÀ³Á×§K°£¯ó©Î±Äªá7.¦p¹J¨ì¸Á¸s¡AÀ³«O«ù§NÀR¡AºCºC²¾°Ê¡AÁ×§K©ç¥´©Î§Ö³t²¾°Ê¡A¦pµLªk°kÂ÷¡A¥i´N¦a­w¤U¨Ã¥Î¤â©ê¦íÀY³¡¡C

¡@

»jµï

¡@¡@¤j¦h¼Æªº»jµï¡A¦b¤f¾¹¤º¨ã¦³¬r¸¢¡A¦ý¨ä¬r©Ê³q±`¥u¯à¦M®`¤p°Êª«©Î©øÂΡA¦Ó¹ï©ó¤HÃþ¡A¥i¥H»¡¬OµL¬rªº¡C¦b¥i©Èªº»jµï¤¤¡A³Ì¦³¦Wªº´N¬O¶Â¹è°ü»jµï¡A¦Ó¥xÆW¦³¤@ºØ¬õ­I»jµï¡A©M¶Â¹è°ü»jµï¬O¦P¤@Äݪº»jµï¡A¥L­Ì³£¨ã¦³±j¯Pªº¯«¸g¬r¡A«Ü¤Ö²£¥Í§½³¡¤ÏÀ³¡A±`¨£ªº¯gª¬¥]¬A¦åÀ£¤É°ª¡BÁy³¡¼é¬õ¡B¥X¦½¡B¤f¬n²´Üo¡B¦Ù¦×¯kµh¡B©âÝz¡Bäú¤ß¡B¹Ã¦Rµ¥¡AÄY­«®É¥i­P©I§l¦ÙµjÅË¡A©I§l°IºÜ¦Ó¦º¤`¡C¤@¯ë³o¨Ç¯gª¬·|¦b«r¶Ë«á¤Q¤ÀÄÁ¦Ü¤G¤p®É¤º¥X²{¡C

¡@¡@¥xÆW¥t¦³¤@ºØ¬r»jµï¬Oµ·»jµï¡AÃþ¦ü¬ü°êªº´Ä¦âÁô¤h»jµï¡C¤H­Ì³Q«r¶Ë®É±`¨S¦³¹îı³Q«r¶Ë¡]¦]¨ä«r¶Ëªì´Á±`¤£µh¡A¨S¦³·Pı¡^¦ý¼Æ¤p®É«á¡A«h·|²£¥ÍÄY­«ªº¸~µh¡A¬Æ¦Üµo¥ÍÄ[¦º¡A¼ìºÅµ¥¯gª¬¡C

»jµï«r¶Ë²{³B²z­ì«h¥]¬A¡G

1¡B í©w¥Í©R¼x¶H¡Aª`·N¥ð§J³B¸m¡]Áa¨Ï¯f±w©|µL¥ð§J¯g«J¡^¡C

2¡B ¥Î¼uÁ^©T©w¶ËªÏ¡A¨Ï¤§¤ñ¤ßŦ§C¡C

3¡B ¥i¥Î§N¼Å´î¤Ö¸~µÈ¡A¦ý¤£­nª½±µ¦B¼Å¡C

  1. ¥ß§Y°eÂå¡C

«æ¶EªvÀø­ì«h

  1. í©w¥Í©R¼x¶H
  2. ²M¬~¶Ë¤f
  3. ¨Ï¥Î§N¼Å
  4. ¥iµ¹¤©¤îµh¾¯¡B§Ü²Õ´Ói¡B§Ü¥Í¯À¡C
  5. µ¹¤©¯}¶Ë­·¹w¨¾¡C
  6. ¦b48-72¤p®É¤º¥iµ¹»P¤fªAdapson,50-100mg¤@¤Ñ¨â¦¸,ªvÀø§½³¡Ãa¦º¡C
  7. ¦Ò¼{µ¹¤©§Ü°ª¦åÀ£ªvÀø¡C

ÃȤl

¡@¡@ÃȤlªº¸¡³¡³Ì¥½¸`¦³Á±¨ë¡A¤º±µ¬r²G¸¢¡A³QÁ±¶Ë®É§½³¡·|²£¥Í±j¯Pªºµhı¡A¦p¤õ¿N¤@¼Ë¡CÃȬr²G¬°¯«¸g¬r¡A¨ä¤¤¬r¯gª¬¬°äú¤ß¡B¹Ã¦R¡BÀû¤ÕÂX±i¡B¤ß¸õ¥[§Ö¡B¦åÀ£¤W¤É¡B©âÝfµ¥¡C

¡@¡@¥xÆW¥»®q¤Îªþªñ¤p®q¤]¦³ÃȤlªºÂܸñ¡AµM®Ú¾Ú¥x¥_ºaÁ`¬rª«¤¤¤ßªºµn¿ý°ê¤º³QÃȤlÁ±¶Ëªº¯f±w¡A³q±`¥u¦³§½³¡¼@µh¤Î¬õ¸~µ¥§½³¡¯gª¬¡A¦ý°ê¥~«h¦³¦º¤`ªº³ø§i¡C

¡@

¸¼°G

¡@¡@¸¼°G«eºÝ²Ä¤@¹ïªþªÏ¯S¤Æ¬°¬r¤ö¡A¥Î¨Ó¨ë±þÂyª«¡C¸¼°Gªº¬r²G§e»Ä©Ê¡A³Q¸¼°G«r¶Ë®É¥i¥H®ò¤ô¨Ó¨R¬~¶Ë¤f¡A®Ú¾Ú¥x¥_ºaÁ`¬rßÓª«¿Ô¸ß¤¤¤ßªºµn¿ý°ê¤º¸¼°G«r¶Ëªº¯f±w¡A³q±`¥u¦³§½³¡ªº¬õ¸~¡A¼@µhµ¥¯gª¬¡A¦Ó°ê¥~¦³¦º¤`ªº³ø§i¡C

¡@

®ü¬v¥Íª««r¶Ë¤ÎÁ±¶Ë

¡@¡@¥xÆW¥|­±Àô®ü¡AÀHµÛ®ü°ìªº¶}©ñ¡A¤@¯ë¥Á²³¦³§ó¦hªº¾÷·|±µÄ²®ü¤¤ªº¥Íª«¡C®ü¬v¥Íª«ªº«r¶Ë©ÎÁ±¶Ë©M³°¦a¥Íª«¦³³\¦hªº¤£¦P¡C²Ä¤@¡A¤ô¤¤ªº¥Íª«¥i¯à²£¥Í§ó¼sªxªº²Õ´¶Ë®`¡A¦¹ºØ¶Ë®`À³·í§@³n²Õ´¶Ë®`¨Ó³B²z¡C²Ä¤G¡A¤ô¤¤¥Íª«ªº¬r²G(¦p³Qäá³½¡B·à³½¡B Ãȳ½¡B¥ÛÀY³½µ¥¨ë¶Ë)¡A³q±`¥i³Q¼ö¯}Ãa¡A©Ò¥H­n¥Î¼ö¼Å¡A¦Ó¤£¬O§N¼Å¡C77,78,79®ü¬v¤¤ªº²Óµß¥H­²Äõ¦¡³±©Ê±ìµß¬°¦h¡A®ü¤ô¤¤¨ü¶Ëªº¶Ë¤f±`¨£°ö¾iªº²Óµß¥]¬AAeromona hdrophila, Bacteroides fragilis, Chromobacterium violaceum, Clostridium perfringens, Erysipelothrix rhusopathiae, Escherichia coli, Mycobacterium marinum, Pseudomonas aeruginosa, Salmonella enteritidis, Staphyloccus aureus, Streptococcus species, ¤ÎVibro species¡C77 ³B²z®ü¤ô¤¤¨ü¶Ëªº¶Ë¤f·P¬V¡A³q±`¥²¶·¥]¬A¥i¹ï§Ü©·µß(Vibro species)ªº§Ü¥Í¯À¡A²Ä¤T¥Nªºcephalosporin(¦pcefoperazone,cefotaxime, ceftazidime)³q±`¦³Àu¨}ªº¹ï§Ü®ÄªG¡A¦Ó²Ä¤@¤Î²Ä¤G¥Nªºcephalosporin(¦pcefazolin, cephalothin, cephapirin, cefamandole, cefonicid, ceforanide,cefoxitin)«h®ÄªG¤£¨Î¡C¨ä¥L§Ü¥Í¯À¥]¬Atrimethoprim-sulfamethoxsole¡Btetracycline¡Bciprofloxacin¡Bcefuroximeµ¥¹ï©·µß·P¬V¤]¦³®Ä¥Î¡C°ò¥»¤W¡A¦b²H¤ô¤¤¤]¬O¥Hªº²Óµß¥H­²Äõ¦¡³±©Ê±ìµß¬°¦h¡A¦p¦b²H¤ô¤¤¨ü¶Ëªº¶Ë¤f·P¬V¡A°£¥H¤WÃĪ«¥~¥ç¥i¥[¤Waminoglycoside©Îimipenem¥H¹ï§Ü Aeromonas species¡C¦¹¥~¡A¥Ñ©óStaphyloccus¤Î Streptococcus¤´¬O¬Û·í±`¨£ªº·P¬Vµß¡A¦]¦¹¿ï¾Ü¹ï§Ü³o¨âºØ­²Äõ¦¡¶§©Êµßªº§Ü¥Í¯À¡A¤]¶·¦Ò¼{¡C

67,77,78,79

¡@

¹ï®ü¤ô¦Ã¬V¶Ë¤f§Ü¥Í¯À¨Ï¥Î­ì«h¦p¤U¡G67,77,78,79

  1. ¤pªºÀ¿¶Ë©Îµõ¶Ë¡A¨S¦³·P¬V²{¶H: ¹ï©ó¥¿±`¤H¡A¤pªºÀ¿¶Ë©Îµõ¶Ë¡A¥i¤£¥Î¨Ï¥Î¹w¨¾©Ê§Ü¥Í¯ÀªvÀø¡C¦p¯f±w¦³ºC©Ê¯e¯f¡]¦p¿}§¿¯f¡B¨xµw¤Æ¡^©Î§K¬Ì¤£¥þ¡]¦p·R´þ¯f¡Bªø´Á¨Ï¥ÎÃþ©T¾J±wªÌ¡^¡AÀ³¬I¤©¹w¨¾©Ê§Ü¥Í¯ÀªvÀø¡A¥iµ¹¤©¤fªAtrimethoprim-sulfamethoxsole(­º¿ïÃĪ«)¡Btetracycline(©Îdoxycycline)¡Bciprofloxacin¡B©Îcefuroximeµ¥¡C
  2. ¤pªºÀ¿¶Ë©Îµõ¶Ë¡A¦³·P¬V²{¶H:À³¤©¥HÂX³Ð¡A¨Ã¨Ï¥Î§Ü¥Í¯À¡C°£¤F(1)ªº³B¸m¥~¡AÀ³¿ï¾Ü¥i¹ï§ÜStaphyloccus¤Î Streptococcusªº§Ü¥Í¯À(¦]¨ä¤´¬O³Ì±`¨£ªº·P¬Vµß)¡C
  3. ÄY­«ªº¶Ë®`¡A¥]¬A¤jªºµõ¶Ë¡B²`ªº¨ë¶Ë¡B¤Î¥~ª«´Ý¯d(foreign body retention)µ¥¡A¦pÃT³½«r¶Ë¡Bäá³½¨ë¶Ë¡B®üÁx¨ë¶Ë¡B©Î¥þ«p«×ªº¬À·ä³Î¶Ëµ¥¡G¦p¯f±w»Ýª`°|©Î¥~¬ì¤â³N¡A«ØÄ³¨Ï¥Îªº§Ü¥Í¯À¥]¬Aimipenem-cilastatin, gentamicin, tobramycin, amikacin, trimethoprim-sulfamethoxsole, cefoperazone,cefotaxime, ceftazidime,¤Îchloramphenicol. ¦p¯f±w¥i¦bªù¶EªvÀø¡A¿ï¾ÜªºÃĪ«À³¥]¬A¥i¹ï§Ü©·µß·P¬Vªº§Ü¥Í¯À¥]¬Aciprofloxacin¡Btrimethoprim-sulfamethoxsole¡Btetracycline(©Îdoxycycline)¡B©Îcefuroximeµ¥¡C

¡@

ºò«æ³B²z

  1. í©w¥Í©R¼x¶H
  2. ¤jªº«r¶Ë¡]¦pÃT³½«r¶Ë¡^¡A¥D­n·|¦]¥X¦å»P·Ä¤ô¦Ó­P©R¡A¨äªvÀø¤@¯ë¤j³Ð¶Ë¤@¼Ë¡C
  3. ¶Ë¤fÀ³¤©¥H²M¬~¤ÎÂX³Ð¡]debridement¡^
  4. ¦Ò¼{ªw·Å¤ô¡]¥H113¢K©Î45¢J·Å¤ô¡A®ûªw30-90¤ÀÄÁ©Îª½¨ì¯kµhÅãµÛ½w¸Ñ¡^¡A¦Ó¤£­n¦B¼Å¡C
  5. µ¹¤©¯}¶Ë­·¹w¨¾¡C
  6. ¶Ë¤fÀ³ºû«ù¶}©ñ¡Aª½¨ì¹w¦X«á¦A¤©¥HÁ_¦X(secondary closure or delayed primary closure) ¡C
  7. ¦Ò¼{¨Ï¥Î§Ü¥Í¯ÀªvÀø¡C

¡@

¡@

³Q¦³¬rªº®ü¤¤¥Íª««I®`®É¡A¯f±w¥i¯à¥u¦³»´·Lªº¨ü¶Ë¡A¤]¥i¯à²£¥ÍÄY­«ªº¯gª¬¦Ó­P¦º¡C¦Ó³Q®ü¤¤¥Íª««r¶Ë©ÎÁ±¶Ë¡A±`µLªk²M·¡ªº¬Ý²M¬°¦óºØ¥Íª«©Ò¶Ë¡C¦¹®É§Ú­Ì¥i®Ú¾Ú¶Ë¤fªº¯S·L¡A¨Ó±À´ú¬°¦óºØ¥Íª«©Ò¶Ë¡A¥H¨M©wªvÀøªº¤è°w¡A¨äºò«æªvÀø­ì«h¦p¤U¹Ï¡G77,79

¡@

¡@

¦³¬rªº®ü¬v¥Íª«

¡@

¦³¬ï¨ë¶Ë¤f ¬õ¯l¡B¤ôªw

ëC³Â¯l¡BIJÄG²ª

®ü³D äá³½¡B®ü¬P ¤ô¥À ®üºø

³¹³½ ®üÁx¡B·à³½ ¬À·ä

®ü¨© Ãȳ½¡B¥ÛÀY³½ ®ü¸ª

Æt³½¡Bóγ½ ¶K½¦¥¬

ÂH¥X¨ë°w

1¥i¥Î§l§m¾¹ 1ªw·Å¤ô¡]45¡CC¡^

©P³¡§l§m¬r¯À 30~90¤ÀÄÁ¡A©Îª½ 1¥H5%¾L»Ä©Î40-70%

2©T©w ¨ì¯kµh®ø¥¢ ¨R¬~¦Ü¤Ö30¤À©Î¤£ ¥H5%¾L»Ä©Î40-70

3ªvÀø¦p¤@¯ë¬r³D 2¨R¤ô µh¬°¤î %²§¤þ¾J¨R¬~

«r¶Ë¡A¥i¨Ï¥Î¼u 3©Þ°£¬r¨ë 2¥H¤M¤ù¬A°£¨ë¤ò

©ÊÁ^±a¡Aºò«×¥H 4µ¹¤©¤îµh¾¯

¤£¼vÅTÀR¯ß¦^¬y

¬°­ì«h

1.¤ä«ù©ÊªvÀø 1.§½³¡¨Ï¥ÎÃþ

1.¤ä«ù©ÊªvÀø 2.¦Ò¼{¨Ï¥ÎÃþ©T¾J ©T¾JªvÀø»´

1.¤ä«ù©ÊªvÀø 2.¥ÛÀY³½§Ü¬r¦å²M* «×¯gª¬

2.ºû«ù©I§l 3.¦Ò¼{µ¹¤©§Ü¥Í¯À** 2ªvÀø¹L±Ó¤Ï 3.§Ü¬r¦å²M À³

¡@

*°ê¥~¦³¡A¦ý¥Ø«e°ê¤º¨S¦³¥ÛÀY³½§Ü¬r¦å²M¡C

**À³¿ï¾Ü¥i¹ï§ÜStaphyloccus¤Î Streptococcus¡A¥H¤Î¥i¹ï§Ü®ü¬v¤¤«D±`Â×´Iªº²Óµß¦p©·µß(Vibro species)ªº§Ü¥Í¯À¡C

¡@

¡@

°Ñ¦Ò¸ê®Æ:

  1. ·¨®¶©÷¡B¬x¾Ë©¾¡BÂĤ俳¡B³¯²Q¬¯¡B¾H¬LªÚ.»OÆW¦a°Ï¦Û¥Á°ê¤C¤Q¥|¦~¦Ü¥Á°ê¤K¤Q¤G¦~¤¤¬r­Ó®×¤§²Î­p¸ê®Æ¤ÀªR.¦æ¬F°|½Ã¥Í¸p¬Ì±¡³ø¾É.1994; 11(6): 139-58.
  2. Bryson PD. Theophylline. Comprehensive review in toxicology for emergency physician. 3rd edition, 1997:643-53.
  3. Ellenhorn MJ. The clinical approach. Ellenhorn s Medical Toxicology, 2nd edition 1997, 3-46.
  4. Kulig K. Initial management of ingestions of toxic substances. N Engl J Med 1992; 326:1677-81
  5. Bryson PD. General Management of overdose patient.Comprehensive review in toxicology for emergency physician. 3rd edition, 1997. 3-19.
  6. Landsberg L, Young JB. Pheochromocytoma. Harrison¡¦s principles of internal medicine. 14th edition, 1998:2057-60.
  7. Linden CH, Lovejoy FH. Illness due to poisons, drug overdosage, and envenomation. Harrison¡¦s principles of internal medicine. 14th edition, 1998:2523-2544.
  8. Ropper AH. Traumatic injuries of the head and spine. Harrison¡¦s principles of internal medicine. 14th edition, 1998:2390-98.
  9. Vance MV. Toxicology. Emergency medicine-A comprehensive study guide 4th ed. JE, Tintinalli. McGraw Hill CO. 1996; 735-841.
  10. Goldfrank LR. Goldfrank¡¦s Toxicological emergencies. 5th 1997.
  11. Ellenhorn MJ. Gut decontamination. Ellenhorn s Medical Toxicology, 2nd edition 1997, 66-78.
  12. Bryson PD. £]-Adrenergic blocking agents. Comprehensive review in toxicology for emergency physician. 3rd edition, 1997.p162-172.
  13. Cummins RO and subcommittee on advanced cardiac life support, American Heart Association: Special resuscitation Situations. Textbook of Advanced Cardiac Life Support. 1997; 11-1¡X11-19.
  14. Ellenhorn MJ. Chemical disaster. Ellenhorn s Medical Toxicology, 2nd edition 1997:1236-1266.
  15. ·¨®¶©÷¡B³¯²Q¬¯¡B¾H¬LªÚ.±`¨£°£¯ó¾¯¤Ú©Ô¤Â»P¦~¦~¬K¤¤¬rªº³B²z. ¬rÃĪ«©u¥Z. ¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå¬rÃĪ«¿Ô¸ß¤¤¤ß, ¤K¤Q¤»¦~¤@¤ë.
  16. Ellenhorn MJ. Pesticides. Ellenhorn s Medical Toxicology, 2nd edition 1997:1614-64.
  17. ¹AÃĤ¤¬r«æ±Ï¤â¥U.¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ß, ¥Á°ê¤K¤Q¤T¦~ª©
  18. ·¨®¶©÷. ±`¨£¹AÃĤ¤¬r¤§³B²z,¦³¾÷ÁC±þÂξ¯¤¤¬r¤§³B²z.¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ß,¦Û°Ê¶Ç¯u¦^´_¨t²Î, 1998.¸ê®Æ¥N¸¹:40401, 40402.
  19. Bryson PD. AchE inhibitors Comprehensive review in toxicology for emergency physician. 3rd edition, 1997.765-777.
  20. ·¨®¶©÷. ±j»Ä»P±jÆP¤¤¬r.¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ß,¦Û°Ê¶Ç¯u¦^´_¨t²Î, 1998.¸ê®Æ¥N¸¹:40505.
  21. Bryson PD. Corrosive agents. Comprehensive review in toxicology for emergency physician. 3rd edition, 1997.277-321.
  22. °ª°¶®p, ¾H¬LªÚ, §õ«Ø½å:¥b¾ÉÅé¤u·~³Ì­«­nªº¬r©Êª«½è-----²B¬t»Ä¤¤¬r¤§³B¸m. ¤¤µØ¥Á°ê«æ¶EÂå¾Ç·|Âø»x, 1999; 1(2) (in press)
  23. Litovitz TL, Veltri JC. 1984 Annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1985; 3(5):423-450.
  24. Litovitz TL, Smilkstein M, and Felberg, et al. 1996 Annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1997; 15(5):447-500.
  25. ªL¬Õ¨q¡B·¨®¶©÷¡B¸¯ÂÔ¡B¾H¬LªÚ¡GHydrofluoric acid intoxication: An analysis of the poison center data. ¤¤µØ¥Á°ê«æ±Ï¥[Å@Âå¾Ç·|¤K¤Q¤»¦~¤Q¤ë¦~·|¯S¥Z, 1997: p94.
  26. Wing JS, Brender JD, and Sanderson LM, et al. Acute health effects in a community after a release of hydrofluoric acid. Arch Environ Health 1991; 46: 155-60.
  27. Himes JE. Occupation medicine in Oklahoma: hydrofluoric acid dangers. J Okla State Med Assoc 1989; 82: 567-9.
  28. Kirkpatrick JR, Enion DS, and Burd DAR: Hydrofluoric acid burns: A review. Burns. 1995; 21(7): 483-493.
  29. Bryson PD. Hydrofluoric acid. Comprehensive Review in Toxicology for Emergency Clinicians. Taylor & Francis Inc., 1997; 3rd edition: 307-13.
  30. Poisindex. USA: Hydrofluoric acid. Denver, Micromedex Inc., 1998.
  31. Bertolini JC: Hydrofluoric acid: A review of toxicity. The Journal of Emergency Medicine, 1992; Vol 10: 163-8.
  32. King R. Poisoning by hydrofluoric acid: death in 35 minutes. Trans Pathol Soc (London) 1873; 24:98-100.
  33. Tepperman PB: Fatality due to acute systemic fluoride poisoning following a hydrofluoric acid skin burn. J Occup Med 1980; 22: 691-2.
  34. Ellenhorn MJ. Hydrofluoric acid. Ellenhorn¡¦s Medical Toxicology---Diagnosis and treatment of human poisoning. Williams & Wilkins Inc. 2nd edition, 1997: 1089-90.
  35. Wei-Fong Kao, RC Dart, E Kuffner, et al. Factors influencing morbidity and mortality associated with low concentration hydrofluoric acid. Clin Toxi 1998; 36(5): 448-9.
  36. Watson A, Oliver JS, Thorpe JW. Accidental death due to inhalation of hydrofluoric acid. Med Sci Law, 1973; 13: 277-9.
  37. Bennion JR, Usaf M, and Franzblau A. Chemical pneumonitis following household exposure to hydrofluoric acid. Am J Industrial Med 1997; 31:474-8.
  38. McCulley JP, Whiting DW, and Petitt MG, et al. Hydrofluoric acid burns of the eye. J Occup Med 1983; 25: 447-50.
  39. Cox RD, Osgood KA: Evaluation of intravenous magnesium sulfate for the treatment of hydrofluoric acid burns. Clinical Toxicology, 1994;32(2), 123-136.
  40. William JM, Hammad A, Cottington EC, et al: Intravenous magnesium in the treatment of hydrofluoric acid burns in rats. Annals of Emergency Medicine 1994, March; 23:3; 464-9.
  41. Harris JC, Rumack BH, Bregman, DJ: Comparative efficacy of injectable calcium and magnesium salts in the therapy of hydrofluoric acid burns. Clinical Toxicology 1981, 18(9), pp. 1027-1032.
  42. Siegel DC, Heard JM: Intra-arterial calcium infusion for hydrofluoric acid. Aviat Space Environ Med 1992; 63: 206-11.
  43. Velvart J. Arterial perfusion for hydrofluoric acid burns. Human Toxicol. 1983; 2: 233-8.
  44. Henry JA: Intravenous regional calcium gluconate for hydrofluoric acid burns. Clin Toxi ol 1992; 30: 203-7.
  45. Bentur Y, Tannenbaum S, and Yaffe Y, et al. The role of calcium gluconate in the treatment of hydrofluoric acid eye burns. Ann Emerg Med 1993; 22: 1488-90.
  46. Trevino MA, Herrmann GH, Sprout WL: Treatment of severe hydrofluoric acid exposures. J Occup Med 1983; 25: 861-3.
  47. Bryson PD. Acetaminophen. Comprehensive review in toxicology for emergency physician. 3rd edition, 1997.537-50.
  48. ·¨®¶©÷. Âíµh¸Ñ¼ö¾¯: ¤AñQ®ò×ô¤¤¬r.¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ß,¦Û°Ê¶Ç¯u¦^´_¨t²Î, 1998.¸ê®Æ¥N¸¹:40102.
  49. °ª°¶®p.ºC©ÊAcetaminophen¤¤¬r.¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ß,¦Û°Ê¶Ç¯u¦^´_¨t²Î, 1998.¸ê®Æ¥N¸¹:50108.
  50. ½²ºûºÕ. ÃĪ«ÀÝ¥Î. ¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ß,¦Û°Ê¶Ç¯u¦^´_¨t²Î, 1998.¸ê®Æ¥N¸¹:20101-11.
  51. Bryson PD. Drugs of abuse. Comprehensive review in toxicology for emergency physician. 3rd edition, 1997.421-534.
  52. Ellenhorn MJ. Natural toxins. Ellenhorn s Medical Toxicology, 2nd edition 1997:1737-1896.
  53. ·¨®¶©÷. ´Óª«¬r¯À, ¼Ì¸£ªo¤¤¬r: ¤AñQ®ò×ô¤¤¬r.¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ß,¦Û°Ê¶Ç¯u¦^´_¨t²Î, 1998.¸ê®Æ¥N¸¹:40301, 40405.
  54. Jou-Fang Deng, Tzeng-Jih Lin, and Wei-Fong Kao et al: The difficulty in handling poisonings associated with Chinese tranditional medicine: A poison control center experience for 1991-1993. Vet Human Toxicol, April 1997; 39(2): 106-114.
  55. Bryson PD. Gases and abnormal hemoglobin formation. Comprehensive review in toxicology for emergency physician. 3rd edition, 1997.421-534.
  56. ¬xªFºa¡B¾H¬LªÚ.¥V¤ÑªºµL§Î±þ¤â---¤@®ñ¤ÆºÒ. ¬rÃĪ«©u¥Z. ¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå¬rÃĪ«¿Ô¸ß¤¤¤ß, ¤K¤Q¦~¤G¤ë.
  57. Leikin JB, Kaufman D, Lipscomb JW, Burda AM et al: Methylene chloride: report of five exposures and two deaths. Am J Emerg Med 1990; 8:534.
  58. Thom SR,Keim LW: Carbon monoxide poisoning: A review of epidermiology, pathophysiology, clinical findings, andtreatment options including hyperbarbic oxygen therapy. J Toxicol Clin Toxicol 1989;27:141-65.
  59. Mann R, Heimbach DM. Emergency care of the burned patient-Wildness medicine-Management of wildness and environmental emergencies 3rd edition. 1995, P243-60.
  60. Ellenhorn MJ. Respiratory toxicology. Ellenhorn s Medical Toxicology, 2nd edition 1997, 1448-1531.
  61. ¸¯ÂÔ. ´â®ð¤¤¬r.¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ß,¦Û°Ê¶Ç¯u¦^´_¨t²Î, 1998.¸ê®Æ¥N¸¹:30201-4.
  62. Smith R, Gossellin R: Hydrogen Sulfide poisoning. J occup Med 1979;21:93-7.
  63. Seidel JS. Tintinalli JE. Diarrhea and food poisoning. Emergency medicine-A comprehensive study guide 4th ed. 1996; 488-95.
  64. ¬xªFºa¡B¾H¬LªÚ.¥xÆW±`¨£ªº¬r³D¤Î«r¶Ë¤§ªvÀø. ¬rÃĪ«©u¥Z. ¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå¬rÃĪ«¿Ô¸ß¤¤¤ß, ¤K¤Q¤­¦~¤T¤ë.
  65. ·¨®¶©÷. ¬r³D«r¶Ë.¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ß,¦Û°Ê¶Ç¯u¦^´_¨t²Î, 1998.¸ê®Æ¥N¸¹:40208.
  66. Dart RC, Gomez HF. Reptile bite and scorpion stings. Emergency medicine-A comprehensive study guide 4th ed. JE, Tintinalli. McGraw Hill CO. 1996;864-7.
  67. Norris RL, Oslund S, and Auerbach PS. Disorders caused by reptile bites and marine animal envenomations. Harrison¡¦s principles of internal medicine. 14th edition, 1998:2544-8.
  68. Bryson PD. Venomous creatures. Comprehensive review in toxicology for emergency physician. 3rd edition, 1997.717-46.
  69. Sullivan JB, Wingert WA, and Norris RL. North American Venomous reptile bites Wilderness Medicine- Management of Wilderness and Environmental Emergency 3rd ed, PS Auerbach. St. Louis, Mosby.1995;680-709.
  70. Curry SH. et al. Non-invasive vascular studies in amnagement of rattlesnake envenomations to extremities. Ann Emerg Med 1985;14:1081-9.
  71. ¹ù©ú¤@¡B³Å¯ª¼z.¥xÆW²£¬r³D³D¬rÃþ¬r¯À¤Î§Ü¦å²M¤§¬ã¨s.°ê¥ß¥xÆW¤j¾ÇÃ~Âå¬ã¨s©Ò³Õ¤h½×¤å. June, 1991.
  72. Salluzzo RF. Insect and spider bites. Emergency medicine-A comprehensive study guide 4th ed. JE, Tintinalli. McGraw Hill CO. 1996;856-64.
  73. Spielman A, Magguire JH. Ectoparasite infections and arthropod bites and stings. Harrison¡¦s principles of internal medicine. 14th edition, 1998:2548-54.
  74. ¾H¬LªÚ¡B¬xªFºa. ¸ÁÁ±ªº¯gª¬¤Î¨äªvÀø.¸Á²£«~¥[¤u»P§Q¥Î¬ã°Q·|½×¤å¶°.1993, 91-3.
  75. ·¨®¶©÷. ­J¸ÁÁ±¶Ë.¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ß,¦Û°Ê¶Ç¯u¦^´_¨t²Î, 1998.¸ê®Æ¥N¸¹:40209.
  76. ¤×«T¤å.22¨Ò¸ÁÁ±¦í°|¯f¤HªºÁ{§Éªí²{.¦æ¬F°|½Ã¥Í¸pº[¥x¥_ºa¥ÁÁ`Âå°|¬rÃĪ«¿Ô¸ß¤¤¤ß,¦Û°Ê¶Ç¯u¦^´_¨t²Î, 1998.¸ê®Æ¥N¸¹:50107.
  77. Guenin DG, Auerbach PS. Trauma and envenomations from marine fauna. Emergency medicine-A comprehensive study guide 4th ed. JE, Tintinalli. McGraw Hill CO. 1996;868-73.
  78. Auerbach PS, Halstead BW. Injuries from nonvenomous aquatic animals. Wilderness Medicine- Management of Wilderness and Environmental Emergency 3rd ed, PS Auerbach. St. Louis, Mosby.1995; 1303-26.
  79. Auerbach PS. Marine¡@envenomation. Wilderness Medicine- Management of Wilderness and Environmental Emergency 3rd ed, PS Auerbach. St. Louis, Mosby.1995;1327-74.